Pr ot oc ol I 8 F- M C- G P GI( b) 
A Ra n d o mize d, P hase 3, D o u ble- bli n d Trial C o m pari n g t he Effect of t he A d diti o n of Tirze pati de Vers us 
Place b o i n Patie nts Wit h T y pe 2 Dia betes I na de q uatel y C o ntr olle d o n I ns uli n Glar gi ne Wit h or Wit h o ut 
Metf or mi n 
N C T 0 4 0 3 9 5 0 3    
A p pr o val Date: 2 6-J u n- 2 0 2 0 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e 1
LY 3 2 9 8 1 7 6 Pr ot o c ol I 8 F -M C -G P GI ( b) 
A R a n d o mi z e d, P h a s e [ADDRESS_526225] a c e b o i n 
P ati e nt s wit h T y p e 2 Di a b et e s I n a d e q u at el y  C o ntr oll e d o n 
I n s uli n Gl ar gi n e wit h or wit h o ut M etf or mi n ( S U R P A S S - 5) 
2 0 1 9 -0 0 0 8 6 0 -9 9 
C o nfi d e nti al I nf or m ati o n 
T h e i nf or m ati o n c o nt ai n e d i n t hi s d o c u m e nt i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of 
cli ni c al i n v e sti g at or s.  It i s t h e pr o p ert y of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d 
s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli ni c al i n v e sti g ati o n of 
tir z e p ati d e ( L Y 3 2 9 8 1 7 6) , u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt 
wit h Eli Lill y a n d C o m p a n y or it s s u b si di ari e s .  
N ot e t o R e g ul at or y A ut h oriti e s:   T hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a 
a n d/ or c o m m er ci all y c o nfi d e nti al i nf or m ati o n e x e m pt fr o m p u bli c di s cl o s ur e. Eli Lill y a n d 
C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o a n y p u bli c r el e a s e. I n 
t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e ct t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) 
E x e m pti o n 4 a n d m a y n ot b e r e pr o d u c e d or ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n 
a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s. 
Tir z e p ati d e ( L Y 3 2 9 8 1 7 6) 
Eli Lill y a n d C o m p a n y 
I n di a n a p oli s, I n di a n a U S A 4 6 2 8 5 
Pr ot o c ol El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y : 0 1 M ar c h 2 0 1 9 .
A m e n d m e nt ( a) El e ct r o ni c all y Si g n e d a n d A p pr o v e d b y Lill y : 3 0 A pril 2 0 2 0. 
A m e n d m e nt ( b) El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y o n a p pr o v al d at e pr o vi d e d 
b el o w. 
A p pr o v al D at e: 2 6- J u n- 2 0 2 0 G M T 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e 2
LY 3 2 9 8 1 7 6 T a bl e of C o nt e nt s 
S e cti o n P a g e 
Pr ot oc ol I 8 F -M C -G P GI( b) A Ra n d o mize d, P hase 3, D o u ble -bli n d Trial 
C o m pari n g t he Effect of t he A d dit i o n of Ti rze pat i d e vers us Place b o 
i n Pat ie nt s wi t h  T y pe 2 Di a betes I na de q uatel y  C o ntr olle d o n I ns uli n 
Gl ar gi ne wi t h  or wi t h o ut Metf or mi n ( S U R P A S S - 5) ............................................................ [ADDRESS_526226] u d y  Rati o n a le ............................................................................................................ 2 3 
3. 2. Bac k gr o u n d .................................................................................................................. 2 3 
3. 3. Be nefit/ Ris k Assess me nt .............................................................................................. [ADDRESS_526227] u g ...................................................... 4 4 
7. 3. Bli n di n g ....................................................................................................................... 4 4 
7. 4. D osa ge M o dificati o n .................................................................................................... 4 5 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526228] u gs ......................................................................................................... 4 5 
7. 4. 2. Re d ucti o n a n d/ or Disc o nt i n uat i o n of C o nc o mit a nt 
A nt i h y per gl yce mic Me dicat i o ns ........................................................................... 4 5 
7. 5. Pre parati o n/ Ha n dli n g/ St ora ge/ Acc o u nta bilit y............................................................... [ADDRESS_526229] u g A nt i b o dies ..................................................................................... 6 1 
9. 2. 2. 1 0. Di a bet ic Ret i n o pat h y  C o m plicat i o ns ............................................................... 6 1 
9. 2. 2. 1 1. He pat o biliar y  Dis or ders .................................................................................. 6 1 
9. 2. 2. 1 2. Se vere Gastr oi ntesti nal A d verse E ve nts .......................................................... 6 1 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e 4
LY 3 2 9 8 1 7 6 9. 2. 2. 1 3. Ac ute Re nal E ve nts ........................................................................................ 6 1 
9. 2. 2. 1 4. Meta b o lic Aci d osis, I ncl u di n g Dia betic Ket oaci d osis ..................................... 6 1 
9. 2. 2. 1 5. A m p utati o n/ Peri p heral Re vasc ularizat i o n....................................................... 6 2 
9. 2. 2. 1 6. Maj or De pressi ve Dis or der/ S uici dal I deat i o n.................................................. [ADDRESS_526230] ics .................................................................................... 70
1 0. 3. 2. 3. C o nc o mita nt T hera p y ..................................................................................... 7 0 
1 0. 3. 2. 4. Treat me nt C o m plia nce .................................................................................... 7 1 
1 0. 3. 3. Efficac y A nal yses ................................................................................................ 7 1 
1 0. 3. 3. 1 .Pri mar y A nal yses ........................................................................................... 7 1 
1 0. 3. 3. 2. Sec o n dar y  A nal yses ........................................................................................ 7 2 
1 0. 3. 3. 3. Terti ar y/ E x pl orat or y  A nal yses ........................................................................ 7 3 
1 0. 3. 4. S af et y A nal yses .................................................................................................... 7 3 
1 0. 3. 4. 1. H y p o gl yce mic E ve nts ..................................................................................... 7 3 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e 5
LY 3 2 9 8 1 7 6 1 0. 3. 4. 2. Gastr oi ntesti nal E ve nts ................................................................................... 7 3 
1 0. 3. 4. 3. A d j u dicate d Car di o vasc ular E ve nts ................................................................ 7 3 
1 0. 3. 4. 4. Ce ntral  La b orat or y  Meas ures, Vi t al  Si g ns, a n d 
Electr ocar di o gra ms ......................................................................................... 7 4 
1 0. 3. 5. P har mac o ki net ic/ P har mac o d y na mic A nal yses ...................................................... 7 4 
1 0. 3. 6. E val uat i o n of I m m u n o ge nicit y............................................................................. 7 4 
1 0. 3. 7. Ot her A nal yses ..................................................................................................... 7 5 
1 0. 3. 7. 1. Heal t h  Ec o n o mics ........................................................................................... 7 5 
1 0. 3. 7. 2. S u b gr o u p A nal yses ......................................................................................... 7 5 
1 0. 3. 8. I nteri m A nal yses .................................................................................................. 7 5 
1 1. Refe re nces ........................................................................................................................ 7 6 
1 2. A p pe n dices ....................................................................................................................... 7 9 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526231] i ves a n d E n d p o i nt s............................................................................... 2 5 
Ta ble G P GI. 3. Treat -t o -Tar get Al g ori t h m ............................................................................. 4 2 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526232] u d y  desi g n f or Cli nical Pr ot oc ol I 8 R -M C -G P GI. ................... 2 8 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526233] u d y  Pr oce d ures d ue t o t he C O VI D -1 9 Pa n de mic ...................... 9 6 
A p pe n di x 9. Pr ot oc ol  A me n d me nt I 8 F -M G -G P GI( b) 
A Ra n d o mize d, P hase 3, D o u ble -bli n d Tri al  C o m pari n g t he Effect of 
t h e A d dit i o n of Ti rze pati de vers us Pl ace b o i n Pati e nts wi t h  T y pe 2 
Di a betes I na de q uatel y  C o ntr olle d o n I ns uli n Glar gi ne wi t h  or wi t h o ut 
Metf or mi n ( S U R P A S S - 5) .............................................................................. 9 7 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526234] u d y: 
A Ra n d o mize d, P hase 3, D o u ble -bli n d Tri al  C o m pari n g t he Effect of t he A d dit i o n of Ti rze pat i de 
vers us Pl ace b o i n Pati e nts wi t h  T y pe 2 Di a betes I na de q uatel y  C o ntr olle d o n I ns uli n Glar gi ne 
wit h or wit h o u t M et f o r mi n ( S U R P A S S - 5). 
R ati o n ale: 
C urre nt i ncret i n - base d i njecta ble treat me nt o pti o ns f or t y pe 2 dia betes mellit us ( T 2 D M) are 
di recte d at a si n gle i ncreti n m o lec ular tar get ( G L P -1 [ gl uca g o n -li ke pe pti de -1]) a n d t heref ore ,
c o ul d ha ve t hera pe utic li mitati o ns.  T hese treat me nt o pti o ns offer i m pr o ve d gl yce mic c o ntr ol a n d 
a l o w ri s k of h y p o gl yce mia, a n d ha ve a p ote ntial f or cli nicall y rele va nt wei g ht l os s.  H o we ver, a 
lar ge pr o p orti o n of patie nts still d o n ot reac h t he treat me nt tar gets des pi[INVESTIGATOR_040] a hi g h le vel o f 
c o m plia nce wi t h  t he treat m e nt re gi me ns.  T heref ore, it is i m p orta nt t o pr o vi de a d dit i o nal 
treat m e nt o pti o ns f or pati e nts t hat all o w f or e n ha nce d gl uc ose c o ntr ol  a n d wei g ht l oss w hile 
preser vi n g a n o verall acce pta ble be nefit/ris k pr ofile ( Star k Casa gra n de 2 0 1 3; Zaccar di et al . 
2 0 1 6). 
Ti rze pati de ( L Y 3 2 9 8 1 7 6) is a o nce -wee kl y d ual GI P ( gl uc ose -de pe n de nt i ns uli n otr o pi c 
p ol y pe pt i de)/ G L P -[ADDRESS_526235] u d y  I 8 F -M C -G P GI ( G P GI) will c o m pare tirze pati de ( 3 d oses) t o place b o, a d de d t o titrate d 
o nce -dail y  basal i ns uli n glar gi ne i n pat ie nt s wi t h  T 2 D M pre vi o usl y treate d wit h i ns uli n glar gi ne 
( wi t h  or wi t h o ut m et f o r m i n).  T here are n o a vaila ble p u blis he d re p orts o n t he effects of t he 
c o m bi nat i o n of basal i ns uli n a n d a l o n g -acti n g, o nce -wee kl y ( Q W) d ual  GI P/ G L P -[ADDRESS_526236] o n bl o o d gl uc ose ( B G) t o date.  T he c o m bi nat i o n of i ns uli n glar gi ne wit h t ir ze pat i de is 
e x pecte d t o pr o vi de i m pr o ve d gl uc ose c o ntr ol a n d atte n uate t he w ei g ht gai n a n d h y p o gl yce mi a 
ri s k ass o ci ate d wi t h  t h e m o re i nte nsi ve titrati o n a n d hi g her dail y  d oses of i ns uli n glar gi ne .C CI 
I8F-MC-GPGI( b) Clinical Protocol Page 10
LY3298176Objective(s)/Endpoints:
Obje ctives Endpoints
Primary
To demonstrate superiority of QW tirzepatide 
10 mg and /or [ADDRESS_526237] to glycemic 
control at 40weeks for:Mean change in HbA1c from baseline 
Key Secondary (controlled for type 1 error)
Efficacy
To demonstrate superiority of QW tirzepatide
[ADDRESS_526238] to glycemic control at 
40 weeks for:
To demonstrate superiority of QW tirzepatide 
5mg, 10 mg, and /or15 mg versus placebo 
when added to titrated b asal insulin glargine, 
with or without metformin, at 40weeks for :Mean change in HbA1c from baseline
Mean change in body weight from baseline 
Proportio n of patients with HbA1c target 
values of <7.0% (53 mmol/mol) 
Mean change in fasting serum gluco se (central 
laborato ry) from baseline
Additional Secondary (not controlled for type 1 
error)
Efficacy
To compare QW tirzepatide 5 mg, 10 mg, and 
15 mg to placebo at 40weeks for:Proportio n of patients achieving HbA1c target 
≤6.5% (48 mmol/mol) ,<5.7% (39 mmol/mol)
Mean change in daily  average 7-point 
self-monitored blood glucose profiles from 
baseline
Proportio n of patients who achieved weight 
loss of ≥5%, ≥10%, and ≥15% from baseline
Change f rom baseline in daily mean insulin 
glargine dose
I8F-MC-GPGI( b) Clinical Protocol Page 11
LY3298176Obje ctives Endpoints
Safety
To compare QW tirzepatide 5 mg, 10 mg, 
and 15 mg to placebo to the end of safety 
follow -up for:Treatment -emergent adverse events (TEAEs)
Early  discontinuation of study drug due to 
adverse events (AEs)
Adjudicated pancreatic AEs
Serum calcitonin
Incidence of allergic and hypersensitivity 
reactions 
Incidence of treatment -emergent antidrug 
antibodies to tirzepatide
Mean change in systolic and diastolic blood 
pressure and heart rate from baseline 
Occurrence of hypoglycemic epi[INVESTIGATOR_1841]
Incidence of init iation of rescue therapy for 
severe, persistent hyperglycemia 
Pharmacokinetics
To characterize the pharmacokinetics (PK) of 
QW tirzepatide 5 mg, 10 mg, and 15 mg and 
the relatio nships between tirzepatide exposure 
and safety, tolerability, and efficacy measures
for:Population PK and pharmacodynamic 
parameters
Abbreviations: HbA1c =hemoglobin A1c ; QW =once weekly .
I8F-MC-GPGI( b) Clinical Protocol Page 12
LY3298176Summary of Study Design:   
Study  GPGI is a m ulticenter, randomized, double- blind, parallel, mult inational, 
placebo -controlled Phase 3 study  which will assess the safety  and efficacy  of the addi tion of  
5mg, 10 mg, or 15 mg t irzepat ide or placebo for change fro m baseline in hemoglo bin A1c
(HbA1c )in pat ients with T2DM receiving t itrated basal insulin glargine (with or wi thout 
metformin) over a 40-week treatment.  Approximately, [ADDRESS_526239] been 
treated with insulin glargine (U100), once daily with or without metformin ≥3 m onths pri or to 
Visit 1, will be randomized.
Treatment Arms and Duration:   
Study  GPGI will consist of 3 periods:  an approximately 3- week screening/lead -in period, 
followed by a 40-week treatm ent peri od and a 4 -week safet y follow-up peri od.  Patients will be 
rando mized in a 1:1:1:1 ratio (tirzepat ide 5 mg, tirzepatide 10 mg, tirzepat ide 15 mg, and 
placebo).  Patients will be stratified based on country , baseline HbA1c ( ≤8.0% or >8.0% [≤64,
˃64mmo l/mol]), and baseline metformin use (Yes or No) .
Number of Patients :
A total o f approximately  472 patients (118 patients per treatment group or placebo) will be 
rando mized.
Statistical Analysis:
Sample Size:
The tri al is powered to evaluate superiorit y of tirzepati de 10 m g and ti rzepat ide 15 mg versus 
placebo inparallel relative to the primary  endpoi nt (mean change fro m baseline in HbA1c at 
40weeks) under the fo llowing assumpt ions:  
use of [ADDRESS_526240] to make stati stical com parisons amo ng treatment means ,
use of HbA1c data collected before init iation of any rescue medicat ion or 
prem ature treatm ent discont inuat ion,
no m ore than 28% patients in t irzepat ide groups and placebo init iating any 
rescue m edicati on or prem aturely discont inue study drug ,
at least 0.60% (placebo adjusted) mean reduction in HbA1c from baseline to 
40 weeks for the tirz epatide doses ,and 
a commo n standard deviat ion (SD) of 1.1%.  
Based on these assumpt ions, randomizing approximately 472 subjects using a 1:1:1:[ADDRESS_526241] 90% power to establish superiorit y of tirzepat ide 10 mg and/or 15 mg 
doses versus placebo, each evaluated at a 2 -sided significance level o f 0.025.  Furthermore, this 
sample size will ensure 90% power to establish superiorit y using an analysis of covariance 
(ANCOVA) utilizing all available HbA1c data at 40weeks, irrespective of adherence to study  
drug or init iation of rescue therapy , and wi th missing data imputed with a conservat ive multiple 
I8F-MC-GPGI( b) Clinical Protocol Page 13
LY3298176imputati on m ethod (as described in the Efficacy Analyses section below).   It is assumed that 
efficacy  (placebo adj usted) remains unchanged and SD increases to no more than 1.3% due to 
the inclusio n of data on rescue medicat ions, inclusion of data after premature treatment 
discontinuat ion, and imputation of missing data.  
Efficacy:
Efficacy and safet y will be assessed using the modified intent ion-to-treat populat ion, which 
consists of all rando mly assigned participants who are exposed to at least onedose of study  drug.  
There will be [ADDRESS_526242] in comparing efficacy o f tirzepati de doses wi th placebo 
relative to the primary measure of mean change in HbA1c fro m baseline to 40-week visit.  The 
“efficacy” est imand represents efficacy prior to discontinuat ion of stu dy drug wi thout 
confounding effects of rescue therapy  for persi stent severe hyperglycemia.  The 
“treatm ent-regimen” est imand represents the efficacy irrespect ive of adherence to invest igational 
product or introduction of rescue therapy  for persi stent sever e hyperglycemia.
For the FDA, the primary efficacy  assessment will  be guided by [CONTACT_941] “treatment -regimen” 
estimand.  This assessment will analyze change from baseline in HbA1c to 40-week visit using 
an ANCOVA wit h term s, treatm ent, country , metformin use (Ye s or No) , and baseline HbA1c as 
a covari ate.  The ANCOVA analysis will be conducted using full analysis set at 40-week visit, 
which consists of all available change from baseline in HbA1c data at the 40-week visit, 
irrespect ive of whether they were obtaine d while the participants had discontinued the study  drug 
or whether the participant had been given rescue medicat ion.  Addit ionally, data for subjects with 
missing values will be imputed based on observed data in the same treatment arm fro m subjects 
who ha d thei r efficacy measure at the Week 40visit assessed after early discont inuat ion of study  
drug and/or init iation of rescue medicat ion (retrieved dropouts).  Analysis will be conducted with 
multiple imputations, and statistical inference over mult iple imputations will be guided by [CONTACT_82404] (1987).
For all other purposes, the primary efficacy  assessment will be guided by  [CONTACT_941] “efficacy” 
estimand.  This assessment will use efficacy analysis set which consists of data obtained before 
theinitiation of any  rescue therapy  and before premature treatment discont inuat ion.  The analysis 
model for change from  baseline in HbA1c assessed over time will be a mixed model for repeated 
measures (MMRM), with terms treatment, visit, treatment -by-visit i nteracti on, country , 
metformin use (Yes or No), and baseline HbA1c as a covariate.  An unstructured covariance 
matri xwill model relati onship of wi thin-patient errors.  
Since they  are intended for different purposes, each of the [ADDRESS_526243] ical 
analysis plan (SAP).
I8F-MC-GPGI( b) Clinical Protocol Page 14
LY3298176Safety:
Safety assessment will be based on all available data, irrespect ive of whether they were obtained 
while the participants had discont inued the study drug or whether the participant had been given 
rescue m edicati on.  Summary stati stics will be provided for i ncidence of TEAEs, serious AEs , 
and study  discont inuat ion due to AEs or deaths from first dose to end of safet y follow-up.  
Counts and proportions o f subjects experiencing AEs will be reported for each treatment group, 
and Fisher’s exact test will be used to com pare the treatm ent groups.  For continuous laboratory  
analytes, summary  stati stics will be provided by [CONTACT_765], with statist ical com parisons am ong 
treatm ent at each visit conducted using an MMRM analysis.  Addit ional details, including 
analysis of AEs of special interest, will be provided in the SAP.
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526244] o m e c or o na vi r us 2 ( S A R S -C o V - 2 ), t he vir us t hat ca uses t he n o vel 
Cor o na vir us Disease 2 0 1 9 ( C O VI D -1 9), please refer t o A p pe n di x 8 f o r a d di ti o nal  i nstr ucti o ns. 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526245] u d y 
Peri o d 
III 
Scree ni n g 
Le a d i n Tre at me nt Peri o d S afet y 
F/ U 
Visit [ADDRESS_526246] 
e n d of 
T x 
All o w a ble De vi ati o n 
( d a ys) c- ± 3 ± 7 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 -± 3 ± 3 ± 3 ± 3 -± 3 ± 3 -± 3 ± 7 -± 7 ± [ADDRESS_526247] circ u mfere nce X X X  X X  X  X  X  X  X 
Electr ocar di o gra m fX X  X  X 
Vital si g ns ( 2 sitti n g 
B P a n d H R) gX  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X 
A d verse e ve nts X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X 
Dilate d fu n d osc o pic 
exa m i nati o n hX
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526248] u d y 
Peri o d 
III 
Scree ni n g 
Le a d i n Tre at me nt Peri o d S afet y 
F/ U 
Visit [ADDRESS_526249] 
e n d of 
T x 
All o w a ble De vi ati o n 
( d a ys) c- ± 3 ± 7 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 -± 3 ± 3 ± 3 ± 3 -± 3 ± 3 -± 3 ± 7 -± 7 ± 7 
F asti n g Visit dX X X X X X X X X X X
P K o nl y Visit X X X X
Tele p h o ne Visit X X X X
C o nc o mita nt 
me dicati o ns X  X  X  X  X  X  X  X  X X X  X  X  X  X  X  X  X  X  X  X  X  X  X 
Re vie w 
h y p o gl yce mic e ve nts 
c ollecte d i n t he diar y X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X 
P atie nt E d uc ati o n 
Dia betes e d ucati o n i,j X
B G meter, S M B G 
trai ni n g jX
Dis pe nse B G 
meter/s u p plies, as 
nee de d X  X  X  X  X  X  X  X X  X  X  X 
St u d y  dr u g i njecti o n 
trai ni n g jX
Ha n d o ut diar y, 
i nstr uct i n use jX  X X X X
Re mi n d patie nts 
a b o ut 7 -p oi nt 
S M B G kX X
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526250] u d y 
Peri o d 
III 
Scree ni n g 
Le a d i n Tre at me nt Peri o d S afet y 
F/ U 
Visit [ADDRESS_526251] 
e n d of 
T x 
All o w a ble De vi ati o n 
( d a ys) c- ± 3 ± 7 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 -± 3 ± 3 ± 3 ± 3 -± 3 ± 3 -± 3 ± 7 -± 7 ± [ADDRESS_526252] n X
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526253] u d y 
Peri o d 
III 
Scree ni n g 
Le a d i n Tre at me nt Peri o d S afet y 
F/ U 
Visit [ADDRESS_526254] 
e n d of 
T x 
All o w a ble De vi ati o n 
( d a ys) c- ± 3 ± 7 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 -± 3 ± 3 ± 3 ± 3 -± 3 ± 3 -± 3 ± 7 -± 7 ± [ADDRESS_526255] /Estra di ol pX
C he mistr y pa nel XqX X X  X  X 
Fasti n g ser u m 
gl uc ose 
(ce ntral la b orat or y) X  X  X X  X X  X  X X  X  X 
Li pi d pa nel X X  X  X 
Uri nar y 
al b u mi n/creati ni ne 
rati o XqX  X  X 
Ser u m creati ni ne, 
e G F R ( C K D -E PI) r XqX X X  X  X 
Calcit o ni n XqX X X  X  X 
He mat ol o g y XqX X X  X  X 
H b A 1c X  X X X  X X  X  X X  X  X 
Pa ncreatic a m ylase, 
li pase XqX X X  X  X 
I m m u n o ge nicit y sX X X X X  X  X 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526256] u d y 
Peri o d 
III 
Scree ni n g 
Le a d i n Tre at me nt Peri o d S afet y 
F/ U 
Visit [ADDRESS_526257] 
e n d of 
T x 
All o w a ble De vi ati o n 
( d a ys) c- ± 3 ± 7 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 -± 3 ± 3 ± 3 ± 3 -± 3 ± 3 -± 3 ± 7 -± 7 ± [ADDRESS_526258] ore d sa m ple X X X X  X 
P atie nt Re p orte d O utc o mes -t o be c o m plete d b y p atie nt at site v
A P P A D L X X  X 
I W -S P X X  X 
D T S Qs X
D T S Qc X  X 
E Q - 5 D- 5 L X X  X 
I8F-MC-GPGI( b) Clinical Protocol Page 21
LY3298176Abbreviations:  ADA =antidrug antibodies; APPADL =Ability to Perform Physical Activities of Daily Living ; BG =blood glucose; BP =blood pressure; 
CKD -EPI =Chronic Kidney Disease -Epi[INVESTIGATOR_623]; DTSQc =Diabetes Treatment Satisfaction Questionnaire change; DTSQs =Diabetes Treatment 
Satisfaction Questionnaire status; ECG =electrocardiogram; eCRF =electronic case report form; eGFR =estimated glomerular filtration rate; 
EQ-5D-5L = European Qualtiy of Life - 5dimension s-5 levels ;ET=early  termination; F/U =follow -up; GAD =glutamic acid decarboxylase; 
HbA1c =hemoglobin A1c; HR =heart rate; IW-SP=Impact of Weight on Self -Perception; PK =pharmacokinetics; PRO =patient -reported o utcome; ; 
SMBG =self-monito red blood glucose; TTT =treat to target; Tx =treatment.
aBaseline assessments must be completed before processing in the interactive web -response sy stem (IWRS).
bPatients who are unable or unwilling to continue in the study for any reason will perform an ET visit.  If the patient is discontinuing during an unscheduled 
visit, that visit should be performed as the ET visit.  If the patient is discontinuing during a scheduled visit, that visit should be performed as an ET visit.   
Visit 801 ( safety  follow -up v isit) should be performed 4 weeks after the ET visit as the final study visit.
cThe visit date is determined in relation to the date of the randomization visit (± the allowed visit window). 
dOn visits 3, 5, 7, 11, 13, 16, 17, 19, 22, ET, and at follow -up, patients should be reminded to report to the site in a fasting condition, after a period of 
approximately 8 hours without eating, drinking (except water), or any significant physical activity and before taking study d rug(s ), insulin glargine and 
metformin (if used) .
eMedical history includes assessment of preexisting conditions (including history of gall bladder disease, cardiovascular dise ase, and medullary thyroid 
carcinom a) and substance usage (such as; alcohol and toba cco).
fElectrocardiograms (ECG) occurring on visits with PK collection should be collected at least 30 minutes prior to obtaining th e sample for PK measurement.
gVital sign measurements should be taken before obtaining an ECG tracing and before collectio n of blood samples for laboratory testing, at visits where 
required.  The participant should sit quietly for 5 minutes before vital sign measurements are taken. For each parameter, 2 measurements will be taken using 
the same arm; the recordings should be taken at least [ADDRESS_526259] be taken with an automated blood pressure machine .
hDilated fundoscopic exam will be performed by a qualified eye care professional (ophthalmologist or optometrist) for all patients between Visit 2 and V isit 3 
to exclude patients with proliferative diabetic retinopathy and/or diabetic maculopathy (macular edema), or nonproliferative diabetic retinopathy that requires 
acute treatment.  The results from this exam will be recorded on a specific retinopathy e CRF as a baseline measure of retinopathy.  Follow up dilated 
fundoscopic exam should be performed when clinically indicated, and, the results recorded on the retinopathy eCRF.
iIncludes counseling on diet and exercise, management of hypoglycemia, etc.
jAll training should be repeated as needed to ensure patient compliance. 
kPatient is required to collect two [ADDRESS_526260] a daily fasting BG and a 
4-point SMBG once weekly between Visit 2 and 3, twice weekly from Visits 3 -7 (Weeks 0-4) followed by [CONTACT_417383] .
lPatients should administer their first dose of study drug at the end of this visit, after other study procedures and randomiz ation.
mAssessment of the patient’s compliance to the TTT algorithm will be collected in the eCRF at Visits 7, 9, 11, 13, 16, 19 ,and 22for the period since the 
previous clinic visit.
I8F-MC-GPGI( b) Clinical Protocol Page [ADDRESS_526261] injection of study drug(s) for women of 
childbearing potential only.  Additional pregnancy tests willbe performed at Visits 1 3, 19, and22. Pregnancy tests may be also performed at the 
investigator’s discretion during the study.  If required per local regulations and/or institutional guidelines, pregnancy tes ting can also occur at other times 
during the study treatment period.
pFollicle -stimulating hormone test performed at Visit [ADDRESS_526262] had spontaneous amenorrhea for more than 6 months and less than 12 months and estradiol l evels consistent with a postmenopausal state (FSH 
≥40mIU/mL and estradiol <30 pg/mL).
qScreening visit assessment will serve as baseline.
rThe CKD -EPI [INVESTIGATOR_81092]. 
sInthe event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional blood samples will be collected including ADA, PK, and an 
exploratory biomarker sample.
tPharmacokinetic samples for immunogenicity must be taken prior to drug administration.
uPharmacokinetic samples will be collected for all patients at these visits at time windows of [ADDRESS_526263] dose, as 
assigned by [CONTACT_417384].  Dependent on the time -windows to which a patient gets assigned, they may be required to come to site for 
PK-specific visits.
vAll PROs should be completed before any other study procedures if the patient is not adversely affected by [CONTACT_417385].
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526264] u d y R ati o n al e 
C urre nt i ncret i n - base d i njecta ble treat me nt o pti o ns f or t y pe 2 dia betes mellit us ( T 2 D M) are 
di recte d at a si n gle i ncreti n m o lec ular tar get ( G L P -1 [ gl uca g o n -li ke pe pti de -1]) a n d t heref ore 
c o ul d ha ve t hera pe utic li mitati o ns.  T hese treat me nt o pti o ns offer i m pr o ve d gl yce mic c o ntr ol a n d 
a l o w ri s k of h y p o gl yce mia, a n d ha ve a p ote ntial f or cli nicall y rele va nt wei g ht l oss.  H o we ver, a 
lar ge pr o p orti o n of patie n ts still d o n ot reac h t he treat me nt tar gets des pi[INVESTIGATOR_040] a hi g h le vel o f 
c o m plia nce wi t h  t he treat m e nt re gi me ns.  T heref ore, it is i m p orta nt t o pr o vi de a d dit i o nal 
treat m e nt o pti o ns f or pati e nts t hat all o w f or e n ha nce d gl uc ose c o ntr ol a n d wei g ht l oss w hile 
prese r vi n g a n o verall acce pta ble be nefit/ris k pr ofile ( Star k Casa gra n de et al. 2 0 1 3; Zaccar di et al. 
2 0 1 6). 
Ti rze pati de ( L Y 3 2 9 8 1 7 6) is a o nce -wee kl y d ual GI P ( gl uc ose -de pe n de nt i ns uli n otr o pi c 
p ol y pe pt i de) a n d G L P -[ADDRESS_526265] u d y  I 8 F -M C -G P GI ( G P GI) will c o m pare tirze pati de ( 3 d oses) t o place b o, a d de d t o titrate d 
o nce -dail y  basal i ns uli n glar gi ne i n pat ie nt s wi t h  T 2 D M pre vi o usl y treate d wit h basal i ns ul i n 
( wi t h  or wi t h o ut m et f o r m i n). Des pi[INVESTIGATOR_040] a n i na de q uate gl yce mic c o ntr ol, i ns uli n t hera p y is o ft en 
n ot i nte nsifie d i n t hese patie nts, f or m ult i p le reas o ns, s uc h as c o ncer n f or h y p o gl yce mia or 
w ei g ht gai n ( K h u nt i et al . 2 0 1 6). Se veral st u dies ha ve assesse d t he efficac y a n d safet y of  t he 
a d di ti o n of  a o nce -wee kl y  G L P -[ADDRESS_526266] t o basal i ns uli n i n t his t y p e of  p ati e nts 
( P ozzilli et al .2 0 1 7; G uja et al . 2 0 1 8; R o d bar d et al. 2 0 1 8). H o we ver, there is n o a vaila ble 
e vi de nce o n t he effects of t he c o m bi nat i o n of basal i ns uli n a n d a l o n g -act i n g, o nce -wee kl y  d ual 
GI P/ G L P -[ADDRESS_526267] o n bl o o d gl u c ose ( B G) t o date.  T he c o m bi nati o n o fi ns uli n glar gi ne 
wi t h  ti rze pat i de is e x pecte d t o pr o vi de i m pr o ve d gl uc ose c o n tr ol  a n d atte n uate t he w ei g ht gai n 
a n d h y p o gl yce mi ari s k ass o ci at e d wi t h  t h e m o re i nte nsi ve titrati o n a n d hi g her dail y  d oses of 
i ns uli n glar gi ne .
3. 2. B a c k gr o u n d 
F o ur ti rze pat i de cli nical st u dies ha ve c o m plete d d osi n g a n d a nal ysis:  t w o P hase [ADDRESS_526268] u d y I 8 F -M C -G P G A ( G P G A) a n d I 8 F -M C -G P G C ( G P G C) a n d t w o P hase [ADDRESS_526269] u d y 
I 8 F -M C -G P G B ( G P G B) a n d I 8 F -M C -G P G F ( G P G F). 
P hase [ADDRESS_526270] i gate d safet y,  t ol era bilit y,  p har mac o ki net ics ( P K), a n d 
p har mac o d y na mics ( P D) of ti rze pat i de a d mi nistere d as s u bc uta ne o us (S C )i njecti o ns.  T he C CI 
I8F-MC-GPGI( b) Clinical Protocol Page 24
LY3298176resul ts of this study supported further development of tirzepatide for once weekly ( QW)dosing 
in patients with T2DM (Coskun et al. 2018) .
Study  GPGC was a Phase 1, multiple ascending dose study  conducted in 48 Japanese pat ients 
with T2DM . Safet y, tolerabilit y,and PK/PD profiles of tirzepat ide appeared co mparable to 
previous studies in non -Japanese patients with T2DM, all o f which supports the development of 
QW tirzepat ide in this populat ion.
A 26 -week Phase 2 study  (GPGB) assessed the efficacy, tolerabilit y, and safet y of QW 
administration of 4 doses (1 mg/5 mg/10 mg and 15 mg) of tirzepati deversus placebo and an 
active co mparator (dulaglutide 1.5 mg QW) in 318 pati ents wi th T2DM wi th inadequate 
glycemic control on diet and exercise alo ne or on a stable dose of metformin mo notherapy .  The 
doses of 10 mg and 15 mg were attained by t itration (Frias et al. 2018) .
Study  GPGB dem onstrated that ti rzepat ide 5 mg, 10 mg, and 15 mg doses significantly lowered 
hemoglo bin A1c (HbA1c) and bod y weight in a dose -dependent manner in pat ients with T2DM 
in comparison to pl acebo .  In addit ion, reducti ons in HbA1c in the tirzepat ide 5, 10, and [ADDRESS_526271] of  the tirzepati deadverse events (AEs) were gastrointestinal
(GI)-related, consisting mainly o f nausea, vo miting, and di arrhea and were dose -dependent.  The 
GI AEs were usually mild to m oderate in intensit y.  Seri ous AEs (SAEs) were balanced across 
the treatment groups and none of the groups reported severe hypoglycemia (Frias et al. 2018) . 
As it was recognized that the titration scheme emplo yed in Study GPGB was unlikely to be 
optimal for the reduction of GI -related AEs expected with tirzepat ide, Study  GPGF was designed 
to explore alternat ive titration schemes (longer time intervals between dose escalations and 
different dose escalat ions) to support eval uation of optimized dosing regimen(s) in Phase 3
clinical studies . This was a 12 -week, placebo -controlled study  to assess the efficacy  and safet y 
of 3 different titration schemes to attain doses as high as 15 mg of tirzepatide in patients with 
T2DM.
These data support continued development of tirzepati de as a therapy  for T2DM.  
3.3. Benefit/Risk Assessment
More informat ion about the known and expected benefits, risks, SAEs and reasonably 
anticipated AEs of tirzepatide are to be found in the Invest igator’s Brochure (IB).
In addit ion, detailed informat ion about the known and expected benefits and risks of insuli n 
glargine may be found in the marketed insulin glargine package insert .
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526272] u d y .
T a bl e G P GI . 2. O bj e cti v e s a n d E n d p oi nt s 
O bjecti ves E n d p oi nts 
Pri m ar y 
T o de m o nstrate s u peri orit y of Q W tirze pati de 
1 0 m g a n d / or [ADDRESS_526273] t o 
gl yce mic c o ntr ol at 4 0 wee ks f or: Mea n c ha n ge i n H b A 1c fr o m baseli ne 
Ke y Sec o n d ar y (c o ntr olle d f or t y pe 1 err or) 
Efficac y 
T o de m o nstrate s u peri orit y of Q W tirze pati de 
[ADDRESS_526274] t o gl y ce mic c o ntr ol at 
4 0 wee ks f or: 
T o de m o nstrate s u peri orit y of Q W tirze pati de 
5m g, 1 0 m g, a n d / or [ADDRESS_526275] b o  
w h e n a d de d t o titrate d basal i ns uli n glar gi ne, 
wit h or wit h o ut metf or mi n, at 4 0 wee ks f or :Mea n c ha n ge i n H b A 1c fr o m baseli ne 
Mea n c ha n ge i n b o d y wei g ht fr o m base li ne 
Pr o p orti o n of patie nts wit h H b A 1c tar get 
val ues of < 7. 0 % ( 5 3 m m ol/ m ol) 
Mea n c ha n ge i n fasti n g ser u m gl uc ose (ce ntral 
la b orat o r y ) fr o m baseli ne 
A d diti o n al Sec o n d ar y ( n ot c o ntr olle d f or t y pe 1 
err or) 
Efficac y 
T o c o m pare Q W tirze pati de [ADDRESS_526276] b o at 4 0 wee ks f or: Pr o p orti o n of patie nts ac hie vi n g H b A 1c tar get 
≤ 6. 5 % ( 4 8 m m ol/ m ol) ,< 5. 7 % ( 3 9 m m ol/ m ol) 
Mea n c ha n ge i n dail y  a vera ge 7-p oi nt 
self -m o nit ore d bl o o d gl uc ose pr ofiles fr o m 
baseli ne 
Pr o p orti o n of patie nts w h o ac hie ve d wei g ht 
l oss of ≥ 5 %, ≥ 1 0 %, a n d ≥ 1 5 % fr o m baseli ne 
C ha n ge f r o m baseli ne i n dail y mea n i ns uli n 
glar gi ne d ose 
Safet y 
T o c o m pare Q W tirze pati de [ADDRESS_526277] b o t o t he e n d of safet y 
f oll o w -u p f or: Treat me nt -e mer ge nt a d verse e ve nts ( T E A Es) 
Earl y  disc o nti n uati o n of st u d y dr u g d ue t o 
a d verse e ve nts ( A Es) 
A dj u dicate d pa ncreatic A Es 
Ser u m calcit o ni n 
I nci de nce of aller gic a n d h y perse nsiti vit y 
reacti o ns 
I8F-MC-GPGI( b) Clinical Protocol Page 26
LY3298176Objectives Endpoints
Incidence of treatment -emergent antidrug 
antibodies to tirzepatide
Mean change in syst olic and diastolic blood 
pressure and heart rate from baseline 
Occurrence of hypoglycemic epi[INVESTIGATOR_1841]
Incidence of initiation of rescue therapy for 
severe, persistent hyperglycemia 
Pharmacokinetics
To characterize the pharmacokinetics (PK) of 
QW tirzepatide 5 mg, 10 mg, and 15 mg 
doses and the relationships between 
tirzepatide exposure and safety, tolerability, 
and efficacy measures for:Population PK and PDparameters
Tertiary/Exploratory
To compare QW tirzepatide 5 mg, 10 mg, and 
15 mg to placebo at 40 weeks for :Mean change in lipi[INVESTIGATOR_805] (total cholesterol, HDL, 
LDL, VLDL, and TG)
Mean change in waist circumference
Changes from baseline in mean body mass 
index 
Biomarkers
Patient- reported outcomes
o Ability to Perform Physical 
Activities of Daily Living
o Impact of Weight on Self -Perception
o Diabetes Treatment Satisfaction 
Questionnaire status/ Diabetes 
Treatment Satisfaction Questionnaire 
change
o European Quality of Life -5 
Dimensions-5 level
Abbreviations: HbA1c =hemoglobin A1c ; HDL= high -density lipoprotein; LDL = low -density  lipoprotein; 
PD=pharmacodynamics; PK=pharmacokinetics; QW = once weekly; TG = triglycerides; VLDL = very 
low-density  lipoprotein.
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526278] ace b o f or c ha n ge fr o m baseli ne i n H b A 1c i n patie nts 
wi t h  T 2 D M recei vi n g titrate d basal i ns uli n glar gi ne ( wi t h  or wi t h o ut m et f o r mi n) o ver a 4 0 -wee k 
treat m e nt.  A p pr o xi matel y, 4 7 2 patie nts wit h T 2 D M w h o ha ve bee n treate d wit h i ns uli n glar gi ne 
( U 1 0 0), o nce dail y wit h or wit h o ut metf or mi n ≥ 3 m o n t h s pri or t o Vi si t 1, will be ra n d o mize d 
(see Secti o n 2). 
St u d y  G P GI will c o nsist of 3 peri o ds:  a n a p pr o xi matel y 3 -wee k scree ni n g/lea d -i n peri o d, 
f o ll o we d b y a 4 0 -wee k treat m e nt peri o d a n d a 4 -wee k safet y f o ll o w- u p peri o d.  Patie nts will be 
ra n d o mize d i n a 1: 1: 1: 1 rati o (tirze pat i de [ADDRESS_526279] ace b o).  Patie nts will be stratifie d base d o n c o u ntr y , baseli ne H b A 1c ( ≤ 8. 0 % or >8. 0% [≤ 6 4, 
˃ 6 4m m o l/ m o l]), a n d baseli ne met f o r mi n use ( Yes or N o) .
St u d y  g o ver na nce c o nsi derati o ns are descri be d i n detail i n A p pe n di x [ADDRESS_526280] u d y desi g n .
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e 2 8 
LY 3 2 9 8 1 7 6 aSta bilizati o n Peri o d = first [ADDRESS_526281] me nts.  I ns uli n Glar gi ne Titrati o n Peri o d Wee ks 4  t o 4 0 (e n d of 
treat me nt/e n d of st u d y), wit h u nrestricte d i ns uli n d ose a dj ust me nts.  Mai nte na nce 
Peri o d = Wee ks 2 4 t o 4 0 (e n d of treat me nt/e n d of st u d y), t he peri o d w he n i ns uli n 
glar gi ne d ose is e x pecte d t o be sta ble. 
Fi g ur e G P GI . 1. Ill u str ati o n of st u d y d e si g n f or Cli ni c al Pr ot o c ol I [ADDRESS_526282] u d y Peri o d I ( Scree ni n g a n d Le a d -i n) 
Scree ni n g ( Visit 1) 
T he p ur p ose of scree ni n g pr oce d ures at Visit 1 is t o esta blis h i nit ial eli gi bilit y a n d t o o btai n 
bl o o d sa m ples f or l a b orat or y  assess me nts nee de d t o c o nfir m eli gi bilit y at Vi si t 2. 
T he patie nt will si g n t he i nf or me d c o nse nt f or m (I C F) be f o re a n y  st u d y  
pr oce d ures are perf or me d. 
Pr oce d ures at t his visit will be p erf or me d as s h o w n i n t he St u d y  Sc he d ule of 
Act i vit ies, Secti o n 2.
P ati e nts w h o m eet all a p plica ble i ncl usi o n cri t eri a a n d n o ne of t he a p plica ble 
e xcl usi o n cri teria ( Secti o n 6) at Vi si t [ADDRESS_526283] u d y  t h era p y  
d oses bet wee n Visits 1 a n d 2. 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e 2 9 
LY 3 2 9 8 1 7 6 Le a d -i n ( Visit 2 t o Visit 3) 
At  Visit 2 :
Scree ni n g la b orat or y  res ul ts will be re vie we d.  F or t h ose patie nts meet i n g all ot her 
eli gi bilit y re q ui re me nts, a dilate d f u n d osc o pic e xa mi nat i o n perf or me d b y a n 
o p ht hal m o l o gist or o pt o m etri st, m ust be c o m plete d bet wee n Visit 2 a n d Visit 3 t o e ns ure 
t h at pa ti e nts wi t h  pr oliferat i ve dia betic reti n o pat h y, dia bet ic mac ul o pat h y, or 
n o n pr o liferat i ve dia bet ic reti n o pat h y w h o re q uire ac ute treat me nt, are i de ntifie d a n d n ot 
e nr o lle d. 
Pati e nts a n d t heir care gi ver(s), if a p plica ble, will recei ve a gl uc o meter a n d trai n i n g o n 
h o w t o perf or m self -m o nit ori n g o f bl o o d gl uc ose ( S M B G). 
P ati e nts will  b e pr o vi de d diaries a n d will be trai ne d as a p pr o priate t o rec or d ;
oB G val ues, 
oh y p o gl yce mic e ve nts, 
oi ns uli n d ose assess me nts usi n g t he treat t o tar get (T T T )al g orit h m, 
ome dicat i o ns, a n d 
oa d verse e ve nts .  
P ati e nts will  b e trai ne d o n disease ma na ge me nt a n d st u d y  pr oce d ures; t hi s trai ni n g ca n be 
re peate d at s u bse q ue nt visit s as dee me d a p pr o priate. 
P ati e nts will  b e trai ne d (if nee de d ) t o f o ll o w i nstr ucti o ns f or use of t he i ns uli n gla r gi ne 
pr efille d pe n t hat t he y  are usi n g. 
After Vi si t 2 :
P ati e nts will  start i ns uli n d ose assess me nts o nce wee kl y f or t he re mai n der of t he lea d -i n 
p eri o d (t he use of t he al g orit h m is restricte d d uri n g t he lea d -i n a n d sta bilizati o n peri o ds, 
as descri be d bel o w). 
P ati e nts will be re q ueste d t o perf or m 4-p oi nt S M BG pr ofiles at least o nce wee kl y , 
starti n g at Visit 2 .
P ati e nts will  n ee d t o perf or m t w o 7 -p oi nt S M B G pr ofiles d o ne o n 2 n o nc o nsec ut i ve da ys 
i n t h e 2- wee k p eri o d pri or t o Vi si t 3 (ra n d o mizati o n) a n d Visit 2 2 ( Wee k 4 0). 
D uri n g t he l ea d -i n peri o d, patie nts s h o ul d c o nti n ue t heir prest u d y  t hera p y  a n d s h o ul d n ot 
c ha n ge t he d ose , i n or der t o all o w relia ble assess me nt o f H b A 1c at baseli ne ( Visit 3). 
I ns uli n d oses s h o ul d be a dj uste d o nl y f or t he safet y o f t h e st u d y  p arti ci pa nts ( occ urre nce 
of  h y p o gl yce mia d ue t o i na de q uate i ns uli n d ose or se vere h y per gl yce mia, defi ne d as 
mea n dail y  B G f r o m  4 -p oi nt S M BG pr ofile > 2 7 0 m g/ d L [ > 1 5 m m o l/ L]. I n t hese 
si t u ati o ns, t he pati e nt s h o ul d c o ntact t he site i n or der t o a dj ust t he d ose per t he T T T 
al g ori t h m  (see Sect i o n 7. 2 ,Ta ble G P GI . 2 ). 
P ati e nts w h o are ta ki n g c o nc o mita nt met f o r mi n a n d de vel o p a n y c o n di ti o n  t h at i s a 
c o ntrai n dicat i o n f o r i ts use will be c o nsi dere d i neli gi ble a n d will be disc o nti n ue d fr o m 
t h e tri al bef ore ra n d o mizati o n. 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526284] u d y Peri o d II ( 4 0 - W ee k Tre at me nt Peri o d) 
R a n d o miz ati o n ( Visit 3) 
At  Visit 3 :
Eli gi ble pat ie nt s will perf or m all re q uire d baseli ne st u d y pr oce d ures (i ncl u di n g t he 
c ollect i o n of all baseli ne la b orat or y meas ures a n d E C G ) pri or t o ra n d o mizat i o n a n d pri or 
t o ta ki n g t he first d ose of st u d y  dr u g.  
P ati e nt ss h o ul d arri ve t o t he cli nic i n t he fast i n g state; t he fast i n g state s h o ul d ha ve laste d 
at l east [ADDRESS_526285] u g, i ns uli n glar gi ne a n d 
met for mi n (i f use d).   
Res p o nsi ble st u d y -si te pers o n nel will re vie w t he diar y  a n d assess t he nee d t o a dj ust t he 
i ns uli n glar gi ne d ose per t h e T T T al g ori t h m  cri teria ( Ta ble G P GI. 3). O nl y patie nts w h o 
re q ui r e f urt her i ns uli n glar gi ne d ose i ncrease, as i n dicate d b y  F BG a b o ve t he tar get 
c o nce ntrati o n per t he T T T al g orit h m (see Secti o n 7. 1 ) d uri n g t he wee k pri or t o t he visit, 
will be eli gi ble f or f urt her partici pati o n i n t he st u d y. 
T he q uest i o n naires ( E ur o pea n Q ualit y of Life [ E Q - 5 D- 5 L], A bilit y t o Perf or m P h ysical 
Act i vit ies o f Dail y Li vi n g [ A P P A D L], I m pact of Wei g ht o n Self -Perce pt i o n[I W -S P], 
a n d Dia betes Treat m e nt Sati sfact i o n Q uest i o n naire stat us [ D T S Qs]) s h o ul d be c o m p lete d 
bef ore a n y ot her st u d y  pr oce d ures if t he patie nt is n ot a d versel y  affecte d b y  t he fast i n g 
c o n di ti o n or c o m plete d after t he patie nt has s ufficie nt l y rec o vere d fr o m t he prece di n g 
visit pr oce d ures.  
P ati e nts will  b e i nstr ucte d o n h o w t o use t he si n gle -d ose pe n ( S D P) wit ha de m o nstrati o n 
pe n .
Tre at me nt peri o d :Ge ner al C o nsi der ati o ns 
T he treat m e nt peri o d will last 4 0 wee ks, starti n g wit h a 4 -wee k sta bilizat i o n peri o d i m me diatel y  
af ter ra n d o mizat i o n a n d f o ll o we d b y a 3 6 -wee k gl ar gi ne ti tr ati o n peri o d. T he mai nte na nce 
p eri o d is defi ne d as a part of t he titrati o n peri o d w he n i ns uli n glar gi ne d os e i s e x pecte d t o be 
sta ble a n d o pti mize d ( Wee ks 2 4 t o 4 0 [ Visits 1 9 t o 2 2 ]). Patie nts s h o ul d i nject t heir first d ose of 
st u d y  dr u g u n der t he s u per visi o n o f t h e staff at Visit 3 ( baseli ne) w hile st ill at t he st u d y  si t e. T he 
date a n d ti me of t he first d ose of st u d y  dr u g s h o ul d be rec or de d o n t he el ectr o nic case re p ort 
f o r m  ( e C R F) .
P ati e nts will :
perf or m  dail y B G meas ure me nts per t heir wee kl y S M B G pla n as o utli ne d i n t his sect i o n 
a n d i n Sect i o n 2. 
perf or m  i ns uli n glar gi ne d ose assess me nts o nce or t wice per wee k, de pe n di n g o n t he 
st u d y  p eri o d, as descri be d i n t he secti o ns bel o w. 
di sc uss ot her rel e va nt cli nical i nf or mati o n, f or e xa m ple, A Es a n d c o n c o mita nt 
me dicat i o ns at eac h visit. Patie nts w h o are ta ki n g c o nc o mita nt metf or mi n d uri n g t he 
lea d -i n peri o d will be re q uire d t o c o nti n ue usi n g t he sa me d ose of met f o r mi n t hr o u g h o ut 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e 3 1 
LY 3 2 9 8 1 7 6 t h e treat me nt peri o d. Disc o nti n uati o n o f met f o r mi n or c ha n ges i n its d ose will n ot be 
per mitte d, e xce pt i n t he cases of de vel o p me nt of c o ntrai n dicat i o ns ( per c o u ntr y -s pecific 
la bel) f or its use or i n t he case of i ncrease d ri s k of h y p o gl yce mia (see Sect i o n7. 4. 2 f o r 
details). 
T he starti n g d ose of ti rze pat i de will be 2. [ADDRESS_526286] u d y  i n t he 5 m g gr o u p.  F or t he 1 0 m g gr o u p, t he star ti n g d ose of 
ti rze pat i de will be 2. 5 m g Q W f or 4 wee ks, t he n t he d ose will be i ncrease d b y 2. 5 m g e ver y 
4wee ks ( 2. 5 t o 5 t o 7. 5 t o 1 0 m g) u ntil t he [ADDRESS_526287] u d y .  F or t he 1 5 m g gr o u p, t he starti n g d ose of  ti rze pat i de will be 2. 5 m g Q W 
f o r 4 wee ks, t he n t he d ose will be i ncrease d b y  2. 5 m g e ver y  4 wee ks ( 2. 5 t o 5 t o 7. 5 t o 1 0 t o 
1 2. 5 t o 1 5 m g) u nt il t he [ADDRESS_526288] r a n d o miz ati o n peri o d (e n d of Visit 3 t o Visit 2 2): 
Sta bilizat i o n Peri o d ( E n d of Vi si t 3 t hr o u g h Visi t 7 [ Wee ks 0 t hr o u g h 4]) 
T he m ai n p ur p oses of t hi s peri o d are t o i ntr o d uce ra n d o mize d st u d y  dr u gs ( Q W ti rze pati d e or 
Q W place b o) i n a safe ma n ner, t o ass ure re g ular a n d c orrect use of t he self -m o nit ori n g a n d 
i ns uli n d ose a dj ust me nt  pr oce d ures ,a n d t o st u d y diaries d uri n g t he e ntire st u d y . Patie nts will be 
re q ui re d t o perf or m 4-p oi nt S M B G pr ofiles a n d i ns uli n d ose assess me nt per t he T T T al g orit h m 
t wi ce wee kl y d uri n g t his peri o d. I n a n eff ort t o all o w a p pr o priate ti me f or ti rze pat i de t o reac h 
stea d y state, i ns uli n glar gi ne d ose a dj ust me nt s d uri n g t he 4 -wee k sta bilizat i o n peri o d s h o ul d be 
restri cte d t o t h ose nee de d i n t he case of si g nifica nt safet y ri s ks d ue t o i na de q uate i ns uli n d ose: 
occ urre nce of h y p o gl yce mia; (see Secti o n s7. 4. 2 a n d 9. 2. 2. 1 ); i n t his case, t he i ns uli n 
gl ar gi ne d ose will be decrease d per t he T T T al g orit h m; or 
de vel o p me nt of se vere h y per gl yce mia, defi ne d as mea n dail y  P G f r o m  4 -p oi nt S M BG 
pr ofile > 2 7 0 m g/ d L ( > 1 5 m m o l/ L); i n t his case, i ns uli n d ose will be i ncrease d per t he 
T T T al g ori t h m . 
P ati e nts s h o ul d be i nstr ucte d t o c o n tact t he si tes if a n y of t he a b o ve sit uati o ns occ urre d, i n or der 
t o a dj ust t he i ns uli n glar gi ne d ose per t he T T T al g orit h m. I n a d dit i o n, f or patie nts wit h baseli ne 
H b A 1c ≤ 8. 0 %, t he i ns uli n glar gi ne d ose will be decrease d b y 2 0 % i m me diatel y  af t er 
ra n d o mizat i o n, n ot later t ha n [ADDRESS_526289] u g, a n d will t he n re ma i n 
u nc ha n ge d d uri n g t he sta bilizat i o n peri o d t o decrease t he ris k of h y p o gl yce mia. T he i ns uli n 
gl ar gi ne d ose will re mai n u nc ha n ge d if baseli ne H b A 1c is > 8. 0%. If t he baseli ne H b A 1c val ue 
f o r a pati e nt i s n ot a vaila ble wit hi n t he first [ADDRESS_526290] u d y  si te s h o ul d 
i m me diatel y  c o ns ul t t he res p o nsi ble Lill y p h ysicia n ( n ot later t ha n t he date of Visit 4) t o disc uss 
if a n a dj ust me nt  i n i ns uli n d ose w o ul d be a p pr o priate base d o n t he a vaila ble cli nical data f or t he 
patie nt. 
I n a d dit i o n t o t h e cli nic visit s, o ne tele p h o ne visit will be sc he d ule d d uri n g t his peri o d ( V isit  6, 
Wee k 3). At  t his visit, pr oce d ures will i ncl u de 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e 3 2 
LY 3 2 9 8 1 7 6 assess me nts of S M B G, 
a dj ust m e nt of  i ns uli n d ose f or safet y reas o ns ( h y p o gl yce mia a n d/ or se vere 
h y per gl yce mia) , 
st u d y  dr u g c o m plia nce ( will be re -assesse d at t he office visit), 
h y p o gl yce mic e ve nts, 
c o nc o mita nt me dicat i o ns, a n d 
A Es. 
T he data o btai ne d at t hese tele p h o ne visit s will be e ntere d i nt o t he case re p ort f o r m s ( C R Fs )at 
t h e ne xt office visit. 
Ti tr ati o n Peri o d ( E n d of  Visi t 7 t hr o u g h Visit 2 2 [ Wee ks 5 t hr o u g h 4 0]) 
T hr o u g h o ut t he treat me nt p eri o d, patie nts will c ollect t he f o ll o wi n g data i n t he patie nt diar y  t o be 
re vie we d at t he ne xt office visit :
S M B G, 
i ns uli n d ose assess me nts, 
i ns uli n d oses a d mi nistere d, 
dates w he n st u d y dr u g was a d mi nistere d, a n d 
h y p o gl yce mic e ve nts. 
F or t hat p ur p ose, at eac h visit, st u d y  di ari es f or t he peri o d af ter t he pre vi o us office visit, will be 
c ollecte d, a n d i nstr ucti o ns will be re vie we d at eac h visit.  St u d y  dr u g a n d i nject i o n s u p pli es will  
be ret ur ne d per t he Sc he d ule of Act i vit ie s ( Secti o n 2) a n d acc or di n g t o l ocal re q uire me nts.  Ne w 
s u p plies will be dis pe nse d as nee de d.  
I n a d di ti o n t o t he cli nic visit s, 3 tele p h o ne visits will be sc he d ule d d uri n g t his peri o d . At eac h of 
t h ese visit s, pr oce d ures will i ncl u de 
assess me nts of S M B G, 
c o m plia nce wi t h  i ns uli n t it rati o n al g orit h m, 
i ns uli n d ose, 
st u d y  dr u g c o m plia nce ( will be re -assesse d at t he office visit), 
h y p o gl yce mic e ve nts, 
c o nc o mita nt me dicat i o ns, a n d 
A Es. 
T he data o btai ne d at t h ese tele p h o ne visit s will be e ntere d i nt o t he C R Fs at t he ne xt office visit. 
At  t he be gi n ni n g of t he titrati o n peri o d, t he patie nt will be i nstr ucte d t o start usi n g t he T T T 
al g ori t h m  wi t h o ut restri ct i o ns i n or der t o reac h t he o pti mal d ose of i ns uli n glar gi ne as s o o n as 
p ossi ble. T he patie nt will be re q ueste d t o perf or m i ns uli n d os e assess me nt o nce wee kl y  d uri n g 
t hi s peri o d. Res ults of S M B G a n d h y p o gl yce mic e ve nts will be use d b y t he patie nt t o assess 
i ns uli n glar gi ne d oses per t he titrati o n al g orit h m. A d dit i o nal assess me nts ma y  b e re q ueste d b y  
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526291] u g a d mi nistrati o n sc he d ule a n d c o m plia nce wi t h  t he i ns uli n glar gi ne 
ti tr ati o n al g ori t h m will be assesse d at e ver y  office visit a n d c ollecte d i n t he e C R F at pres pecifie d 
visit s ( Secti o n 2). Base d o n t he o utc o me of t hese re vie ws, t he site staff s h o ul d disc uss a d di ti o nal 
i ns uli n glar gi ne d ose a dj ust me n ts w hile t he patie nt is st ill at t he site a n d pr o vi de retrai ni n g , if  
nee de d. 
P ati e nts s h o ul d be i nstr ucte d t o c o n tact t he i n vesti gati ve site f or assista nce as s o o n as p ossi ble if 
t h e y  e x perie nce a n y  diffic ul ti es a d mi nisteri n g t heir st u d y dr u gs or wi t h  t he ti tr ati o n al g ori t h m at 
a n y ti me d uri n g t he st u d y .  Pati e nts s h o ul d als o be a d vise d a b o ut t he a p pr o priate c o urse of act i o n 
i n t he e ve nt t hat st u d y  dr u g i s n ot ta ke n as i nstr ucte d (f or e xa m ple; missi n g d oses). 
St u d y Peri o d I II ( S afet y Foll o w -u p Peri o d) 
S afety f oll o w -u p ( Visit 8 0 1) visits: 
All patie nts w h o c o m plete t he treat me nt peri o d are re q uire d t o c o m plete Visit [ADDRESS_526292] visit.  
P ati e nts di sc o nt i n ui n g t he st u d y earl y a n d perf or mi n g a n earl y ter mi nat i o n ( E T) visit will 
als o be as ke d t o perf or m t he safet y f o ll o w- u p visit, s o t hat t he safet y f o ll o w- u p visit will 
be t heir fi nal visit.  
D uri n g t he safet y f o ll o w- u p peri o d, pati e nt s will n ot recei ve st u d y  dr u g. 
P ati e nts will  b e treate d wi t h  a n ot h er gl uc ose -l o weri n g i nter ve nt i o n deci de d u p o n b y t he 
i n vesti gat or.  I nit iat i o n of ne w a nt i h y per gl yce mic t hera p y f or t he safet y f o ll o w- u p peri o d 
will n ot be classifie d as “resc ue t hera p y . ” 
P ati e nts are als o re q uire d t o ret ur n a n y  re mai ni n g st u d y  di aries t o t h e st u d y site at t he e n d 
of  t hi s peri o d. 
St u d y Pr oce d ures 
P ati e nts will  p erf or m  st u d y  pr oce d ures liste d i n t he Sc he d ule of Acti vit ies ( Secti o n 2). 
P ati e nts will  b e per mitte d t o use c o nc o mita nt me dicati o ns t hat t he y  r e q ui re d uri n g t he st u d y , 
e xce pt certai n me dicat i o ns t hat ma y i nterfere wit h t he assess me nt of efficac y a n d safet y 
c haracterist ic s of t he st u d y  tr e at m e nts.  A nt i h y per gl yce mic me dicat i o ns ot h er t ha n st u d y  dr u gs 
are n ot all o we d at a n y  ti me d uri n g t he st u d y  e xce pt as all o we d f or resc ue t hera p y  a n d/ or after 
earl y  st u d y  dr u g disc o nt i n uat i o n.  Resc ue t hera p y  wi t h  ot her gl u c os e -l o weri n g a ge nts, i ncl u di n g 
pra n dial i ns uli n, ma y be me dicall y  i n dicat e d i n certai n sit uat i o ns after ra n d o mizati o n d ue t o 
se vere, persiste nt h y per gl yce mia or earl y disc o nt i n uati o n of st u d y  treat m e nt.  Gl uca g o n -li ke 
pe pti de- 1 rece pt or a g o ni sts, di pe pt i d yl pe pt i dase ( D P P -4) i n hi bit ors, a n d pra mli nt i de are 
pr o hi bite d me dicat i o ns a n d are n ot all o we d as resc ue t hera pi[INVESTIGATOR_014].  N o ot her basal i ns uli ns are 
all o we d d uri n g t he c o urse of t he st u d y .
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e 3 4 
LY 3 2 9 8 1 7 6 P ati e nts w h o de vel o p se vere, persiste nt h y per gl yce mia base d o n pres pecifie d t hres h o l d s (see 
Secti o n 9. 2. 2. 2 ) will recei ve a ne w gl uc ose -l o weri n g i nter ve nt i o n (“resc ue t hera p y”) a n d will 
als o c o nti n ue t o a d mi nister st u d y  dr u g.  Pati e nts w h o nee d h y per gl yce mic resc ue t hera p y  will 
c o nti n ue i n t h e st u d y  u nt il t he y c o m p lete all st u d y  visit s.  
St u d y  g o ver na nce c o nsi derati o ns are descri be d i n detail i n A p pe n di x 3 .
5. 2. N u m b er of P arti ci p a nt s 
A t otal  of  a p pr o xi matel y  4 7 2 pat ie nt s ( [ADDRESS_526293] b o) will be 
ra n d o mize d. 
5. 3. E n d of St u d y D efi niti o n 
E n d of t he st u d y is t he date of t he last visit or last sc he d ule d pr oce d ure s h o w n i n t he Sc he d ule o f 
Act i vit ies ( Secti o n 2)f o r t he last patie nt .
5. 4. S ci e ntifi c R ati o n al e f or St u d y D e si g n 
St u d y  G P GI is desi g ne d t o deter mi ne t he c o m parati ve be nefit s a n d ri s ks o f Q W ti rze pa ti de 
( 5 m g, 1 0 m g, or 1 5 m g)vers us place b o i n pat ie nt s wit h T [ADDRESS_526294] a n ne d treat me nt d urati o n of 4 0 wee ks is c o nsi dere d 
a p pr o priate t o assess t he f ull effects a n d be nefit/ris k of eac h mai nte na nce d ose of tirze pat i de o n 
b ot h gl yce mic c o ntr ol a n d b o d y  wei g ht as re q ueste d b y t he F D A. M ore o ver, t he d urati o n of t he 
st u d y  i s c o nsi dere d s ufficie nt a n d a p pr o priate f or patie nts t o o pti mize d osi n g of i ns uli n glar gi ne 
i n t he place b o gr o u p f or c o m paris o n wit h t he tirze pati de treat me nt gr o u ps wit h res pect t o c ha n ge 
i n H b A 1c. 
T he parallel - g r o u p desi g n f or treat me nt c o m paris o n was c h ose n t o a v oi d a n y i nteracti o n bet wee n 
treat m e nts t hat m a y i nterfere wit h t he i nter pretati o n of t he st u d y  o utc o m e.  T o mi ni mize t he 
p ote nti al  c o nf o u n di n g effect of c ha n ges t o c o nc o mita nt me dicati o ns, patie nts will be per mitte d t o 
use c o nc o mita nt me dicat i o ns t hat t he y  r e q ui re d uri n g t he st u d y .  Me dicat i o ns t hat ma y i nterfere 
wi t h  t he assess me nt of efficac y  a n d safet y c haracteri st ics o f t h e st u d y  treat m e nts will  n ot be 
all o we d (see Sect i o n7. 7 ).  Metf or mi n was c h ose n as all o we d c o nc o mit a nt a nti h y per gl yce mic 
me dicat i o n as it i s c o m m o nl y  use d i n c o m bi nat i o n wi t h  basal i ns uli n i n cli nical pract ice. 
5. 5. J u stifi c ati o n f or D o s e 
Ti rze pati d e d oses of [ADDRESS_526295] u d y . 
T hese d oses a n d ass ociate d escalat i o n sc he mes were selecte d base d o n assess me nt of safet y,  
efficac y  ( gl yce mic a n d wei g ht l oss be nefit), a n d GI t ole ra bili t y  data f oll o w e d b y  e x p os ure 
res p o nse m o deli n g of data i n patie nts wit h T [ADDRESS_526296] u dies.  D osi n g al g orit h ms 
starti n g at a l o w d ose of 2. 5 m g acc o m pa nie d b y d ose escalat i o n of 2. 5 m g i ncre me nts e ver y  
I8F-MC-GPGI( b) Clinical Protocol Page [ADDRESS_526297] level doses in 6 -month monkey and rat toxico logy studi es.
The selected dose and escalation scheme woul d enable further evaluat ion of benefit/risk 
considerations for 5 mg, 10 mg, and 15 mg doses of tirzepat ide.
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526298] u d y  o nl y  if t h e y  m eet all  of  t h e f oll o wi n g criteria at 
scree ni n g :
T y pe of P atie nt a n d Dise ase C h ar acteristics 
[ 1] Ha ve b ee n dia g n ose d wi t h  T 2 D M base d o n t he W orl d H eal t h  O r ga nizat i o n
cl assificat i o n or ot her l ocall y a p plica ble dia g n ostic sta n dar ds a n d ha ve bee n 
treate d wit h i ns uli n glar gi ne ( U 1 0 0), o nce dai l y  wi t h  or wi t h o ut m etf or m i n 
≥ 3 m o nt hs pri or t o Visit 1 
P atie nt C h ar acteristics 
[ 2] Ha ve H b A 1c ≥ 7. 0 % ( 5 3 m m o l/ m o l)  t o ≤ 1 0. 5 % ( 9 1 m m o l/ m o l) , as deter mi ne d b y  
t h e ce ntral  l a b orat or y  at Vi si t 1 
[ 3] Ha ve bee n o n sta ble d oses of o nce -dail y i ns uli n glar gi ne ( > 0. 2 5 U/ k g/ da y  or 
> 2 0 U/ da y ) a n d metf or mi n (if ta ke n) d uri n g t he 3 -m o nt h peri o d pri or t o Vi si t 1.  
Ins uli n glar gi ne d os e i s c o nsi dere d sta ble w he n all d oses d uri n g t his peri o d are 
wi t hi n t he ra n ge defi ne d b y  ± 2 0 % of  t he m ost c o m m o nl y  use d i ns uli n d ose d uri n g 
t hi s sa me peri o d.  D oses of met f o r mi n are c o nsi dere d sta ble if a ll prescri be d d oses 
d uri n g t hi s peri o d are i n t he ra n ge bet wee n t he mi ni m u m re q uire d d ose 
(≥ 1 5 0 0 m g/ da y ) a n d t he m a xi m u m  a p pr o ve d d ose per t he l ocall y  a p pr o ve d la bel 
[ 4] Re q ui r e f urt her i ns uli n glar gi ne d ose i ncrease at Visit 3 per t he T T T al g orit h m 
base d o n t he S M B G data c ollecte d d uri n g t he pri or wee k 
[ 5] Are of sta ble wei g ht ( ± 5 %) ≥ 3 m o nt hs pri or t o Visit 1 a n d a gree t o n ot i nit iate a 
di et a n d/ or e xercise pr o gra m d uri n g t he st u d y wit h t he i nte nt of re d uci n g b o d y 
w ei g ht ot her t ha n t he lifest yle a n d dietar y me as ures f or di a betes treat m e nt 
[ 6] Ha ve b o d y  m ass i n de x ( B MI) ≥ 2 3k g/ m 2 at Vi si t 1 
[ 7] Are 1 8 y e ars ol d or of a n acce pta ble a ge t o pr o vi de i nf or me d c o nse nt acc or di n g t o 
l o cal re g ulati o ns, w hic he ver is ol der 
(a) Mal e pati e n ts: 
Male patie nts s h o ul d be wi lli n g t o use relia ble c o ntrace pti ve met h o ds t hr o u g h o ut 
t h e st u d y  a n d f or at least [ADDRESS_526299] i o n (A p pe n di x 6 )
( b) Fe male patie nts: 
I8F-MC-GPGI( b) Clinical Protocol Page 37
LY3298176Female pat ients not of childbearing potential due to surgical sterilizat ion 
(hysterectomy or bilateral oophorectomy  or tubal  ligat ion), congenital ano maly 
(i.e.,Mulleri an agenesis) or menopause.
oWomen with an intact uterus are deemed postmenopausal if they are 45 
years o ld, and
have not taken hormones or oral contraceptives within the last y ear 
and had cessat ion of menses for at least 1 y ear,
OR
have had at least 6 month s and l ess than 12 m onths of spontaneous 
amenorrhea wi th follicle-stimulat ing hormone (FSH) and estradio l 
levels consistent with a postmenopausal state (FSH ≥ 40 m IU/mL 
and estradio l <30pg/m L).
oFemale pat ients of childbearing potential (not surgically sterilized and
between m enarche and 1 -year postm enopausal ) must:
test negative for pregnancy  at Vi sit [ADDRESS_526300]
AND
if sexually  active, agree to use 2forms of effect ive contraception, 
where at least one form is highly effective for the duration of the 
trial and f or 30 days thereafter 
not be breastfeeding
[8] In the invest igator’s opi[INVESTIGATOR_3078] n, are well -motivated, capable, and willing to: 
(a) perform  fingerst ick BG mo nitoring, including scheduled BG profiles wit h up to 7 
measurements in 1 day  
(b) learn how to self- inject study  drugs as requi red for thi s protocol  (visually  impaired 
persons who are not able to perform the inject ions must have the assistance of a 
sighted individual trained to inject the study  drug; persons wi th physical li mitat ions 
who are not able to perform the inject ions must have the assistance of an individual 
trained to inject the study  drug) 
(c) are willing and able to inject study drugs
(d) maintain a study  diary , as requi red for this protocol
(e) have a sufficient understanding of one of the provided languages of the country  
such that they  will be able to com plete the pati ent questionnaires
Informed Consent
[9]Have given written informed consent to participate in this study  in accordance 
with local regulat ions and the ethical review board (ERB) governing the study  site
I8F-MC-GPGI( b) Clinical Protocol Page 38
LY32981766.2. Exclusion Criteria
Patients will  be excluded from  study  enro llment if they meet any o f the following cri teria at 
screening:
Medical Conditions
[10]Have t ype 1 diabetes mellitus (T1DM)
[11]Had chronic or acute pancreatit is any t ime prior to study entry (Visit 1)
[12]Have history  of:
proliferat ivediabet icretinopathy  
or 
diabetic maculopathy 
or
nonpro liferat ive diabet ic retinopathy that requires acute treatment
(adilated fundoscopic examinat ion per formed by [CONTACT_417386] 2 and Visit 3 is required to confirm eligibilit y) 
[13]Have a history  of severe hypogly cemia and/or hy poglycemia unawareness within 
the 6 m onths pri or to Vi sit 1
[14]Have a history  of diabetic ketoacidosis or hy perosm olar state/com a 
[15]Have a known clinically significant gastric empt ying abnormalit y (for example, 
severe diabet ic gastroparesis or gastric outlet obstruction), have undergone or 
plan to have during the course of the study :  a gastric by[CONTACT_6476] (bariatric) surgery  
or restri ctive bariatric surgery (for example, Lap -Band®), or chroni cally take 
drugs that direct ly affect GImotility
[16]Have any of the fo llowing cardi ovascular (CV)condit ions within 2 months prior 
to Visit 1:  acute my ocardial  infarct ion, or cerebrovascular accident (stroke) or 
hospi [INVESTIGATOR_126145] (CHF)
[17]Have [LOCATION_001] Heart Associat ion Funct ional Classification III and IVCHF
[18]Have acute or chronic hepat itis, signs and symptoms of any other liver disease 
other than nonalcoho lic fatty liver disease (NAFLD), or alanine aminotransferase 
(ALT) level >3.0 times the upper limit of the reference range, as determined by  
[CONTACT_126158]; patients with NAFLD are eligible for 
participat ion in this trial only if thei r ALT level  is ≤3.0times the upper limit of 
norm al (ULN) for the reference range
[19]Have an est imated glomerular filtration rate <30 mL/min/1.73 m2, calculated by  
[INVESTIGATOR_19957] -Epi[INVESTIGATOR_417378] 1; for pati ents on m etformin, estimated glo merular filtrat ion rate 
<45mL/min/1.73 m2(or lo wer than the country -specific thresho ld for using the 
protocol -requi red dose of metformin per local label)
I8F-MC-GPGI( b) Clinical Protocol Page 39
LY3298176[20] Have evidence of a significant, uncontrolled endocrine abnormalit y (for 
example, thy rotoxi cosis or adrenal crises), in the opi[INVESTIGATOR_3078] n of the invest igator
[21]Have family or personal history  of medullary thy roid carcino ma (MTC) or 
multiple endocrine neoplasia syndro me type 2
[22]Have a serum calcitonin level of ≥35ng/L, as determined by [CONTACT_126159] 1
[23] Known or suspected hypersensit ivity to trial product(s) or related products
[24]Have evidence of a significant, active autoimmune abnormalit y (for example, 
lupus or rheumatoid arthrit is) that, in the opi[INVESTIGATOR_35272], is likely to 
requi re concurrent treatment wit h systemic glucocorti coids in the next 12months
[25] Have had a transplanted organ (corneal transplants [keratoplasty] allowed) or 
awaiting an organ transplant
[26]Have a history  of an act ive or untreated malignancy or are in remissio n from a 
clinically significant m alignancy (other than basal or squamous cell skin cancer, 
in situ carcinom as of  the cervix, or in situ prostate cancer) for less than 5 y ears
[27]Have a history  of any other condit ion (such as known drug, alcoho l abuse, or 
psychiatric disorde r) that, in the opi[INVESTIGATOR_1649] o f the investigator, may preclude the 
patient from following and co mpleting the protocol
[28]Have any hematological condit ion that m ay interfere with HbA1c measurement 
(for example, hemo lytic anemias and sickle cell disease)
Prior/ Concomitant Therapy
[29]Treatment with any glucose -lowering agent(s) other than sta ted in the inclusio n 
criteria [4 ] in a period of 3 months prior to Visit 1 and between Visit 1 and 
Visit 3
[30]Have been treated with prescription drugs that promote weigh t loss(for exam ple, 
Saxenda [liraglut ide 3.0 mg], Xenical®[orlistat], Meridia®[sibutramine], 
Acutrim®[phenylpropano lamine], Sanorex®[mazindo l], Api[INVESTIGATOR_82335]®[phentermine], 
BELVIQ®[lorcaserin], Qsymia™[phentermine/topi[INVESTIGATOR_82336]], 
Contrave®[naltrexone/bupropi[INVESTIGATOR_2394]], or similar other body  weight l oss medicat ions 
including over -the-counter (OTC) medications [for example, allī®]) wi thin 3 
months prior to Visit 1 and/or between study  entry  (Visit 1) and randomizat ion 
(Visit 3)
[31]Are receiving c hronic (>2 weeks or 14 day s) systemic glucocortico id therapy 
(excluding topi[INVESTIGATOR_2855], intraocular, intranasal, or inhaled preparations) or have 
received such therapy  within 1 m onth of Visit 1 or between Visit s 1 and 3
Prior/Concurrent Clinical Trial Experience
[32] Are current ly enrolled in any other clinical study  involving an invest igational 
product or any  other ty pe of medical research judged not to be scient ifically or 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526301] u d y 
[ 3 3] Ha ve part ic i pate d, wit hi n t he last [ADDRESS_526302] has a l o n g 
half -life, 5 half -li ves or 3 0 da y s ( w hic he ver i s l o n ger) s h o ul d ha ve passe d 
[ 3 4] Ha ve pre vi o usl y c o m p lete d or wit h dra w n fr o m t his st u d y  or a n y  ot her s t u d y  
i n vesti gat i n g ti rze pat i de 
Ot her E xcl usi o ns 
[ 3 5] A re i n vest i gat or site pers o n nel directl y affiliate d wit h t his st u d y  a n d/ or t hei r 
i m me diate fa milies.  I m me diate fa mil y is defi ne d as a s p o use, pare nt, c hil d, or 
si bli n g, w het her bi o l o gi c al  or l e gall y a d o pt e d 
[ 3 6 ] A re Lill y  e m pl o y ees 
[ 3 7 ] A re u n willi n g or u na ble t o c o m pl y  wi t h  t he use of a pa per diar y t o di rectl y 
rec or d data fr o m t he s u bject 
6. 3. Lif e st yl e Re stri cti o n s 
Per t he Sc he d ule of Act i vit ies ( Secti o n 2), q ualifie d me dical staff will pr o vi de dia betes 
ma na ge me nt c o u nseli n g, w hic h will i ncl u de i nstr ucti o ns o n diet a n d e xercise a n d e d ucat i o n 
a b o ut t he si g ns, s y m pt o ms, a n d treat me nt of h y p o gl yce mia , s h o ul d i t occ ur .
P ati e nts s h o ul d c o nt i n ue t heir us ual e xercise ha bits a n d ge nerall y f o ll o w a heal t h y meal pla n 
( wi t h  c o nsiste nt meal size a n d ti me of da y ) t hr o u g h o ut t he c o urse of t he st u d y .  Dietar y  
c o u nseli n g ma y be re vie we d t hr o u g h o ut t he st u d y , as ne e de d.  Per incl usi o n cri t eri o n [ 5] 
( Secti o n 6), pati e nts s h o ul d n ot i ni ti ate d uri n g t he st u d y  a n or ga ni ze d diet a n d/ or e xercise wei g ht 
re d ucti o n pr o gra m ot her t ha n t he lifest yle a n d dietar y  m eas ures f or di a betes treat m e nt. 
St u d y  p arti ci pa nts s h o ul d be i nstr ucte d n ot t o d o nate bl o o d or bl o o d pr o d ucts d uri n g t he st u d y .
6. 4. S cr e e n F ail ur e s 
I n di vi d uals w h o d o n ot meet t he criteria f or partici pati o n i n t his st u d y  (scree n fail ure) m ust n ot 
be rescree ne d .  
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526303] u d y  will be deter mi ne d at t he i nit ial scree ni n g visit ( Visit 1).  Scree ni n g 
pr oce d ures a n d patie nt trai ni n g will be perf or me d at Visits 1 a n d 2 (scre e ni n g a n d lea d -i n 
p eri o ds).  Pati e nt trai ni n g will i ncl u de disease m o nit ori n g a n d ma na ge me nt pr oce d ures, st u d y  
di aries, a n d st u d y  pr oce d ures.  At Vi si t 3, p ati e nts will  p erf or m  all  re q uire d baseli ne st u d y  
pr oce d ures (i ncl u di n g t he c ollecti o n o f all baseli n e la b orat or y  m eas ures a n d E C G ) pri or t o 
ra n d o mizat i o n a n d pri or t o ta ki n g t he first d ose of st u d y dr u g.  F oll o wi n g ra n d o mizat i o n, t he 
pati e nt will i nject t he first d ose of st u d y dr u g/ place b o at t he st u d y  si t e .  T he date a n d ti me of all  
d ose sof  st u d y  dr u g s h o ul d be rec or de d o n t he el ectr o nic case re p ort f or m ( e C R F).  Be gi n ni n g at 
ra n d o mizat i o n, all pat ie nt s will recei ve st u d y  dr u g acc or di n g t o t he ra n d o mize d treat me nt gr o u p 
f o r t he d urati o n of  t he [ADDRESS_526304] u d y  i n t he 5 -m g gr o u p.  F or t he 1 0 -m g gr o u p , t he 
starti n g d ose of tirze pati de will be 2. 5 m g o nce wee kl y f or 4 wee ks, t he n t he d ose will be 
i ncrease d b y 2. 5 m g e ver y 4 wee ks ( 2. 5 t o 5 t o 7. 5 t o 1 0 m g) u nt il t he [ADDRESS_526305] u d y .  F or t he 1 5 -m g gr o u p , t he starti n g d ose of tirze pat i de 
will be 2. 5 m g o nce wee kl y  f or 4 wee ks, t he n t he d ose will be i ncrease d b y 2. 5 m g e ver y  4 
wee ks ( 2. 5 t o 5 t o 7. 5 t o 1 0 t o 1 2. 5 t o 1 5 m g) u nt il t h e [ADDRESS_526306] i ns uli n glar gi ne d oses t o a tar g et 
F B G of  < 1 0 0 m g/ d L ( 5. 5 m m ol / L) acc or di n g t o t he sc he d ule bel o w ( Ta ble G P GI. 3). F or t hi s 
p ur p ose, patie nts will be re q uire d t o meas ure t heir F BG eac h m or ni n g a n d t o c ollect [ADDRESS_526307] t he 4 - p oi nt S M B G 
pr ofiles o nce wee kl y bet wee n Visit 2 a n d Visit 3 , t wi ce wee kl y fr o m Visi ts 3 -7 ( Wee ks 0 -4) 
f o ll o we d b y o nce wee kl y  f or t h e r e m ai n der of t he st u d y .
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526308] me nt of I ns uli n Gl ar gi ne if 
Dose is < [ADDRESS_526309] me nt of I ns uli n Gl ar gi ne if 
Dose is ≥ 2 0 U nits m g/ d L m m ol/ L 
≤ 7 0 ≤ 3. 9 − 1 o r − 2 u nits b, c − [ADDRESS_526310] me nt 
1 0 1 t o 1 1 9 5. 6 t o 6. 6 + 1 u nits + 2 u nits 
1 2 0 t o 1 3 9 6. 7 t o 7. 7 + 2 u nits + 4 u nits 
1 4 0 t o 1 7 9 7. 8 t o 9. 9 + 3 u nits + 6 u nits 
≥ 1 8 0 ≥ 1 0. 0 + 4 u nits + 8 u nits 
A b bre viati o n:  S M B G = self -m o nit ore d bl o o d gl uc ose. 
aBase d o n t he last 3 S M B G val ues. 
bD ose s h o ul d als o be decrease d b y 1 t o 2 u nits or 2 t o 4 u nits i n t he f oll o wi n g sit uati o ns: 
If m ulti ple e pis o des of n o nse vere h y p o gl yce mia were rec or de d d uri n g t he assess me nt peri o d at a n y ti me d uri n g 
t he da y ; a n d/ or 
If at least 1 e pis o de t hat met t he criteria f or se vere h y p o gl yce mia (e ve nts re q uiri n g assista nce of a t hir d pers o n t o 
a d mi nister t h e ra p y ) or was ass ociate d wit h S M B G val ue < 5 4 m g/ d L ( < 3. 0 m m ol/ L) was rec or de d d uri n g t he 
assess me nt peri o d. 
cIf o nl y 1 h y p o gl yce mic e pis o de wit h S M B G val ue ≥ 5 4 m g/ d L ( ≥ 3. 0 m m ol/ L) a n d ≤ 7 0 m g/ d L ( ≤ 3. 9 m m ol/ L) was 
rec or de d, i ns uli n d ose s h o ul d n ot be c ha n ge d. 
S o urce:  A da pte d fr o m Ri d dle et al. [ADDRESS_526311] m e nts (self -a dj ust me nt ). Assess me nt of i ns uli n d oses per t he T T T al g orit h m a n d 
a d mi nistere d i ns uli n d oses will be rec or de d b y  t he pati e nt i n st u d y p eri o d -s pecific diaries. 
P ati e nts s h o ul d be i nstr ucte d t o c o n tact t he st u d y  site if t he y  are u na ble t o deci de o n t he 
a p pr o priate d ose a dj ust me nt  at a n y  ti me d uri n g t he trial. Si te pers o n nel will verif y at eac h office 
or tel e p h o ne visit t h at t he assess me nt(s) has bee n ma de a n d t hat t he i ns uli n a dj ust me nt was 
a p pr o priate. If nee de d, t he y will pr o p ose f urt her a dj ust me nt s base d u p o n t heir re vie w of data 
c ollecte d si nce t he pre vi o us visit. If assess me nts were n ot ma de or t he al g orit h m was n ot 
c orrectl y  f oll o we d, pati e nts will  recei ve a d di ti o n al  trai ni n g a n d i nstr ucti o ns. 
D uri n g t he l ea d -i n peri o d ( Visit s 2 a n d 3 [ baseli ne]), i ns uli n d oses s h o ul d be a d j u ste d per T T T 
al g ori t h m  ( Ta ble G P GI. 3) o nl y w he n nee de d t o pr otect t h e safet y of  p ati e nts ( occ urre nce of 
h y p o gl yce mia or se vere persiste nt h y per gl yce mia). See Secti o n 5. [ADDRESS_526312] 2 
m o nt hs ,a n d t hereafter e ver y  4 t o 8 wee ks t o e na ble t he site t o pr o perl y  m o ni t or p ati e nts’ usa ge 
of  t he T T T al g ori t h m. After ra n d o mizati o n, d uri n g t he 4 -wee k sta bilizat i o n peri o d, t he i ns uli n 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e 4 3 
LY 3 2 9 8 1 7 6 gl ar gi ne d ose will re mai n u nc ha n ge d if t he pat ie nt ’s baseli ne ( Visit 3 ) H b A 1c is > 8. 0 %. F or 
pati e nts wi t h  baseli ne H b A 1c ≤ 8. 0 %, t he i ns uli n glar gi ne d ose will be decrease d b y 2 0 % 
i m me diatel y  ( wi t h i n 7 da ys) after ra n d o mizati o n a n d will t he n re mai n u nc ha n ge d d uri n g t he 
sta bilizati o n peri o d. A d dit i o nal i ns uli n d ose a dj ust me nt s d uri n g t he sta bilizat i o n peri o d will o nl y 
be all o we d usi n g t he T T T al g orit h m ( Ta ble G P GI. 3) i n case of t he occ urre nce of h y p o gl yce mia 
or t he de vel o p me nt of se vere h y per gl yce mia. See Secti o n 5. [ADDRESS_526313] 3 dail y F B G ( S M B G) val ues c ollecte d aft er t he pre vi o us d ose 
assess me nt. If o nl y [ADDRESS_526314] u d y  i ns uli n f or l ess t ha n 1 4 da y s is all o w e d f or 
certai n cli nical sit uati o ns (f or e xa m ple, elect i ve s ur ger y , d uri n g h os pi [INVESTIGATOR_90730] i o n, h y per os m o lar 
states).  If i ns uli n is prescri be d as a resc ue t hera p y , i t m ust be differe nt iat e d f r o m  s h ort -t er m  use 
of  i ns uli n t hera p y  f or m e dical e mer ge ncies w he n re p orte d i n t he e C R F. 
All n o nst u d y  m e dicati o ns will be rec or de d o n s o urce d oc u me nts at all visit s. 
N o n st u d y  m e dicat i o ns ta ke n b y  pat ie nt s w h o are scree ne d ,b ut n ot ra n d o mize d will n ot be 
re p orte d t o Lill y  u nless a S A E or A E occ urs t hat t he i n vest i gat or belie ves ma y ha ve bee n ca use d 
b y a st u d y  pr oce d ure. 
7. 1. 4. P a c k a gi n g a n d L a b elli n g 
T he s p o ns or will pr o vi de t ir ze pat i de a n d place b o i n S D Ps.   T hese will be dis pe nse d via a n 
i nt eract i ve we b -res p o nse s yste m (I W R S).  Si n gle -d ose pe ns will be pac ka ge d i n cart o ns t o be 
di s pe nse d.  Cli nical st u d y  m at eri als will  b e la bele d acc or di n g t o t he c o u ntr y ’s re g ul at or y  
re q ui re me nts. 
I8F-MC-GPGI( b) Clinical Protocol Page 44
LY32981767.1.5. Medical Devices
The combinat ion products used in the study  are tirzepati deinvestigational SDP and a marketed 
insulin glargine prefilled pen.
7.2. Method of Treatment Assignment
Patients who m eet all cri teria for enrollment will be randomized to oneof the study  treatm ent 
groups at Visit 3.  Assignment to treatment groups will be determined by a co mputer -generated 
rando m sequence using an IWRS.  Patients will be randomized in a 1:1:1:[ADDRESS_526315] acebo .
7.2.1. Selection and Timing of Doses of Study Drug
Assignment to tirzepat ide(3 doses) or placebo will occur at randomization.  
There are no restrict ions on the time of day  each weekly dose of study  drug is given, but it is 
advisable to administer the SCinjecti ons on the same day  and same time each week.  The actual 
date and time of all dose administrations will be recorded by  [CONTACT_25034].  If a dose of study  drug 
is missed, the patient should take it as soon as possible unless it is within 72hours of the next 
scheduled dose, in which case, that dose should be skipped and the next dose should be taken at 
the appropriate time.  
All patients will inject study  drug subcutaneously in the abdo men or thi gh using the SDP; a 
caregiver may  administer the inject ion in the patient’s upper arm . A new SDP will be used for 
each inject ion.If study  drug is to al ways be injected in the same body  region, pati ents shoul d be 
advised to use a different inject ion site each week.
7.3. Blinding
This is a double -blind study .
To preserve the blinding of the study , a minimum number of Lilly  personnel  will see the 
rando mizat ion table and treatm ent assignments before the study  is complete.
Emergency  codes, generated by  a com puter drug -labeling system, will be available to the 
investigator.  These codes, which reveal the patient’s treatment group when opened, may be 
opened during the study  ONLY if the patient’s well -being requires knowledge of the patient’s 
treatm ent assi gnment.
Emergency  unblinding for AEs m ay be perform ed through the IWRS , which m ay supplement or 
take the place of emergency  codes generated by  a com puter drug -labeling system.  This option 
may be used ONLY if the patient’swell-being requires knowledge of thepatient’s treatm ent 
assignment.  All calls result ing in an unblinding event are recorded and reported by  [CONTACT_8784] .
If an invest igator, site personnel performing assessments, or patient is unblinded, the patient
must be discont inued fro m the study .  In cases where there are ethical reasons to have the patient
remain in the study , the investigator must obtain specific approval fro m a Lilly clinical research 
physician (CRP) for the patientto continue in the study .
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526316] i gat or has t he s o le res p o nsi bilit y f o r deter mi ni n g if u n bli n di n g 
of  a pati e nt ’s treat me nt assi g n me nt is warra nte d f o r m e dical ma na ge me nt of t he e ve nt.  T he 
pati e nt safet y m u st al wa ys be t he first c o nsi derat i o n i n ma ki n g s uc h a deter mi nat i o n.  If a 
pati e nt ’s treat me nt assi g n me nt is u n bli n de d, Lill y m ust be n otifie d i m me diatel y.   If t he 
i n vesti gat or deci des t hat u n bli n di n g is warra nte d, it is t he res p o nsi bilit y of  t he i n vesti gat or t o 
pr o m ptl y d oc u m e nt t he decisi o n a n d rati o nale a n d n otif y Lill y as s o o n as p ossi ble. 
7. 4. D o s a g e M o difi c ati o n 
7. 4. 1. St u d y Dr u g s 
N o a dj ust me nt  i n st u d y  dr u g d oses will be all o we d. Details a b o ut d ose a d mi nistrati o n of 
ti rze pat i de d uri n g t he st u d y  are descri be d i n Sect i o n 7. 1 .
7. 4. 2. R e d u cti o n a n d/ or Di s c o nti n u ati o n of C o n c o mit a nt 
A nti h y p er gl y c e mi c M e di c ati o n s 
1) If i ncrease d ris k of h y p o gl yce mia d uri n g t he peri o d bet wee n 2 i ns uli n d ose assess me nts is 
j u d ge d t o be relate d t o t he treat me nt re gi me n, t he f oll o wi n g c ha n ges s h o ul d be ma de: 
Decrease t he i ns uli n glar gi ne d ose b y  2 t o 4 U, per t he T T T al g orit h m, i n t he 
f o ll o wi n g cases: 
oIf t he me dia n F P G val ue f or t he assess me nt peri o d is ≤ 7 0 m g/ d L ( ≤ 3. 9 
m m o l/ L); a n d/ or 
oIf m ult i p le e pis o des of n o nse vere h y p o gl yce mia were rec or de d at a n y  ti me 
d uri n g t he da y  f or t he assess me nt peri o d; a n d/ or 
oIf at least 1 e pis o de t hat met t he criteria f or se vere h y p o gl yce mia (e ve nts 
re q ui ri n g assista nce t o a d mi nister t hera p y ) or was ass ociate d wit h S M B G 
val ue < 5 4 m g/ d L ( < 3. 0 m m o l/ L) was rec or de d d uri n g t he assess me nt 
p eri o d; 
I n t he case of re peate d h y p o gl yce mic e ve nts, e ve n wit h a ver y  l o w glar gi ne d ose 
a n d des pi[INVESTIGATOR_417379] d ose decreases per t he T T T al g orit h m, a d mi nistrati o n of 
i ns uli n glar gi ne ma y be t e m p oraril y or per ma ne nt l y disc o nti n ue d; 
If i ncrease d ris k of h y p o gl yce mia persists des pi[INVESTIGATOR_417380] o nti n uat i o n of i ns uli n 
gl ar gi ne, t he n d ose re d ucti o n or disc o nt i n uat i o n of met f o r mi n (f or patie nts w h o 
are ta ki n g it) s h o ul d be c o nsi dere d. 
2) I n certai n si t u ati o ns s h ort -t er m  disc o nt i n uat i o n will be re q uire d i n li ne wit h t he pr o d uct(s) 
la beli n g f or eac h res pecti ve c o u ntr y (f or e xa m ple, f or metf or mi n:  se vere de h y drat i o n, 
el ect i ve s ur ger y, or nee d f or ra di o l o gi c e xa mi nat i o n i n v o l vi n g I V i o di nate d c o n trast d ye). 
O nce t he sit uat i o n t hat l e d t o te m p orar y  disc o nt i n uati o n of t he dr u g res ol ve d, treat me nt 
s h o ul d be restarte d at i n vest i gat or discreti o n. 
I8F-MC-GPGI( b) Clinical Protocol Page 46
LY32981763)If a patient develops contraindicat ions to met formin (if used), such that the use of the 
drug i s contraindicated according to the country -specific label, the drug should be 
discontinued; in this case, the insulin glargine dose may  need to be further adj usted.
A pat ient will be considered nonco mpliant wi th the protocol (protocol deviat ion) if he or she 
changes the do se or discont inues metformin (if used) for reasons other than those described here.  
In the case of noncompliance that lasts >14 day s during the treatment period, the patient will not 
be included in the per -protocol analyses.
7.5. Preparation/Handling/Storage/Accountability
The invest igator or his or her designee is responsible for the following:
confirming appropriate temperature condit ions have been maintained during 
transi t for all study  treatm ent received and any discrepancies are reported and 
resolved befor e use of the study  treatm ent.
ensuring that only participants enro lled in the study may receive study treatment 
and only  authori zed si te staff may  supply  or administer study  treatm ent. All study 
treatm ents m ust be stored in a secure, environmentally  contr olled, and mo nitored 
(manual  or autom ated) area i n accordance with the labeled storage condit ions 
with access limited to the invest igator and authorized site staff .
the invest igator, inst itution, or the head of the medical inst itution (where 
applicable) is responsible for study  treatm ent accountabilit y, reconciliat ion, and 
record m aintenance (such as receipt, reconciliat ion and final disposit ion records).
The study  site must store the study  drug in a l ocked and secure environment. Please refer to the 
study drug l abel for specific storage condit ions.  Pati ents will  receive insulated bags with cooling 
gel packs for use in transporting the study  drug carton from  the si te to hom e. 
Study  site staff must regul arly assess whether the patient is correctly administ ering the assigned 
study  drug and storing the study  drug according to the provided instructions. 
7.6. Treatment Compliance
Study  drug com pliance will  be determined by  [CONTACT_82374]: 
Study  drug administration data will be recorded by [CONTACT_417387].
The pati ents will  be instructed to return any  unused study  drug and/or em pty 
cartons at the next visit to the study  site for the purpose of performing drug 
accountabilit y.
In the3 tirzepat idetreatment groups, as well as the placebo group, treatment compliance for each 
visit interval is defined as taking at least 75% of the required doses of study  drug.  Patients will 
be consid ered to be nonco mpliant with their insulin glargine treatment if they miss their daily 
dose of insulin glargine for more than 7 consecut ive day s or f or more than 7 days within a month 
(that i s, a pati ent is considered to be compliant if they are ≥75% com pliant wi th their requi red 
I8F-MC-GPGI( b) Clinical Protocol Page 47
LY3298176insulin glargine therapy ).  Similarly, a patient will be consider ed noncom pliant if he or she is 
judged by  [CONTACT_417388].  
In addit ion to the assessment of a patient’s co mpliance with the study drug administration, other 
aspects of com pliance wi th the study  treatments will be assessed at each visit based on the 
patient’s adherence to the visit schedule, complet ion of study  diari es, the resul ts of home BG 
monitoring, and any other parameters the investigator considers necessary .
Patients consi dered not to be compliant with their medicat ion and/or the study  procedures will 
receive addit ional training and instruction, as required, and will be reminded of the importance of 
complying wi th the protocol . 
7.7. Concomitant Therapy
Patients will be permitted to use concomitant medications that they  requi re during the study , 
except certain medicat ions that may interfere with the assessment of efficacy and safet y 
characterist ics of the study  treatm ents.
Invest igative site staff will inform pat ientsthat they must consult with the investigator or a 
designated site staff member upon being prescribed any new medicat ions during the study .  Thi s 
may not be possible when init iated for treatment of medical emergencies, in which case ,the 
patient will infor m the invest igator or a designated site staff member as soon as possible.  Any 
additional medicat ion initiated during the course of the study  (including OTC drugs, such as 
paracetamo l or aspi [INVESTIGATOR_248]) must be docum ented, and the name [CONTACT_81155](s) of 
administration must be recorded on the “Conco mitant Medicat ions” sect ion of the eCRF. 
Antihyperglycemic medicat ions other than study  drugs are not allowed at any  time during the 
study  except as allowed for those pati ents who requi re perm anent di scont inuation of study  drug, 
but rem ain in the study ; rescue therapy  after randomizat ion due to severe, persistent 
hyperglycemia ;or during the safet y follow-up period .  Glucagon -like pept ide-[ADDRESS_526317] commo nly reported treatment -emergent AEs (TEAEs) for 
patients receiving tirzepat ide were nausea, vomit ing, and di arrhea.  
The ti rzepat ide dose escalat ion scheme has been designed to minimize the development of 
intolerable GI symptom s.  The escalat ion peri od is considered to be 24 weeks, which allows 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526318] u g d osa ge. 
T o mit i gate GI s y m pt o ms a n d ma na ge pati e nts wi t h  i nt ol era ble GI A Es d uri n g t he escalat i o n 
p eri o d ( Wee k s0 t o 2 4) , t he i n vest i gat or s h o ul d: 
A d vise patie nts t o eat s maller meals, f or e xa m ple, s plitt i n g [ADDRESS_526319] o p eati n g w he n t he y  f eel f ull. 
Pr escri be s y m pt o mat ic me d icati o n (f or e xa m ple, a nt i- e metic or a nti diarr heal me dicat i o n) 
per l o c al  c o u ntr y  a vaila bilit y a n d i n di vi d ual patie nt nee ds. Use of s y m pt o mat ic 
me dicat i o n s h o ul d be ca pt ure d as c o nc o mita nt me dicat i o n i n t he e C R F. 
T e m p oraril y  i nt err u p t ti rze pat i de ( o mit 1 d ose, t he patie nt will ta ke 3 of 4 d oses at t hat 
d ose l e vel).  After t he i nterr u pti o n, restart at t he sa me d ose wit h t he patie nt ta ki n g 
me dicat i o n t o alle viate t heir GI s y m pt o ms .  T he data relate d t o te m p orar y  i nt err u pti o n of  
st u d y  tr e at m e nt s h o ul d be d oc u m e nte d i n s o urce d oc u me nts a n d e ntere d o n t he e C R F.  
If i nt olera ble GI s y m pt o ms or e ve nts persist des pi[INVESTIGATOR_040] t he a b o ve meas ures, t he i n vest i gat or 
ma y deci de t o disc o nt i n ue st u d y  dr u g s.  De -escalati o n of st u d y  dr u gs will n ot be all o we d.  
P ati e nts w h o st o p t he st u d y  dr u g per ma ne nt l y will recei ve a n ot her gl uc ose -l o weri n g 
i nt er ve nt i o n ( Secti o n 8. 1. 1 ) a n d will c o nt i n ue partici pat i n g i n t he st u d y  acc or di n g t o t he 
pr ot oc ol  t o c ollect all pla n ne d efficac y a n d safet y meas ure me nts.  T he ne w 
gl uc ose -l o weri n g i nter ve nt i o n will be rec or de d o n t he e C R F s pecifie d f or c ollect i n g 
a nt i h y per gl yce mic m e dicat i o ns .   
I n t he e ve nt of i nt ol era ble persiste nt GI s y m pt o ms t h at occ ur after t h e escalati o n peri o d 
(Wee k 2 4 ), t he i n vest i gat or s h o ul d ta ke t he a b o ve meas ures t o kee p t he patie nt o n st u d y 
treat m e nt bef ore st o p pi n g t he st u d y  dr u g per ma ne ntl y  a n d i ni ti ate a n ot her gl uc ose -l o weri n g 
i nt er ve nt i o n.  
7. 8. Tr e at m e nt aft er t h e E n d of t h e St u d y 
St u d y  c o m pl et i o n will occ ur after all pat ie nt s c o m pl ete t he f oll o w -u p visit.   I n vest i gat ors will 
c o nti n ue t o f o ll o w Sc he d ule of Act i vit ies ( Secti o n 2) f or all  patie nts u ntil n otifie d b y Lill y t hat 
st u d y  c o m plet i o n has occ urre d. 
Ti rze pati d e will n ot be ma de a vaila ble after c o nc l u si o n of  t he st u d y  t o pati e nts. 
I8F-MC-GPGI( b) Clinical Protocol Page [ADDRESS_526320] :
Patien t Decision
othe patient requests to discont inue invest igational product.
Discontinuation due to a hepatic event or liver test abnormality .  Patientswho are 
discontinued fro m invest igational product due to a hepat ic event or liver test abnormalit y 
shoul d have addi tional hepatic safet y data collected via electroni c case report form.
Discontinuati on of  the invest igational product for abnormal liver test s should be
considered by [CONTACT_82378] a patient meets one of the fo llowing condi tions af ter 
consultation wit h the Lilly designated medical monitor:
oALT or aspartate aminotransferase (AST) >8X ULN
oALT or AST >5X ULN for more than 2 weeks
oALT or AS T >3X ULN and total bilirubin level (TBL) >2X ULN or 
internat ional norm alized rati o (INR)>1.[ADDRESS_526321] >3X ULN with the appearance of fat igue, nausea, vo miting, 
right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
oalkaline ph osphatase (ALP) >3X ULN
oALP >2.5X ULN and TBL >2X ULN
oALP >2.5X ULN with the appearance of fatigue, nausea, vo miting, right 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
In addition, patients willbe discont inued fro m theinvestigat ional product in the 
following circumstances:
If a patient is inadvertent ly enro lled and it is determined that continued treatment 
with study  drug woul d not be m edically  appropri ate
Acute or chronic p ancreat itis 
If a patient is diagnosed with MTC after randomization , or has postrandomization 
calcitonin value ≥35 ng/L thathas increased at least 50% over baseline
If a patient is diagnosed with an active or untreated malignancy (other than basal 
or squam ous cell skin cancer, in situ carcino mas of the cervi x, or in situ prostate 
cancer) after randomization
Any significant study  drug -related hypersensit ivity reacti on
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e 5 0 
LY 3 2 9 8 1 7 6 A n y ot her T E A E, S A E, or cli nicall y si g nifica nt la b orat or y  v al ue f or w hic h t he 
i n vesti gat or belie ves t hat per ma ne nt st u d y  dr u g di sc o nti n uat i o n is t h e a p pr o priate 
meas ure t o be ta ke n 
If fe male patie nt bec o me s pre g na nt 
If a patie nt is dia g n ose d wit h T [ADDRESS_526322] pre mat urel y f or a n y reas o n s h o ul d 
c o m plete a d verse e ve nt a n d ot her f o ll o w- u p pr oce d ures per Secti o n 2( Sc he d ule of Act i vit ies), 
Secti o n 9. 2 ( A d verse E ve nts) ,a n d Secti o n 9. 4 ( Safet y) of t his pr ot oc ol. 
8. 1. 2. T e m p or ar y Di s c o nti n u at i o n fr o m St u d y Tr e at m e nt 
I n certai n sit uat i o ns after ra n d o mizat i o n, t he i n vesti gat or ma y nee d t o te m p oraril y i nterr u pt st u d y  
dr u g.  E ver y  eff ort s h o ul d b e m a de b y  t he i n vest i g at or t o m ai ntai n pat ie nt s o n st u d y  dr u g a n d t o 
restart st u d y  dr u g after a n y  t e m por ar y  i nt err u pti o n, as s o o n as it is safe t o d o s o.  
If t he n u m ber of d oses misse d is ≤ 2, t he treat m e nt ca n be restarte d at t he sa me d ose , if t he 
dr u g was well t olerate d pri or t o disc o nt i n uat i o n. 
If t he n u m ber of misse d d oses is ≥ 3, t he n t he I W R S will dis pe nse 5 m g/ matc he d pl ace b o 
irres pect i ve of t he d ose t he patie nt was recei vi n g bef ore t he i nterr u pti o n a n d s u bse q ue nt l y 
escalate d as re q uire d b y pr ot oc ol .
If st u d y  dr u g i nterr u pti o n is d ue t o a n A E, t he e ve nt is t o be d oc u me nte d a n d f o ll o we d acc or di n g 
t o t he pr oce d ures i n Secti o n 9. [ADDRESS_526323] u g i nterr u pti o n is d ue t o 
i nt ol era ble persiste nt GI A E (f or e xa m ple, na usea, v o mit i n g, or diarr hea), t he patie nts s h o ul d be 
treate d as s u g geste d i n Sect i o n 7. 7. [ADDRESS_526324] i o n 2( Sc he d ule of Act i vit ies), 
Secti o n 9. 2 ( A d verse E ve nts), a n d Secti o n 9. 4 ( Safet y) of t he pr ot oc ol. 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526325] i ve of t h e f ol l o wi n g: 
a d here nce t o st u d y  dr u g 
a d here nce t o visit sc he d ule 
missi n g assess me nts 
st u d y  dr u g di sc o nt i n uat i o n d ue t o A E 
de vel o p me nt of c o m or bi dit ies , a n d 
de vel o p me nt of cli nical o utc o me s. 
T he ci rc u msta nces liste d a b o ve are n ot vali d reas o ns f or disc o nt i n uat i o n fr o m t h e st u d y . 
P ati e nts will be disc o nt i n ue d i n t he f o ll o wi n g ci rc u msta nces: 
enr o ll me nt i n a n y ot her cli nical st u d y  i n v o l vi n g a n i n vest i gat i o nal pr o d uct or 
e nr o ll me nt i n a n y ot h er t y p e of  m e dical researc h j u d ge d n ot t o be 
scie ntificall y or me di call y  c o m pati ble wit h t his st u d y 
parti ci pat i o n i n t he st u d y nee ds t o be st o p pe d f or me dical, safet y,  re g ul at or y , 
or ot her reas o ns c o nsiste nt wit h a p plica ble la ws, re g ulat i o ns, a n d g o o d cli nical 
practi ce ( G C P), 
if a fe male pati e nt bec o m es pre g na nt 
if a pat ie nt  is di a g n ose d wi t h  T 1 D M 
pati e nt re q uests t o be wit h dra w n fr o m t he st u d y 
P ati e nts w h o a gree t o pr o vi de i nf or mat i o n rel e va nt t o a n y  st u d y e n d p oi nt at t he e n d of t he st u d y  
are n ot c o nsi dere d t o ha ve disc o nti n ue d fr o m t he st u d y .
A pat ie nt  w h o wit h dra ws c o nse nt a n d clearl y i n dicates t hat t here will be n o f urt her c o ntact of a n y 
ki n d wit h t he site will be c o nsi dere d t o ha ve disc o nt i n ue d fr o m t h e st u d y .
Pri or t o earl y  st u d y  di sc o nti n uati o n, t he patie nt ma y disc o nt i n ue st u d y  dr u g a n d will ha ve 
e n d -of -st u d y  pr oce d ures ( E T vi si t) p erf or m e d as s h o w n i n t he Sc he d ule of Act i vit ies ( Secti o n 2).  
D uri n g t he E T visit, t he patie nt will be prescri be d a n a p pr o priate gl uc ose -l o weri n g re gi me n a n d 
gl uc ose self -m o nit ori n g pla n. Visit 8 0 1 ( safet y fol l o w- u p v isit) s h o ul d be perf or m e d 
a p pr o x i matel y [ADDRESS_526326] u d y  pr e m at urel y f or a n y  reas o n s h o ul d c o m plete a d verse e ve nt 
a n d ot her safet y f o ll o w- u p per Secti o n 2( Sc he d ule of Act i vit ies), Secti o n 9. 2 ( A d verse E ve nts) ,
a n d Sect i o n 9. 4 ( Safet y) of t his pr ot oc ol. 
I8F-MC-GPGI( b) Clinical Protocol Page [ADDRESS_526327] 
inform ation to the study  site when necessary .
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526328] u d y  pr oce d ures a n d t heir ti mi n g (i ncl u di n g 
t ol era nce li mit s f or ti mi n g). 
A p pe n di x [ADDRESS_526329] u d y  Sc he d ule ( see Secti o n2). 
Mea n c ha n ge i n b o d y  w ei g ht 
Pr o p orti o n of  patie nts ac hie vi n g a tar get H b A 1c < 7 % ( 5 3 m m o l/ m o l) ,≤ 6. 5 % ( 4 8 
m m o l/ m o l) , or < 5. 7 % ( 3 9 m m o l/ m o l) 
Mea n c ha n ge i n fast i n g ser u m gl uc ose (F S G )val ues meas ure d i n t he ce ntral la b orat or y 
Mea n c ha n ge i n dail y  a vera ge 7 -p oi nt S M B G pr ofiles 
Pr o p orti o n of  patie nts w h o ac hie ve d wei g ht l oss ≥ 5 %, ≥ 1 0 %, a n d ≥ 1 5 % 
C ha n ge i n dail y mea n i ns uli n glar gi ne d ose 
9. 1. 3. E x pl or a t or y A s s e s s m e nt s a n d Pr o c e d ur e s 
T he f o ll o wi n g sec o n dar y  efficac y meas ures will be assesse d base d o n data c o llecte d at t he ti mes 
s h o w n i n t he St u d y  Sc he d ule (see Sect i o n 2). 
Mea n c ha n ge i n waist circ u mfere nce 
C ha n ges fr o m baseli ne i n mea n B MI 
Mea n c ha n ge i n li pi [INVESTIGATOR_805] (t otal c h olester ol, hi g h -de nsit y li p o pr otei n , l o w- de nsit y 
li p o pr otei n , v er y  l o w -de nsit y li p o pr otei n , a n d tri gl yceri des )
Bi o m ar kers 
A P P A D L sc ores 
I W -S P sc ores 
D T S Qs/ D T S Qc 
E Q - 5 D- 5 L sc ores 
I8F-MC-GPGI( b) Clinical Protocol Page [ADDRESS_526330].
After the informed consent form ( ICF) is signed, study site personnel  will record vi a electroni c 
case r eport form  (eCRF)the occurrence and nature of each patient’s preexist ing condit ions, 
including clinically significant signs and symptoms of the disease under treatment in the study.   
In addit ion, site personnel will record any  change in the condi tion(s) a nd any new condit ions as 
AEs. Invest igators should record their assessment of the potential relatedness of each AE to 
protocol  procedure, invest igational product, via eCRF.
The invest igator will interpret and document whether or not an AE has a reasonabl e possibilit y 
of being related to study  treatm ent, study  device, or a study  procedure, taki ng into account the 
disease, concomitant treatment or pathologies.
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the
investi gational product, study  device and/or study  procedure and the AE.
The invest igator answers yes/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient ’s investigational product is discontinued as a result of an AE, study site perso nnel 
must report this to Lilly or its designee via eCRF , clarifying if possible, the circumstances 
leading to any  dosagemodifications, or discontinuations o f treatm ent.
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526331] u d y  t hat res ul ts i n o ne of t he f o ll o wi n g o utc o m es: 
deat h 
i nit ial or pr ol o n ge d i n patie nt h os pi[INVESTIGATOR_90730] i o n
a life -t h reate ni n g e x perie nce (t hat is, i m me diate ris k of d yi n g) 
persiste nt or si g nifica nt disa bilit y/ i nca pacit y
c o n ge nital a n o ma l y/ birt h defect 
i m p orta nt me dical e ve nts t hat ma y n ot be i m me diatel y life -t h reate ni n g or res ult i n 
deat h or h os pi[INVESTIGATOR_417381] i o n b ut m a y je o par di ze t he patie nt or m a y  re q uire i nter ve nt i o n 
t o pre ve nt o ne of t he ot her o utc o mes liste d i n t he defi nit i o n a b o ve.   E xa m ples of 
s uc h m e dical e ve nts i ncl u de aller gic br o nc h os pa s m  re q uiri n g i nte nsi ve treat me nt 
i n a n e m er ge nc y r o o m  or at h o m e, bl o o d d y scrasias or c o n v ulsi o ns t hat d o n ot 
res ul t i n i n pat ie nt  h os pi [INVESTIGATOR_90730] i o n, or t he de vel o p me nt of dr u g de pe n de nc y  or dr u g 
a b use. 
All A Es occ urri n g after si g ni n g t he I C F are rec or de d i n t h e eC R F a n d assesse d f or seri o us 
cri teria.  T he S A E re p orti n g t o t he s p o ns or be gi ns after t he pati e nt has si g ne d t he I C F a n d has 
recei ve d i n vest i gat i o nal pr o d uct.  H o we ver, if a n S A E occ urs after si g ni n g t he I C F, b ut pri or t o 
recei vi n g i n vest i gat i o nal pr o d uct, t he S A E s h o ul d be re p orte d t o t he s p o ns or as per S A E 
re p orti n g re q uire me nts a n d t i meli nes ( see Sect i o n9. 2 )if it  i s c o nsi dere d reas o na bl y p ossi bl y  
r el ate d t o st u d y  pr oce d ure. 
St u d y  si te pers o n nel  m ust al ert Lill y or i ts desi g n e e of  a n y S A E wit hi n [ADDRESS_526332] u d y -s pecific S A E f or ms.  T his 
2 4 -h o ur n otificat i o n re q uire me nt refers t o t he i nit ial S A E i nf or mati o n a n d all f o ll o w- u p S A E 
i nf or m at i o n. Patie nts wi t h  a seri o us he pat ic a d verse e ve nt s h o ul d ha ve a d dit i o nal data c ollecte d 
usi n g t he e C R F. 
Pre g na nc y ( d uri n g mat er nal or pater nal e x p os ure t o i n vest i gat i o nal pr o d uct) d oes n ot meet t he 
defi nit i o n o f a n A E.  H o we ver, t o f ulfill re g u lat or y re q uire me nts a n y pre g na nc y s h o ul d be 
re p orte d f o ll o wi n g t he S A E pr ocess t o c ollect data o n t he o utc o me f or b ot h m ot her a n d fet us. 
I n vest i gat ors are n ot o bli gate d t o acti vel y  see k A Es or S A Es i n s u bjects o nce t he y  h a ve 
di sc o nti n ue d a n d/ or c o m plete d t he st u d y (t he pati e nt dis p osit i o n case re p ort f or m (C R F )has bee n 
c o m plete d).  H o we ver, if t he i n vesti gat or lear ns of a n y S A E, i ncl u di n g a deat h, at a n y  ti me after 
a s u bject has bee n disc har ge d fr o m t h e st u d y , a n d he or s he c o nsi ders t h at t h e e ve nt reas o na bl y 
p ossi bl y  relate d t o t he st u d y  treat m e nt or st u d y  p arti ci pat i o n, t he i n vest i gat or m ust pr o m pt l y 
n otif y Lill y. 
I8F-MC-GPGI( b) Clinical Protocol Page [ADDRESS_526333] ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to investigational product or procedure.  
[LOCATION_002] [ADDRESS_526334] ive 2001/20/EC and the 
associ ated detailed guidances or nati onal regulatory  requirements in parti cipat ing countries 
requi re the reporting of S[LOCATION_003]Rs.  Lilly has procedures that will be followed for the 
ident ificat ion,recording and expedited reportin g of S[LOCATION_003]Rs that are consistent with global 
regul ations and the associated detailed guidances.
9.2.2. Adverse Events of Special Interest
[IP_ADDRESS]. Hypoglycemia 
Patients will  collect inform ation on epi [INVESTIGATOR_82341] [ADDRESS_526335] 
study  visit (Follow-up Vi sit or Early Terminat ion Visit).  For that purpose, pati ents will  be 
trained about signs and symptoms o f hypoglycemia, how to treat hy poglycemia, and how to 
collect appropriate informat ion for each epi[INVESTIGATOR_82342].  Site personnel will enter this informat ion into the eCRF at each visit. 
Invest igators should use the fo llowing definit ions and criteria when diagnosing and categorizing 
an epi[INVESTIGATOR_417382] (the plasma glucose [PG]values in this 
section refer to values determined by a laboratory  or Internati onal Federat ion of Clinical 
Chemistry  and Laboratory  Medicine plasma -equival ent gl ucose m eters and strips) (ADA 2017, 
ADA 2018 ):
Glucose Alert Value (Level 1):
Documented symptomatic hypoglycemia is defined as any time a pat ient feels 
thathe or she is experiencing symptoms and/or signs associated with 
hypoglycemia, and has a PG l evel of ≤70 mg/dL (≤3.9 mmo l/L).
Documented asymptomatic hypoglycemia is defined as any event not 
accompanied by [CONTACT_11017][INVESTIGATOR_10921], but with a measured PG 
≤70mg/dL (≤3.9 mmo l/L).
Documented unspecified hypoglycemia is define d as any  event wi th no 
inform ationabout sym ptoms of hypoglycemia available, but with a measured PG 
≤70 m g/dL (≤3.9 mmo l/L).
Clinically Significant Hypoglycemia (Level 2):
Documented symptomatic hypoglycemia is defined as any time a pat ient feels 
thathe/she is experiencing symptoms and/or signs associ ated wi th hypoglycemia, 
and has a PG l evel of <54 m g/dL (<3.0 mmo l/L).
Documented asymptomatic hypoglycemia is defined as any event not 
accompanied by [CONTACT_11017][INVESTIGATOR_10921], but with a measured PG <54 
mg/dL (<3.0 mm ol/L).
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e 5 7 
LY 3 2 9 8 1 7 6 D oc u me nte d u ns pecifie d h y p o gl yce mi a is defi ne d as a n y  e v e nt wi t h  n o 
i nf or m at i o na b o ut s y m pt o ms of h y p o gl yce mia a vaila ble, b ut wit h a meas ure d P G 
< 5 4 m g/ d L ( < 3. 0 m m o l/ L) .
Severe hy p o glyce mi a ( Level 3): 
Se vere h y p o gl yce mi a is defi ne d as a n e pis o de wit h se vere c o g nit i ve i m pair me nt 
re q ui ri n g t he assista nce of a n ot her pers o n t o acti vel y  a d mi nister car b o h y drate, 
gl uca g o n, or ot her res uscitati ve act i o ns.  T hese e pis o des ma y  b e ass oci at e d wi t h  
s ufficie nt ne ur o gl yc o pe nia t o i n d uce sei z ure or c o ma. Bl o o d gl uc ose 
meas ure me nts ma y  n ot be a vaila ble d uri n g s uc h a n e ve nt, b ut ne ur ol o gical 
rec o ver y  attri b uta ble t o t he rest orati o n of B G t o n or mal is c o nsi dere d s ufficie nt 
e vi de nce t hat t he e ve nt was i n d uce d b y a l o w B G c o nce ntrati o n. 
Ot her hy p o glyce mi a c ate g ories: 
N oct ur n al h y p o gl yce mi a is defi ne d as a n y h y p o gl yce mic e ve nt t hat occ urs 
bet wee n be dt i me a n d wa ki n g. 
If a h y p o gl yce mic e ve nt meets t he criteria of se vere, it nee ds t o be rec or de d as seri o us o n t he A E 
C R F a n d re p orte d t o Lill y as a n S A E. 
T o a v oi d d u plicate re p orti n g, all c o nsec uti ve B G val ues ≤ 7 0 m g/ d L ( 3. 9 m m o l/ L) occ urri n g 
wi t hi n a 1- h o ur peri o d ma y be c o nsi dere d t o be a si n gle h y p o gl yce mic e ve nt ( Wei n ber g et al. 
2 0 1 0; Da n ne et al. 2 0 1 3). 
I n eac h case of s us pecte d or c o nfir me d h y p o gl y ce mia, i t is i m p orta nt t hat t he e ve nt be pr o perl y  
cate g ori ze d, t he effect of t he i nter ve nti o n be assesse d, a n d t he fre q ue nc y of h y p o gl yce mia be 
e val uate d.  T he r ole of dietar y  c ha n ges a n d p h ysical  e xercise ( or a n y  ot her c o ntri b ut i n g fact or) i n 
t h e de vel o p m e nt of a n e ve nt s h o ul d be esta blis he d.  T he patie nt s h o ul d recei ve a d dit i o nal 
e d ucati o n, if dee me d a p pr o pri ate. 
9. 2. 2. 2. S e v er e, P er si st e nt H y p er gl y c e mi a 
Se vere, persiste nt h y per gl yce mia will be c ollecte d d uri n g t he trial t o assess t he ris k of e xtre me 
i m bala nce i n gl yce mic c o ntr ol .
I n vest i gat ors will be trai ne d o n t he a p plicat i o n of cri t eri a f or d e ci di n g w he n a n d h o w t o i nter ve ne 
wi t h  patie nts w h o d o n ot reac h gl yce mic tar gets.  A n a d dit i o n al  t hera pe ut ic i nt er ve nt i o n s h o ul d 
be c o nsi dere d i n pat ie nt s w h o de vel o p se ve re, persiste nt h y per gl yce mia after ra n d o mizat i o n at 
t h e discret i o n of i n vest i gat or i n acc or da nce wit h A merica n Dia betes Ass ociat i o n/ E ur o pea n 
Ass oci at i o n f o r t he St u d y  of  Di a betes g ui da nce (I nz ucc hi et al . 2 0 1 5).  Resc ue me dicat i o n will 
be prescri be d as a d d -o n t o ra n d o mize d treat me nt, a n d patie nts will c o nt i n ue t o f oll o w t he 
pr ot oc ol -s pecifie d visit sc he d ule. 
Beca use i ns uli n glar gi ne d ose a dj ust me nts wit h o ut restrict i o ns will be i nit iate d at t he e n d of t he 
sta bilizati o n peri o d (see Secti o n 5. 1 ), deci si o n  o n t he prese nce of se vere, persiste nt 
h y per gl yce mia ca n be first c o nsi dere d 1 2 wee ks after t h e i nit iati o n of t his peri o d (a p pr o xi matel y 
1 6 wee ks after ra n d o mizat i o n).. 
I8F-MC-GPGI( b) Clinical Protocol Page 58
LY3298176Add-on glycemic rescue therapy  will be allo wed for pati ents who m et any  one of the following 
prespecified criteria for severe, persistent hy perglycemia and no intercurrent cause of the 
hyperglycemia could be ident ified (invest igators shou ld first confirm that the patient is fully 
compliant wi th the assigned therapeutic regimen and that the pati entdoes not have an acute 
condi tion causing severe hyperglycemia): 
(a)average daily  BG f rom the once -weekly  4-point SMBG profile >270 mg/dL 
(>15.0 mmo l/L) over at l east a consecut ive [ADDRESS_526336] rando mizat ion; 
OR 
(b)average daily  BG f rom the once -weekly  4-point SMBG profile >240 mg/dL 
(>13.3 mmo l/L) over a consecut ive [ADDRESS_526337] 
rando mizat ion; 
OR
(c)average daily  BG f rom the once -weekly  4-point SMBG profile >200 mg/dL 
(>11.1 mmo l/L) over a consecut ive [ADDRESS_526338] rando mizat ion.
OR
(d)HbA1c ≥8.5% at [ADDRESS_526339] 3 months ( Week 12 to Week 24) that is ,<0.3%
Rescue therapy option :
The criteria described above for severe, persistent hyperglycemia will only  be applicable after 
Week 16.  The first choice before init iating any rescue therapy  for those pati ents during the 
initial [ADDRESS_526340] igator’s opi[INVESTIGATOR_3078] n, may require an intervent ion that i s not consistent 
with the requi rements provi ded in this section, he or she shoul d also consult the Lilly  physician 
before such intervent ion is implemented, except when an immediate adjust ment of the treatment 
regimen is medically required .
[IP_ADDRESS]. Pancrea titis
Acute pancreat itis is defined as an AE of interest in all trials with tirzepat ideincluding this trial.  
Acute pancreat itis is an acute inflammatory  process of the pancreas that may  also involve 
peripancreat ic tissues and/or remote organ sy stems (Banks and Freeman 2006).  The diagnosis of 
acute pancreatit is requires 2 of the fo llowing 3 features:
abdo minal pain, characterist ic of acute pancreat itis (generally located in the 
epi[INVESTIGATOR_82347] [Banks and 
Freeman 2006; Ko izumi et al . 2006] ;the pain is o ften associated with nausea and 
vomiting);
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e 5 9 
LY 3 2 9 8 1 7 6 ser u m  pa ncreat ic a m ylase a n d/ or li pase ≥ 3 X U L N 
c haracterist ic fi n di n gs of ac ute pa ncreat it is o n c o m p ute d t o m o gra p h y  ( C T) sca n or 
ma g net ic res o na nce i ma gi n g ( M RI). 
If ac ute pa ncreat it is is s us pecte d, a p pr o priate la b orat or y  tests (i ncl u di n g le vels of pa ncreat ic 
a m ylase a n d li pase) s h o ul d be o btai ne d via t he ce ntral la b orat or y  (a n d l ocall y, if nee de d).  
I m a gi n g st u dies, s uc h as a b d o mi nal C T sca n wit h or wit h o ut c o n trast, M RI, or gall bla d der 
ul tras o u n d, s h o ul d be perf or me d.  If la b orat or y  v al ues a n d/ or a b d o mi nal i ma gi n g s u p p ort t he 
di a g n osis of ac ute pa ncreat it is, t he patie nt m ust disc o nti n ue t hera p y wit h i n vest i gat i o nal 
pr o d uct(s) ,b ut will c o nt i n ue i n t he st u d y  o n a n ot her gl uc ose -l o weri n g re gi me n ( details o n resc ue 
i nt er ve nt i o n will be pr o vi de d).  T he m ost a p pr o priate di a betes t hera pe utic re gi me n will be 
deci de d b y  t he i n vesti gat or, base d o n t he patie nt’s cli nical stat us.  A re vie w of t he patie nt’s 
c o nc o mita nt me dicat i o ns s h o ul d be c o n d ucte d t o assess a n y  p ot e nti al ca usal  r el ati o ns hi p wi t h  
pa ncreat it is. 
Eac h case o f A E of pa ncreat it is m u st be re p orte d.  If t y p ical si g ns a n d/ or s y m pt o ms o f 
pa ncreat it is are prese nt a n d c o nfir me d b y la b orat or y val ues (li pase or pa ncreatic a m ylase) a n d 
i ma gi n g st u dies, t he e ve nt m ust be re p orte d as a n S A E.  F or a p ote ntial ca se t hat d oes n ot meet 
all o f t h ese cri t eri a, i t i s u p t o t he i n vest i gat or t o deter mi ne t he seri o us ness o f t h e case ( A E or 
S A E) a n d t he relate d ness of t he e ve nt t o st u d y  dr u g(s). 
Eac h patie nt will ha ve meas ure me nts of p -a m ylase a n d li pase (assesse d at t he c e ntral  l a b orat or y ) 
as s h o w n o n t he Sc he d ule o f Act i vit ies ( Secti o n 2)t o assess t he effects of t he i n vesti gati o nal 
d oses of ti rze pati d e o n pa ncreat ic e nz y me le vels. S eri al  m eas ures of pa ncreat ic e nz y mes ha ve 
li mite d cli nical val ue f or pre dict i n g e pis o des of ac ute pa ncreatit is i n as y m pt o mat ic pat ie nt s 
( Na uc k et al. 2 0 1 7; Stei n ber g et al. 2 0 1 7a; Stei n ber g et al. 2 0 1 7 b). T h us, f urt her dia g n ost ic 
f o ll o w- u p of  cases of as y m pt o mat ic pa ncreat ic h y pere nz y me mia (li pase a n d/ or pa ncreatic 
a m ylase ≥ 3 XU L N) is n ot ma n date d ,b ut ma y be perf or me d base d o n t he i n vesti gat or’s cli nical 
j u d g me nt a n d assess me nt of t he patie nt’s o verall cli nical c o n dit i o n. O nl y cases of pa ncreat ic 
h y pere nz y me mia t hat u n der g o a d diti o nal dia g n ostic f o ll o w- u p a n d/ or are acc o m pa nie d b y 
s y m pt o ms s u g gest i ve of pa ncreat it is will be s u b mitte d f or a dj u dicati o n. 
All s us pecte d cases of ac ute or c hr o nic pa ncreat itis  will be a dj u dicate d b y a n i n de pe n de nt 
cli nical en d p o i nt  c o m mittee ( C E C). I n a d dit i o n, A Es of se vere or seri o us a b d o mi nal pai n o f 
u n k n o w n et i ol o g y  will  als o be s u b mitte d t o t he a dj u dicat i o n c o m mit tee t o assess f or p ossi ble 
pa ncreat it is or ot her pa ncreatic disease. Rele va nt d ata fr o m  patie nts wi t h  ac ute or c hr o ni c 
pa ncreat it is a n d t h ose wit h se vere or seri o us a b d o mi nal pai n will be e ntere d i nt o a s pecificall y 
desi g ne d e C R F pa ge b y st u d y  si te or Lill y  st aff .T he a dj u dicat i o n c o m mittee re prese ntati ve will 
e nter t he res ults of a dj u dicat i o n i n a c orres p o n di n g e C R F pa ge. 
9. 2. 2. 4. T h yr oi d M ali g n a n ci e s a n d C -C ell H y p er pl a si a 
I n di vi d uals wit h pers o nal or fa mil y hist or y  of  M T C a n d/ or m ult i ple e n d ocri ne ne o pl asia t y pe 2 
( M E N- 2 )will be e xcl u de d fr o m t h e st u d y .  T he assess me nt of t h y r oi d safet y d uri n g t he st u d y 
will i ncl u de re p orti n g of  a n y  c as e of  t h y r oi d m ali g na nc y i ncl u di n g M T C a n d pa pi[INVESTIGATOR_5778] y  carci n o ma 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526341] t h y r oi d C -cell f u ncti o n, 
w hic h ma y  i n dicate de vel o p me nt of C -cell h y per plasia a n d ne o plas ms . Ti rze pat i de s h o ul d be 
di sc o nti n ue d (after first c o nfir mi n g t he val ue) i f p ostra n d o mizat i o n calcit o ni n val ue is ≥ 3 5 n g/ L 
a n d has i ncrease d at least 5 0 % o ver baseli ne.  A c o ns ultat i o n wi t h  a t h y r oi d s pecialist (if n ot 
a vaila ble, a n e n d ocri n o l o gi st) s h o ul d be o btai ne d. 
If t he i ncrease d calcit o ni n val ue ( ≥ 3 5 n g/ L a n d i ncreases b y ≥ 5 0 % c o m pare d wi t h baseli ne) is 
o bser ve d i n a patie nt w h o has a d mi nistere d a me dicati o n t hat is k n o w n t o i ncrease ser u m 
cal ci t o ni n, t hi s me dicat i o n s h o ul d be st o p pe d a n d calcit o ni n le vels s h o ul d b e m eas ure d after a n 
a p pr o priate was h o ut peri o d.  If t he c o n fir me d calcit o ni n val ue is < 3 5 ng/ L, ti rze pat i de s h o ul d be 
restarte d w he n it is safe t o d o s o.  
9. 2. 2. 5. M aj or A d v er s e C ar di o v a s c ul ar E v e nt s Deat hs a n d n o nfatal C V A Es will be 
a dj u dicate d b y  a c o m mi tt e e of  p h ysicia ns e xte r nal t o Lill y  wi t h  car di ol o g y  e x pert ise.  
T he n o nfatal C V A Es t o be a dj u dicate d i ncl u de t he f oll o wi n g:   
m y ocar dial  i nfarct i o n, 
h os pi [INVESTIGATOR_1314] o n f or u nsta ble a n gi na ,
h os pi [INVESTIGATOR_1314] o n f or heart fail ure ,
c or o nar y  i nt er ve nt i o ns (s uc h as c or o nar y  arter y  b y pass gr af t or perc uta n e o us c or o nar y  
i nt er ve nt i o n) , a n d 
cere br o vasc ular e ve nts, i ncl u di n g cere br o vasc ular acci de nt (str o ke ) a n d tra nsie nt 
isc he mic attac k .
9. 2. 2. 6. S u pr a v e ntri c ul ar a rr yt h mi a s a n d C ar di a c C o n d u cti o n Di s or d er s 
Treat me nt -e mer ge nt car diac c o n d ucti o n dis or d ers will be f urt her e val uate d.  Patie nts w h o 
de vel o p a n y e ve nt fr o m t h is gr o u p of di s or ders s h o ul d u n der g o a n E C G w hic h s h o ul d be 
s u b mitte d t o t he ce ntral rea di n g ce nter. A d dit i o nal dia g n ostic tests t o deter mi ne e xact dia g n osis 
s h o ul d be perf or m e d, as nee de d. T he s pecific dia g n osis will be rec or de d as a n A E. E ve nts t hat 
meet criteria f or seri o us c o n diti o ns as descri be d i n Secti o n 9. [ADDRESS_526342] u g(s) vi a a C R F create d f or t his p ur p ose. A d dit i o nal sa m ples s h o ul d als o be c o llecte d as 
o utli ne d i n Sect i o n 9. [ADDRESS_526343] u g(s) s h o ul d be te m p oraril y i nterr u pte d i n a n y i n di vi d ual 
s us pecte d of ha vi n g a se vere or seri o us aller gic reacti o n t o st u d y  dr u g(s).  St u d y  dr u g(s) m a y  b e 
restarte d w he n/if it is safe t o d o s o, i n t he o pi [INVESTIGATOR_9384] o n of t he i n vest i gat or.  If st u d y dr u g(s) is 
p er m a ne nt l y disc o nt i n ue d, t he patie nt will recei ve a n ot her gl uc ose -l o weri n g treat m e nt, j u d ge d b y 
t h e i n vest i gat or t o be a p pr o priate base d o n t he patie nt’s cli nical stat us, a n d will c o nt i n ue i n t he 
tri al  t o c ollect all pla n ne d ef ficac y a n d safet y me as ure m e nts. 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526344] u g A nti b o di e s 
T he occ urre nce of A D A f or mat i o n will be assesse d as o utli ne d i n Secti o n 1 0. 3. 6 .
9. 2. 2. 1 0. Di a b eti c R eti n o p at h y C o m pli c ati o n s 
Dilate d reti nal f u n d os c o pi [INVESTIGATOR_126148] i o n will be perf or me d b y  a q ualifie d e ye care pr ofessi o nal 
( o p ht hal m o l o gist or o pt o metrist) f or all patie nts bet wee n Visit 2 a n d Visit 3 t o e xcl u de patie nts 
wi t h  pr oliferat i ve ret i n o pat h y  a n d/ or m a c ul o p at h y .  T he res ul ts f r o m  t his e xa mi nat i o n will be 
rec or de d o n a s pecific reti n o pat h y  e C R F as a baseli ne meas ure of reti n o pat h y .  
A f o ll o w- u p dilate d f u n d os c o pi [INVESTIGATOR_126148] i o n s h o ul d be perf o r m e d w he n cli nicall y  i n dicate d b y  
a n y A E s us pecte d of w orse ni n g reti n o pat h y , a n d t he fi n di n gs s h o ul d be rec or de d o n t he 
reti n o pat h y  e C R F.  
9. 2. 2. [ADDRESS_526345] it is, or ot her s us pecte d e ve nts relate d t o 
gall bla d der disease s h o ul d be e val uate d a n d a d dit i o nal dia g n ostic tests perf or me d, as nee de d. I n 
cases o f el e vate d li v er m ar kers, he patic m o ni t ori n g s h o ul d be i ni ti ate d as o utli ne d i n 
Secti o n 9. 4. 5 a n d A p pe n di x 4 .
9. 2. 2. 1 2. S e v er e G a str oi nt e sti n al A d v er s e E v e nt s 
Ti rze pati d e ma y ca use se vere GI A Es, s uc h as ;na usea, v o mit i n g, a n d diarr hea.  I nf or mat i o n 
a b o ut se vere GI A Es as well as a ntie metic/a nti diarr heal use will be c o llecte d i n t he e C R F/ A E 
f o r m .  F or detaile d i nf or mati o n c o ncer ni n g t he ma na ge me nt of GI A Es, please refer t o 
Secti o n 7. 7. 1.
9. 2. 2. [ADDRESS_526346] i ve o f ac ute or w orse ni n g of c hr o nic re nal fail ure . Gastr oi ntesti nal 
A Es ha ve bee n re p orte d wit h ti rze pat i de , i ncl u di n g na usea, diarr hea, a n d v o mit i n g.  T hese are 
c o nsiste nt wit h ot her G L P -1 rece pt or a g o nists ( Ar o da a n d Rat ner 2 0 1 1).  T he e ve nts ma y lea d t o 
de h y drat i o n, w hic h c o ul d ca use a deteri or ati o n i n re nal f u ncti o n, i ncl u di n g ac ute re nal fail ure.  
P ati e nts s h o ul d be a d vise d t o n otif y i n vest i gat ors i n case of se vere na usea, fre q ue nt v o mit i n g, or 
s y m pt o ms of de h y drat i o n. 
9. 2. 2. 1 4. M et a b oli c A ci d o si s, In cl u di n g Di a b eti c K et o a ci d o si s 
Ket oaci d osis, a seri o us life -t hreate ni n g c o n diti o n re q uiri n g ur ge nt h os pi[INVESTIGATOR_1314] o n, has bee n re p orte d 
rarel y i n patie nts wit h T 2 D M.  Patie nts w h o prese nt wit h si g ns a n d s y m pt o ms c o nsiste nt wit h se vere 
meta b olic aci d osis s h o ul d be assesse d f or ket oaci d osis re gar dless of prese nti n g B G le vels, as 
ket oaci d osis ma y be prese nt e ve n if B G le vels are less t ha n 2 5 0 m g/ d L.  If ket oaci d osis is s us pecte d, 
patie nt s h o ul d be e val uate d, a n d pr o m pt treat me nt s h o ul d be i nstit ute d.  Treat me nt of ket oaci d osis 
ma y  re q uire i ns uli n, fl ui d a n d car b o h y drate re place me nt. 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526347] u d y.  If lactic aci d osis is s us pecte d, metf or mi n s h o ul d be 
te m p oraril y disc o nti n ue d u ntil t he res ol uti o n of t he e ve nt. 
9. 2. 2. 1 5. A m p ut ati o n/ P eri p h er al R e v a s c ul ari z ati o n 
All cases of a m p utati o n a n d peri p heral re vasc ularizati o n s h o ul d be re p orte d as a n A E. 
9. 2. 2. 1 6. M aj or D e pr e s si v e Di s or d er/ S ui ci d al I d e ati o n 
T he pre vale nce of de pressi ve s y m pt o ms a n d dis or ders is i ncrease d i n patie nts wi t h T 1 D M or T 2 D M 
( A D A G ui deli ne, 2 0 1 7).  A n y A E of maj or de pressi ve dis or der or s uici dal i deati o n s h o ul d be 
re p orte d. 
9. 2. 3. C o m pl ai nt H a n dli n g 
Lill y c o llects pr o d uct c o m plai nts o n i n vest i gat i o nal pr o d ucts a n d dr u g deli ver y s yste ms use d i n 
cli nical st u dies i n or der t o e ns ure t he safet y of  st u d y  p arti ci pa nts, m o ni t or q uali t y , a n d t o 
facilitate pr ocess a n d pr o d uct i m pr o ve me nts. 
P ati e nts wil l be i nstr ucte d t o c o ntact t he i n vesti gat or as s o o n as p ossi ble if he or s he has a 
c o m plai nt or pr o bl e m wi t h  t he i n vest i gat i o nal pr o d uct s o t hat t he sit uati o n ca n be assesse d. 
9. 3. Tr e at m e nt of O v er d o s e 
St u d y  dr u g o ver d ose ( m ore t ha n t he s pecifie d n u m ber of i nj e cti o ns) will  b e re p orte d as a n A E.  
I n t he e ve nt of o ver d ose, refer t o t he I B f or ti rze pati de a n d/ or Pr o d uct La bel f o r i ns uli n glar gi ne .
9. 4. S af et y 
9. 4. 1. El e ctr o c ar di o gr a m s 
F or eac h pati e nt , el ectr ocar di o gr a m s ( E C Gs) s h o ul d be c ollecte d acc or di n g t o t he Sc he d ule of 
Act i vit ies ( Secti o n 2).  El ectr ocar di o gra ms s h o ul d be rec or de d acc or di n g t o t he st u d y -s pecific 
rec o m me n dat i o ns i ncl u de d i n Ma n ual o f O perati o ns f or t h e st u d y .  
Electr ocar di o gra ms will i nit iall y  b e i nter prete d b y  a q ualifie d p h ysicia n (t he i n vesti gat or or 
q ualifie d desi g nee) at t he site as s o o n after t he ti me of E C G c ollecti o n as p ossi ble, a n d i deall y  
w hile t he pati e nt i s st ill prese nt, f or i m me diate s u bject ma na ge me nt, s h o ul d a n y cli nicall y 
r el e va nt fi n di n gs be i d e ntifie d .  A n y cli nicall y si g nifica nt fi n di n gs fr o m E C Gs t hat res ult i n a 
di a g n osis a n d t hat occ ur after t h e pati e nt recei ves t he first d ose of t he i n vest i gat i o nal treat me nt 
s h o ul d be re p ort e d t o Lill y or its desi g nee as a n A E via t h e e C R F. 
All di gital E C Gs will be o btai ne d usi n g ce ntrall y pr o vi de d E C G mac hi nes a n d will be 
el e ctr o ni call y tra ns mitte d t o a desi g nate d ce ntral E C G l a b orat or y .T he ce ntral E C G la b orat or y  
will perf or m a basic q uali t y  c o ntr ol  c hec k ( f o r e xa m ple , d e m o gra p hics a n d st u d y  details) a n d 
t h e n st ore t he E C Gs i n a data base. At  a f ut ure ti me, t he st ore d E C G data ma y be o verrea d b y a 
car di ol o gi st at t he ce ntral  E C G l a b orat or y  f or f urt her e val uat i o n of mac hi ne -rea d meas ure me nts 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526348] u d y  re p ort (i n w hic h case, t he o verrea d data w o ul d 
be use d). 
9. 4. 2. Vit al Si g n s 
F or eac h pati e nt , vi t al  si g ns meas ure me nts s h o ul d be c o n d ucte d acc or di n g t o t he Sc he d ule o f 
Act i vit ies ( Secti o n 2). 
A n y cli nicall y  si g nifica nt fi n di n gs fr o m vital si g ns meas ure me nt t hat res ult i n a dia g n osis a n d 
t h at occ ur after t he pati e nt recei ves t he first d ose of st u d y treat me nt s h o ul d be re p orte d t o Lill y or 
it s desi g nee as a n A E via e C R F .
9. 4. 3. L a b or at or y T e st s 
F or eac h pati e nt , l a b orat or y tests detaile d i n ( A p pe n di x 2 ) s h o ul d be c o n d ucte d acc or di n g t o t he 
Sc he d ule of Act i vit ies ( Secti o n 2). 
Wit h t he e xce pti o n o f la b orat or y  test res ul ts t hat ma y  u n bli n d t he st u d y , Lill y or i ts desi g nee will  
pr o vi de t he i n vest i gat or wit h t he res ults of la b orat or y  tests a nal yze d b y  a ce ntral ve n d or, if a 
ce ntral ve n d or i s use d f or t he cli nical trial.  
A n y cli nicall y  si g nifica nt fi n di n gs fr o m la b orat or y tests t hat res ult i n a dia g n osis a n d t hat occ ur 
af ter t he pati e nt recei ves t he first d ose of i n vest i gati o nal pr o d uct s h o ul d be re p orte d t o Lill y or its 
desi g nee as a n A E via C R F .
9. 4. 4. I m m u n o g e ni cit y A s s e s s m e nt s 
W here l ocal re g ulat i o ns a n d E R Bs all o w, bl o o d sa m ples f or i m m u n o ge nicit y testi n g will be 
c ollecte d t o deter mi ne a nt i b o d y  pr o d ucti o n a gai nst ti rze pat i de as s pecifie d i n t he Sc he d ule of 
Act i vit ies ( Secti o n 2).
At  t he visit s a n d t i mes s pecifie d i n t he Sc he d u le of Act i vit ie s ( Secti o n 2), ve n o us bl o o d sa m ples 
will be c o llecte d t o deter m i ne a nt i b o d y  pr o d ucti o n a gai nst ti rze pat i de .  T o i nt er pret t he res ults of 
i m m u n o ge nicit y,  a P K sa m ple will  b e c ollecte d at t he sa me t i me p oi nts as t he i m m u n o ge nicit y 
sa m ple . All sa m ples f or i m m u n o ge nicit y s h o ul d be ta ke n pre d ose w he n a p plica ble a n d p ossi ble. 
In t he e ve nt of dr u g h y perse nsit i vit y react i o ns (i m me diate or n o ni m me diate) , a d diti o nal sa m ples 
will be c o llecte d (i ncl u di n g A D A, P K, a n d e x pl orat or y  i m m u ne safet y sa m ple )as cl ose t o t he 
o nset of t he e ve nt as p ossi ble, at t he res ol ut i o n of t he e ve nt, a n d [ADDRESS_526349] i o n a n d ha n dli n g of bl o o d sa m ples will be pr o vi de d b y t he s p o ns or.  
S a m ple c ollecte d at Visit 8 0 1 will assess i m m u n o ge nicit y at was h o ut of ti rze pat i de ( [ADDRESS_526350] e n d of treat me nt). 
Treat me nt -e mer ge nt A D As are defi ne d i n Sect i o n 1 0. 3. 6 .  
S a m ples wi t h  A D A detecte d will be titere d a n d e val uate d f or t heir a bilit y t o ne utralize t he 
acti vit y of  assi g ne d treat m e nt ( ti rze pat i de -ne utralizi n g a nti b o dies).  Sa m ples wit h ti rze pat i de 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526351] u d y  pati e nt e x perie nces ele vate d A L T ≥ 3 X U L N, A L P ≥ 2 X U L N, or ele vate d T B L ≥ 2 X 
U L N, li ver testi n g ( A p pe n di x 4 ) s h o ul d b e re peate d wi t hi n [ADDRESS_526352] u d y  m e dical m o nit or. M o nit ori n g of A L T, A S T, T B L, a n d A L P s h o ul d 
c o nti n ue u ntil le vels n or malize or ret ur n t o a p pr o xi mate baseli ne le vels. 
He p atic S afet y D at a C ollecti o n 
A d dit i o nal safet y data s h o ul d be c o llecte d via t he e C R F if 1 or m ore of t he f o ll o wi n g c o n di ti o ns 
occ ur: 
ele vat i o n of ser u m  A L T t o ≥ 5 X U L N o n 2 or m ore c o nsec uti ve bl o o d tests 
ele vate d ser u m T B L t o ≥ 2 X U L N (e xce pt f or cases of k n o w n Gil bert’s s y n dr o me )
ele vat i o n of ser u m  A L P t o ≥ 2 X U L N o n 2 or m ore c o nsec uti ve bl o o d tests 
pati e nt disc o nt i n ue d fr o m treat m e nt d ue t o a he patic e ve nt or a b n or malit y of li ver tests 
he pat ic e ve nt c o nsi dere d t o be a S A E 
9. 5. P h ar m a c o ki n eti c s 
P har mac o ki net ic sa m ples will be c o llecte d fr o m all patie nts. Pl as ma ti rze pat i de c o nce ntrati o ns 
will be deter mi ne d f r o m  bl o o d s a m ples o btai ne d fr o m  patie nts recei vi n g ti rze pat i de treat m e nt. 
Bl o o d sa m pl es f or P K assess me nt will be c ollecte d aft er Wee k 7, [ADDRESS_526353] u d y  Sc he d ule or at E T (Secti o n 2). Eac h patie nt will be assi g ne d via I W R S t o o ne of t he 
sa m pli n g P K  ti me wi n d o ws of [ADDRESS_526354] be rec or de d o n t he la b orat or y  accessi o n pa ge. 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e 6 5 
LY 3 2 9 8 1 7 6 C o nce ntrati o ns of ti rze pa ti de will  b e assa ye d usi n g a vali date d li q ui d c hr o mat o gra p h y  m ass 
s pectr o metr y  ( L C/ M S) m et h o d.   Bi o a nal yt ical sa m ples c ollecte d t o meas ure ti rze pat i de 
c o nce ntrati o ns will be retai ne d f or a ma xi m u m o f [ADDRESS_526355] i gat i ve 
si tes or bli n de d pers o n nel ( u nt il t he st u d y  has bee n u n bli n de d). 
9. 6. P h ar m a c o d y n a mi c s 
S a m ples t o assess t he P D pr o perties of tirze pat i de are i ncl u de d i n t he efficac y meas ures a n d n ot 
a p plica ble i n t his sect i o n. 
9. 7. P h ar m a c o g e n o mi c s 
9. 7. 1. W h ol e Bl o o d S a m pl e sf or P h ar m a c o g e n eti c R e s e ar c h 
A w h o le bl o o d sa m ple will  b e c ollecte d f or p har mac o ge net ic a nal ysis as s pecifie d i n t he 
Sc he d ule of Act i vit ies ( Secti o n 2)w here l ocal re g ulat i o ns all o w .  
S a m ples will  n ot be use d t o c o n d uct u ns pecifie d disease or p o p ulat i o n ge net ic researc h eit her 
n o w or i n t he f ut ure.  Sa m ples will be use d t o i n vesti gate varia ble res p o nse t o ti rze pat i de a n d t o 
i n vesti gate ge net ic varia nts t h o u g h t t o pl a y a r ol e i n dia betes .  Assess me nt of varia ble res p o nse 
ma y i ncl u de e val uati o n o f A Es or differe nces i n efficac y .  
All sa m ples will be c o de d wit h t he patie nt n u m ber.  T hese sa m ples a n d a n y data ge nerate d ca n 
be li n ke d bac k t o t he patie nt o nl y b y t he i n vest i gat or site pers o n nel .  
S a m ples will  b e retai ne d at a facilit y selecte d b y  Lill y  or i ts desi g nee f o r a m a xi m u m  of  [ADDRESS_526356] u d y, or f or a s h orter peri o d if l ocal re g ulati o ns a n d/ or 
(E R Bs /i n vest i gati o nal re vie w b oar ds )i m p ose s h orter ti me li mit s.  T hi srete nti o n peri o d e na bles 
use of ne w tec h n o l o gi es, res p o nse t o re g ulat or y  q uesti o ns, a n d i n vest i gat i o n of varia ble res p o nse 
t h at ma y  n ot be o bser ve d u nt il later i n t h e de vel o p me nt of ti rze pati d e or after ti rze pat i de 
bec o me( s) c o m merciall y  a vaila ble .
M olec ular tec h n o l o gi es are e x pecte d t o i m pr o ve d uri n g t he [ADDRESS_526357] i o n, varia bilit y of  p ati e nt res p o nse (i ncl u di n g safet y ), a n d 
cli nical o utc o me.  Sa m ple c o llect i o n is i nc or p orate d i nt o cli nical st u dies t o e na ble e xa mi nat i o n of 
t h ese q uest i o ns t hr o u g h meas ure me nt of bi o m o lec ul es i ncl u di n g de o x y ri b o n ucleic aci d ( D N A ), 
ri b o n ucleic aci d ( R N A ), pr otei ns, li pi [INVESTIGATOR_805], a n d ot her cell ular ele me nts. 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526358] i vit ies ( Secti o n 2)w here l ocal re g ulat i o ns all o w. 
S a m pl es will  b e use d f or researc h o n t he dr u g tar get, disease pr ocess, varia ble res p o nse t o 
ti rze pat i de , pat h wa ys ass ociate d wit h T 2 D M , m ec ha nis m o f acti o n of  ti rze pat i de , a n d/ or researc h 
met h o d or i n vali dat i n g dia g n ost ic t o ols or assa y(s) relate d t o T [ADDRESS_526359] i gat i o n of varia ble res p o nse t hat ma y n ot be o bser ve d u nt il later 
i n t h e de vel o p m e nt of  ti rze pat i de or after ti rze pat i d ebec o me(s) c o m merciall y a vaila ble .
9. 9. H e alt h E c o n o mi c s 
The f o ll o wi n g q uest i o n naires will be c o m plete d b y t he patie nts at s pecific cli nic visit s acc or di n g 
t o t he Sc he d ule of E ve nts ( Secti o n 2). At t hese visits, t he q uesti o n naires s h o ul d be c o m p lete d 
bef ore t he patie nt has disc usse d t heir me dical c o n dit i o n o r pr o gress i n t he st u d y wit h t he 
i n vesti gat or a n d/ or site staff a n d bef ore a n y ot her st u d y  pr oce d ures if t he pat ie nt  is n ot a d versel y 
affecte d b y  t heir fast i n g c o n dit i o n. 
9. 9. 1. A bilit y t o P erf or m P h y si c al A cti viti e s of D ail y Li vi n g 
T he A P P A D L q uest i o n naire c o nt ai ns [ADDRESS_526360] i vit ies c o nsi dere d t o be i nte gral t o n or mal dail y life, s uc h as wal ki n g, sta n di n g ,a n d 
cli m bi n g stairs ( H a y es et al . 2 0 1 1; 2 0 1 2).  Ite ms are sc ore d o n a 5 -p oi nt n u meric rati n g scale, 
w here 5 =“ n ot at all diffic ult” a n d 1 =“ u na ble t o d o.”  A ra w o verall sc ore is calc ulate d b y 
si m pl y s u m mi n g t he sc ores of t he [ADDRESS_526361] of W ei g ht o n S elf -P er c e pti o n Q u e sti o n n air e 
T he I W -S P q uesti o n naire c o ntai ns 3 ite ms t hat assess h o w ofte n t h e pati e nt ’s b o d y  w ei g ht affects 
h o w ha p p y  t he y are wi t h  t h ei r a p peara nce a n d h o w ofte n t he y  f eel self -c o nsci o us w he n o ut i n 
p u blic ( Ha yes a n d De L ozier 2 0 1 5).  Eac h ite m is rate d o n a 5 -p oi nt scale ra n gi n g fr o m “al wa ys” 
t o “ ne ver.”  T otal sc ores f or t he I W- S P are deri ve d b y  s u m mi n g t he i t e m  sc ores a n d di vi di n g b y  
t h e n u m ber of ite ms.  T he sc ore ca n als o be tra nsf or me d t o a ra n ge fr o m 0t o 1 0 0.  Hi g her I W -S P 
sc ores c orres p o n d t o better self -perce pt i o n ( Ha y es a n d De L ozi er 2 0 1 5). 
9. 9. 3. Di a b et e s Tr e at m e nt S ati sf a cti o n Q u e sti o n n air e 
T he stat us (s) a n d c ha n ge (c) versi o ns of t he D T S Q will be use d d uri n g t he st u d y  t o assess t he 
pati e nt ’s sat isfacti o n wit h t heir dia betes treat me nt a n d t he percei ve d fre q ue nc y o f h y per gl yce mia 
I8F-MC-GPGI( b) Clinical Protocol Page 67
LY3298176and hypoglycemia.  The questionnaire contains 8 items (Bradl ey 1994).  Each i tem is rated on a 
7-point Likert scale.  Six items (1 and 4 through 8) are summed to produce a measure of 
treatm ent sati sfact ion ranging fro m 0 “very  dissat isfied” to 6 “very sat isfied.”  The remaining 2 
items (2 and 3) are treated individually.  Item 2 measures the perceived frequency  of 
hyperglycemia on a scale ranging fro m 0 “none of the time” to 6 “most of the time,” and Item [ADDRESS_526362] ion(3 “much more satisfied no w” to -3 “much less 
satisfied now”) .
9.9.4. European Quality of Life 
Generic health-related quali ty of lifewill be assessed using the EQ -5D- 5L (EuroQoL Group 
2015).  The EQ -5D- 5L is a standardized 5-item instrum ent for use as a m easure of healt h 
outcom e.  It pr ovides a simple descriptive profile and a single index value for health status that 
can be used in the clinical and econo mic evaluat ion of healt hcare as well as populat ion health 
surveys.  The EQ-5D- 5L com prises 5 dimensio ns of health (mobilit y, self-care, usual  activities, 
pain/disco mfort, and anxiet y/depressi on).  The 5L versio n, introduced in 2005, scores each 
dimensio n at 5 l evels (no probl ems, slight problems, moderate problems, severe problems, 
unable to perform/extreme problems), for a total of 3125 possible health states.  In addit ion to the 
healt h profile, a single healt h state index value can be derived based on a formula that attaches 
weights to each of the levels in each dimensio n. This index value ranges between l ess than 0 
(where 0is a healt h state equivalent to death; negative values are valued as worse than dead) to 1 
(perfect health).   In addit ion, the EQ Visual Analo g Scal erecords the respondent ’s self -rated 
healt h status on a vertical graduated (0 to 100) visual analogscale.  In conjunct ion with the 
healt h state data ,it provi des a co mposite pi[INVESTIGATOR_10905]’s healt h status.  
The EQ -5D- 5L is used worldwide and is available in more than 130different languages.  Details 
on the instrument, and scoring, organizi ng, and presenting the data collected can be found in the 
EQ-5D- 5L User Guide (EuroQoL Group 2015). 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526363] e Si z e D et er mi n ati o n 
P ati e nts will  b e ra n d o mize d i n a 1: 1: 1: [ADDRESS_526364] b o at a 2 -si de d si g nifica nce le vel of 0. 0 2 5, relat i ve t o t he pri mar y e n d p o i nt  ( m ea n 
c ha n ge i n H b A 1c fr o m baseli ne t o 4 0 wee ks), u n der t he f oll o wi n g ass u m pt i o ns:  use of a 
2-sa m ple t -test utilizi n g H b A 1c data c ollecte d bef o re i nit iat i o n of a n y  resc ue m e dicati o n or 
pr e m at ure treat m e nt disc o nt i n uat i o n wi t h  n o m ore t ha n 2 8 % of s u bjects i nit iat i n g resc ue 
me dicat i o n or pre mat urel y disc o nt i n ui n g treat me nt i n ea c h treat m e nt gr o u p; 0. 6 % greater mea n 
re d ucti o n i n H b A 1c fr o m baseli ne f or [ADDRESS_526365] b o; 1: 1: 1: 1 
ra n d o mizat i o n; a n d a c o m m o n sta n dar d de viat i o n ( S D) of 1. 1 %.  O n t he basis of t hese 
ass u m pt i o ns, a sa m ple size of [ADDRESS_526366] 9 0 % p o wer t o 
d e m o nstrate t hat ti rze pat i de 1 0 m g a n d/ or [ADDRESS_526367] b o relat i ve t o t he pri mar y 
e n d p o i nt .
F urt her m ore, t hi s sa m ple size will e ns ure 9 0 % p o wer f or t he s u peri orit y  e val uat i o n c o n d ucte d 
usi n g a n a n al ysis o f c o vari a nce ( A N C O V A) utilizi n g all a vaila ble H b A 1c data at 4 0 wee ks wit h 
missi n g data i m p ute d wit h a c o nser vat i ve m ult i ple i m p utati o n met h o d (as descri be d i n 
Secti o n 1 0. 3. 3 bel o w), pr o vi de d a 0. 6 % greater mea n re d ucti o n i n H b A 1c fr o m baseli ne f or [ADDRESS_526368] b o a n d S D i ncreases t o n o m ore t ha n 1. 3 % d ue t o t he 
i ncl usi o n of data o n resc ue me dicati o ns a n d after pre mat ure treat me nt disc o nt i n uat i o n a n d 
i m p utati o n of  m issi n g data. 
I8F-MC-GPGI( b) Clinical Protocol Page 69
LY329817610.2. Populations for Analyses
For purposes of analysis, the following popul ations are defined as follows:
Population Description
Screened patients All participants who sign informed consent
Randomized patients All patients who are randomly assigned a treatment group.
modified intention -to-treat 
(mITT) populationAll randomly assigned participants who are exposed to at least 1 dose of study 
drug.  In the event of a treatment error, participants will be analyzed according 
to the treatment then were randomized.
Efficacy analysis set (EAS) Data obtained during Study Peri od II from the mITT population, excluding 
data after initiating rescue antihyperglycemic medication or stoppi[INVESTIGATOR_126149].
Full analysis set Data obtained during Study Period II from the mITT population, regardless of 
adherence to study drug or initiation of rescue antihyperglycemic medication.
Safety analy sis set (SS) Data obtained during Study Periods II or III from the mITT population, 
regardless of adherence to study drug or initiation of rescue antihyperglycemic 
medication.
10.3. Statistical Analyses
10.3.1. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y ofLilly o r its desi gnee .
Any change to the data analysis methods described in the protocol will re quire an amendment 
ONLY if it changes a principal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the statist ical analysis plan (SAP) or clinical study report (CSR) .  Additional exploratory 
analyses o f the data will be conducted as deemed appropriate.
Unless otherwise noted, all tests of treatment effects will be conducted at a 2 -sided alpha level o f 
0.05, and the confidence interval (CI) will be calculated at 95%, [ADDRESS_526369] estimand, the “efficacy” est imand , represents efficacy  prior to di scont inuat ion of study  
drug wi thout the confounding effects of ant ihyperglycemic rescue therapy.  The second 
estimand, the “treatment -regimen” est imand, represents the efficacy irrespective of adherence to 
study  drug or ini tiation of rescue antidiabetic drugs.
The primary  efficacy  assessment, gui ded by [CONTACT_941] “efficacy” est imand, will be conducted using the 
EAS.  The primary  efficacy  assessment, gui ded by [CONTACT_941] “treatm ent-regimen” est imand, will be 
conducted using the full analys is set.  As they  are intended for different purposes, no mult iplicit y 
adjustm ents will be m ade f or conducting [ADDRESS_526370] imand co mpar ing safety  
of tirzepat ide doses with placebo i rrespective of adherence to study  drug or init iation of 
I8F-MC-GPGI( b) Clinical Protocol Page 70
LY3298176antihyperglycemic rescue therapy.  Thus, the safety analysis will be conducted using the SS.  
Selected safet y analysis (for example, hypoglycemia) may be conducted excluding data after 
introducing another antihyperglycemic  therapy .
Summary  statistics for continuous m easures will  include sample size, mean, SD, median, 
minimum, and maximum.  The analysis model to make co mpar isons amo ng treatment groups 
relative to continuous measurements assessed over time will be a mixed model for repeated 
measures (MMRM), with terms: treatment, visit, and treatment -by-visit interaction, country , 
metformin use (Yes or No), and baseline measurement as a covariate.  An unstructured 
covari ance matrix will model the rel ationship of wit hin-patient errors.
The Kaplan -Meier m ethod will be used for estimatio n of cumulative event -free survival rates 
over time, and cox proportional hazards regressio n analysis will be used to compare hazard rates 
among treatm ents.
Summar y statistics for categorical measures (including categorized continuous measures) will 
include sample size, frequency, and percentages.  Fisher’s exact test will be used to examine the 
treatm ent difference in categorical outcomes.  Logistic regression may be used to examine the 
treatm ent difference in binary  efficacy  outcomes.  Summary  statistics for discrete coun t 
measures will include sample size, mean, SD, median, minimum, and maximum.  The negat ive 
binomial regressio n model will be used for the trea tment com parison of discrete count measures.
Other stati stical methods may be used, as appropriate, and details will be documented in the 
SAP.
10.3.2. Treatment Group Comparability
[IP_ADDRESS]. Patient Disposition
Frequency counts and percentages of all pat ients screened, rand omized, and receiving at least [ADDRESS_526371] ing of rando mized patients not 
receiving study  drug will be provided.  Of the patients in the mITT populat ion, frequency , counts 
and percentages of patients c ompleting the study , prem aturely  discontinuing the study , including 
the reason for premature discont inuat ion, will be presented by [CONTACT_1570].  A Kaplan- Meier 
analysis of time fro m randomization to premature discontinuat ion from study  by [CONTACT_417389].
[IP_ADDRESS]. Patient Characteristics
Dem ographics, medical history , and conco mitant illness will be summarized by [CONTACT_417390].
[IP_ADDRESS]. Concomitant Therapy
Concomitant medicat ions, including previous therapy  for diabetes, will be summarized by  
[CONTACT_417391].  
In parti cular, the incidence of rescue therapy  for severe, persistent hy perglycemia will be 
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526372] 7 5 % of re q uire d i nject i o ns of st u d y  dr u g.  
Fre q ue nc y c o u nts a n d perce nta ges of pat ie nt s c o m plia nt t o st u d y  dr u g will be s u m marize d b y 
treat m e nt ar m  usi n g t he m I T T p o p ul at i o n. 
[ADDRESS_526373] b o relat i ve t o mea n c ha n ge i n H b A 1c fr o m 
baseli ne t o t he 4 0 -wee k visit. 
F or t he F D A, t he pri mar y  efficac y  a nal ysis will  b e g ui de d b y  t he “treat m e nt -re gi me n” est i ma n d 
defi ne d i n Sect i o n1 0. 3. [ADDRESS_526374] u g a n d/ or i nit iat i o n of resc ue a nt i h y per gl yc e mic me dicat i o n.  A nal ysis will be c o n d ucte d wit h 
m ult i ple i m p utati o ns, a n d statistical i nfere nce o ver m ult i ple i m p utati o ns will be g ui de d b y  t he 
met h o d pr o p ose d b y  R u bi n ( 1 9 8 7).  
F or t he P har mace uticals a n d Me dical De vices A ge nc y, t he pri mar y efficac y as sess me nt will be 
g ui de d b y  t he “efficac y” est i ma n d, c o ntr olli n g t he o verall fa mil y -wise t y pe [ADDRESS_526375] ace b o i n H b A 1c c ha n ge fr o m baseli ne t o 4 0 wee ks.  A d dit i o nal details will be pr o vi de d i n t he 
S A P. 
T he A N C O V A a nal ysis will re p ort L S Mea n a n d sta n dar d err or ( S E) val ues f or eac h d osi n g ar m 
as well as t he differe nce i n mea n c ha n ge i n H b A 1c fr o m baseli ne t o t he [ADDRESS_526376] b o.  T he 9 7. 5 % CIs a n d bet wee n treat me nt p- val ues will als o be i ncl u de d f or 
t h e differe nces.  If t he differe nce b et wee n eit her ti rze pati de d ose a n d pl ace b o i s di r e cti o nall y 
s u peri or, a n d t he 2-si de d p -v al u e i s < 0. [ADDRESS_526377] ace b o.  
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e 7 2 
LY 3 2 9 8 1 7 6 F or all ot her p ur p oses, t he pri mar y efficac y  a nal ysis will  b e g ui de d b y t he “efficac y” est i ma n d 
defi ne d i n Sect i o n1 0. 3. [ADDRESS_526378] baseli ne 
visit.  T he i n de pe n de nt varia bles of t he M M R M m o del are treat me nt gr o u p ( [ADDRESS_526379] b o), visit, a n d treat me nt - b y- visit i nteract i o n, c o u ntr y , m et f o r mi n use 
( Yes or N o), a n d baseli ne H b A 1c as a c o variate.  A n u nstr uct ure d c o varia nce str uct ure will 
m o d el  t h e r el at i o ns hi p of wit hi n -pat ie nt  err ors.  If t he a nal ysis fails t o c o n ver ge, t he f oll o wi n g 
varia nce - c o varia nce matri x will be use d (i n or der) u nt il c o n ver ge nce is ac hie ve d:  heter o ge ne o us 
c o m p o u n d s y m metr y , c o m p o u n d s y m metr y , a n d first -or der a ut ore gressi ve.  T he Ke n war d -R o ger 
a p pr o xi mat i o n will be use d t o esti mate de n o mi nat or de grees of free d o m.  
T he M M R M a nal ysis will re p ort L S Mea n a n d sta n dar d err or ( S E) val ues f or eac h d osi n g ar m as 
well as t he differe nce i n mea n c ha n ge i n H b A 1c fr o m baseli ne t o t he [ADDRESS_526380] b o.  T he 9 7. 5 % CIs a n d bet wee n treat me nt p- val ues will als o be i ncl u de d f or 
t h e differe nces.  If t he differe nce bet wee n eit her ti rze pati de d ose a n d pl ace b o i s di r e cti o nall y 
s u peri or, a n d t he 2-si de d p -v al u e i s < 0. [ADDRESS_526381] t o t y pe 1 err or rate c o ntr ol are as f oll o ws: 
s u peri ori t y  of  t he [ADDRESS_526382] ace b o rel at i ve t o mea n c ha n ge i n H b A 1c 
fr o m baseli ne t o t he 4 0 -wee k visit 
s u peri ori t y  of  eac h ti rze pat i de d ose t o place b o relati ve t o mea n c ha n ge i n b o d y wei g ht 
fr o m baseli ne t o t he 4 0 -wee k visit 
s u peri ori t y  of  eac h ti rze pat i de d ose t o place b o r elati ve t o t he pr o p orti o n of patie nts 
ac hie vi n g t he tar get val ue of H b A 1c < 7 % at t he 4 0- wee k visit 
s u peri ori t y  of  eac h ti rze pat i de d ose t o place b o relati ve t o mea n c ha n ge i n F S G fr o m 
baseli ne t o t he 4 0 -wee k visit 
T he t y pe I err or -c o ntr olle d strate g y f or t h e pri mar y a n d sec o n dar y  e n d p oi nts will be descri be d i n 
t h e S A P.  All t y pe I err or -c o ntr olle d sec o n dar y efficac y a nal yses will be c o n d ucte d relati ve t o 
b ot h esti ma n ds, t he “efficac y” est i ma n d a n d t he “treat me nt -re gi me n” est i ma n d. 
A nal ysis of c ha n ge fr o m bas eli ne i n H b A 1c f or t he 5 m g tirze pat i de d ose at t he 4 0 -wee k visit 
will be c o n d ucte d i n a ma n ner si milar t o t he pri mar y  efficac y a nal yses as disc usse d i n 
Secti o n 1 0. 3. 3. 1 .
A nal ysis of c ha n ge fr o m baseli ne i n b o d y  wei g ht as well as F S G at t he 4 0 -wee k visit will be 
c o n d ucte d i n a ma n ner si milar t o t he pri mar y efficac y  a nal yses wi t h , res pecti vel y, c ha n ge i n 
w ei g ht f r o m  baseli ne a n d c ha n ge i n F S G fr o m baseli n e as t he res p o nse varia bles a n d baseli ne 
b o d y  wei g ht a n d baseli ne F S G as c o variates. 
I8F-MC-GPGI( b) Clinical Protocol Page 73
LY3298176Com parisons am ong treatm ents relative to the proportion of patients achieving the HbA1c target 
value of <7.0% (53 mmo l/mol) at the 40 -week visit will be conducted using a logistic regressio n 
analysis with terms of treatment, coun try, metformin use (Yes or No), and baseline HbA1c as a 
covari ate.  In the analysis o f patients achieving the HbA1c target value relat ive to the “efficacy” 
estimand, subjects with missing values at the 40-week visit will be excluded.  In the analysis of 
patients achieving the HbA1c target value relat ive to the “treatment -regimen” estimand, missing 
values at the 40 -week visit will be imputed based on observed data at respective visits fro m 
patients in the same treatment group who had their efficacy assessed after early discont inuat ion 
of study  drug and/or init iation of rescue medicat ion.  The analysis will be conducted with 
multiple imputations and statist ical inference over mult iple imputations will b e guided by [CONTACT_82404] (1987).
[IP_ADDRESS]. Tertiary/Exploratory Analyses
All exploratory  efficacy analyses will be guided by [CONTACT_941] “efficacy” estimand without imputati on 
of missing data and will be conducted using the EAS.  Details will be provided in the SAP.
10.3.4. Safety Analyses
Unless specified otherwise, safet y assessments will be guided by  [CONTACT_417392] i rrespective of adherence to study  drug or init iation of rescue 
therapy .  Thus, safet y analyses will be conducted using the SS.  Selected safet y analyses maybe 
conducted excluding data after the introduc tion of  another antihyperglycemi c therapy .
Adverse events will be coded from the actual term using the Medical Dict ionary for Regul atory  
Activities (MedDRA) and reported with preferred terms and system organ class.  Selected 
notabl e AEs of interest may be reported using high -level terms or Standardi zed MedDRA 
Queri es.  Summary  statistics will be provided for incidence of TEAEs, SAEs, study  
discontinuat ion due to AEs, study  drug di scont inuation due to AEs, deaths, and other CV 
endpo ints.  Counts and proportions of subjects experiencing AEs will be reported for each 
treatm ent group, and Fisher’s exact test will be used to compare the treatment groups.
[IP_ADDRESS]. Hypoglycemic Events
Incidence of documented symptomat ic hypoglycemia events and severe hypoglycemia in each 
category  (either total  or nocturna l) will be com pared between tirzepatide doses and placebo using 
negat ive binomial regressi on analysis.  Selected safet y analyses m ay be conducted excluding 
data after introduction of another antihyperglycemic therapy  (for example, rescue therapy ).
[IP_ADDRESS]. Gastroin testinal Events
Summaries and analyses for incidence and severit y of nausea, vo miting, and diarrhea will be 
provi ded by [CONTACT_91014].
[IP_ADDRESS]. Adjudicated Cardiovascular Events
Listings of deaths, myo cardi al infarct ions, strokes, and hospi[INVESTIGATOR_126152].  The dates of rando mizat ion, event, first 
dose and l ast dose of study  drug, and time from  rando mizat ion to the event will be listed.
I8F-MC-GPGI( b) Clinical Protocol Page 74
LY329817610.3.4.4. Central Laboratory Measures, Vital Signs, and Electrocardiograms
Values and change from baseline to postbaseline values of central laboratory  measures, vital 
signs, and selected ECG parameters will be summarized at each scheduled visit.  The analysis 
model to m ake co mpar isons amo ng treatment groups, relat ive to continuous change from 
baseline values assessed over time will be an MMRM similar to the primary  efficacy analysis 
and wit h baseline measurement as a covariate.  An unstructured covariance structure will model 
the relationship of within- patient errors.
The percenta ges of pat ients with TE abnormal, high, or low laboratory  measures at any  time will 
be summarized and compared between treatment groups by  [CONTACT_417393]’s exact test.  A TE 
abnorm al value i s defined as a change from normal value at baseline to a value great er than the 
high limit at any  time during Periods II and III.  A TE low result is defined as a change from a 
value greater than or equal to the low limit at baseline to a value less than the low limit at any  
time during Periods II and III.  High and low la boratory  limits will be determined by  [CONTACT_417394] .
10.3.5. Pharmacokinetic/Pharmacodynamic Analyses
Tirzepati deconcentration data will be analyzed using a populat ion PK approach via nonlinear
mixed -effects m odeling wi th the NONMEM soft ware. The relationships between tirzepat ide
dose and/or concentration and efficacy , tolerabili ty, and safet y endpo ints will be characterized.   
Addit ionally , the impact of intrinsic and extrinsic patient factors such as age, weight, gender, and
renal funct ion on PK and/or PD parameters may be examined as needed. If ADA titers are 
detected from immunogenicit y testing, then the impact of immunogenicit y titers on tirzepat ide
PK or any  relevant PD param eters m ay also be examined.
10.3.6. Evaluation of Immunogenic ity 
The frequency and percentage of patients with preexist ing ADA ,with TE ADA and wi th 
neutralizing TE ADA to tirzepat idewill be tabulated by [CONTACT_417395] . Treatment -emergent 
ADAs are defined as those with a titer 2 -fold (1 dilution) greater than t he minimum required 
dilution (MRD) if no ADAs were detected at baseline (treatment -induced ADA) or those with a 
4-fold (2 dilutions) increase in titer compared to baseline if ADAs were detected at baseline 
(treatment -boosted ADA). The MRD of the ADA assay is 1:10.   For TE ADA patients ,the 
distribut ion of maximum t iters will be described.  The frequency of neutralizing ant ibodies to 
tirzepat ideand/or cross -reactive and neutralizing ant ibodies to endogenous counterparts willbe
tabul ated in patients wi th TE ADA .
The relat ionship between the presence of ant ibodies and tirzepati dePKand PDresponse
including safet y and efficacy to tirzepati demay be assessed.
I 8 F -M C -G P GI( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_526383] ual a n d c ha n ge fr o m baseli ne i n patie nt -re p orte d o utc o m e ( P R O) sc ores will be 
c o n d ucte d usi n g li near m o dels wit h baseli ne P R O sc ores, treat me nt a n d ot her fact ors t hat ma y be 
c o nsi dere d rele va nt.  T hese varia bles will be s pecifie d i n t he S A P. 
1 0. 3. 7. 2. S u b gr o u p A n al y s e s 
S u b gr o u p a nal yses of mea n c ha n ge i n H b A 1c fr o m baseli ne t o Visit 1 8 will be pr o vi de d b y  a ge, 
race, et h nicit y, ge n der, d urati o n of dia betes, baseli ne H b A 1c ( ≤ 8. 0 % or > 8. 0 % [≤ 6 4, 
˃ 6 4m m o l/ m o l] , a n d baseli ne metf or mi n use. 
[ADDRESS_526384] ical a n al ysis pla n 
( S A P) or a se parate u n bli n di n g pla n d oc u me nt. 
I8F-MC-GPGI( b) Clinical Protocol Page 76
LY329817611. References
[ADA] American Diabetes Associat ion. 33. Com prehensive Medical Evaluat ion and Assessment
of Com orbidi ties: standards of m edical Care in diabetes 2017. Diabetes Care. 2017;40(suppl 
1):S25 -S32.
[ADA] American Diabetes Associat ion. 6. Glycemic targets : standards of medical Care in 
diabetes —2018 . Diabetes Care . 2018;41(suppl 1):S55 -S64.
Albert i KG,Zimmet PZ. Definit ion, diagnosis and cl assificat ion of diabetes mellitus and its 
complicat ions. Part 1: diagnosis and classificat ion of diabetes mellitus provisio nal report of a 
WHO consultation. Diabet Med. 1998;15(7):539 -553.
ArodaVR, Ratner R. The safet y and tol erabilit y of GLP -1 receptor agonists in the treatment of 
type 2 di abetes: a review. Diabetes Metab Res Rev 2011 ;27(6):528-542.
Banks PA, Freeman ML. Practice guidelines in acute pancreatit is. Am J Gastroenterol.
2006;101(10 ):[ADDRESS_526385] ion questionnaire: DTSQ. Handbook of Psycho logy 
and Diabetes: a guide to psy chological measurement in diabetes research and pract ice. 
Amsterdam; Harwood Academic Publishers, [ADDRESS_526386], Gimeno RE, D’Alessio DA, 
Haupt A. LY3298176, a novel dual GIP and GLP -[ADDRESS_526387] for th e treatm ent of ty pe 2 
diabetes m ellitus: from discovery  to clinical  proof  of concept. Molecular Metab . 2018 ;18:3 -14.
Danne T, Philotheou A, Gol dman D, Guo X, Pi[INVESTIGATOR_007] L, Cali A, Johnston P. A randomized trial 
comparing the rate of hypoglycemia – assessed using continuous glucose monitoring – in 125 
preschool children with ty pe 1 diabetes treated with insulin glargine or NPH insulin (the
PRESCH OOL study ). Pediatr Diabetes . 2013;14(8):593 -601. 
EuroQoL Group. EQ -5D- 5L User guide: basic info rmation on how to use the EQ -5D- 5L 
instrum ent. Versi on 2.1. Available at: 
https://euroqol.org/wp -content/upl oads/2016/09/EQ -5D- 5L_UserGuide_2015.pdf. Published
April 2015. Accessed August 06, 2018.
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, 
Robins D , Haupt A. Efficacy and safet y of LY3298176, a novel dual GIP and GLP -[ADDRESS_526388], in pat ients with type 2 di abetes : a randomised, pl acebo -controlled and act ive 
comparator -controlled phase 2 trial. Lancet. 2018;392([ZIP_CODE]):2180- 2193.
Guja C, Frias JP, Som ogyi A, Jabbour S, Wang H, Hardy  E, Rosenstock J. Effect of exenatide 
QW or pl acebo, both added to titrated insulin glargine, in uncontrolled t ype 2 diabetes; The 
DURATION- 7 randomized study . Diabetes Obes Metab . 2018; 20(7):[ADDRESS_526389] of  Weight on 
Self-Percept ions Questionnaire (IW -SP) in individuals with ty pe 2 diabetes and obesit y. 
Diabetes Technol Ther . 2015;17(3):210 -214.
I8F-MC-GPGI( b) Clinical Protocol Page [ADDRESS_526390], Meldahl ML, Curtis BH. Abilit y to perform  daily  physical  activi ties in 
individuals wit h type 2 di abetes and m oderate obesit y: a preliminary validation o f the Impact 
of Wei ght on Activit ies of Daily Living Quest ionnaire. Diabetes Technol Ther . 
2011;13(7):[ADDRESS_526391] ionnaire in 
individuals wit h type 2 di abetes and obesit y. Diabetes Technol Ther . 2012;14(12):1118- 1125.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas 
A, Wender R, Matthews DR. Management of hyperglycemia in t ype 2 diabetes, 2015: a 
patient-centered approach: update to a posit ion statem ent of  the Ameri can Diabetes 
Associ ation and the European Associat ion for the Study  of Diabetes. Diabetes Care.
2015;38(1):[ADDRESS_526392] e with type 2 diabetes treated with basal insu lin. 
Diabetes Obes Metab . 2016; 18(4):401 -409.
Koizumi M, Takada T, Kawarada Y, Hirata K, Mayu mi T, Yoshida M, Sekimoto M, Hirota M, 
Kimura Y, [COMPANY_005] K, Isaji S, Otsuki M, Matsuno S; JPN. JPN Guidelines for the management 
of acute pancreatit is: diagnostic criteria for acute pancreat itis. J Hepatobiliary Pancreat Surg .
2006;13(1):25 -32.
Nauck MA, Mei er JJ, Schmidt WE. Incretin -based glucose -lowering medicat ions and the risk o f 
acute pancreatit is and/or pancreati c cancer: reassuring data from cardio -vascular outcome 
trials. Diabetes Obes Metab . 2017;19(9):1327- 1328.
Pozzilli P, Norwood P, Jódar E, Davies MJ, Ivanyi T, Jiang H, Woodward B a nd Milicevic Z. 
Placebo -controlled, randomized tria l on the addi tion of  once weekly  glucagon -like pept ide-[ADDRESS_526393] dulaglut ide to titrated daily  insulin glargine i n pat ients with type 2 diabetes 
(AWAR D-9). Diabetes Obes Metab. 2017;19:1024 -1031.
Riddle MC, Rosenstock J, Gerich J ; Insulin Glargine 4002 Study  Investi gators . The 
treat-to-target tri al: rando mized addit ion of glargine or hum an NPH insulin to oral therapy  of 
type 2 di abetic pat ients. Diabetes Care .2003 ;26(11):[ADDRESS_526394], 
Wijayasinghe N, Norwood P. Semaglutide added to basal insulin in t ype 2 diabetes 
(SUSTAIN 5): A rando mized, controlled trial. J Clin End ocrinol Metab. 
2018; 103(6);2291-2301.
Rubin DB. Multiple Im putati on for Nonresponse in Surveys. [LOCATION_001]: John Wiley  & Sons 
Inc.; 1987.
Stark Casagrande S, Fradkin JE, Say dah SH, Rust KF, Cowie CC. The prevalence of meet ing
A1c, blood pressure, and LDL goa ls amo ng people with diabetes, 1988 -2010. Diabetes Care .
2013;36(8):2271 -2279.
Steinberg WM, Buse JB, Ghorbani MLM, Ørsted DD, Nauck MA; LEADER Steering 
Committee; LEADER Tri al Invest igators. Amylase, lipase, and acute pancreat itis in people 
I8F-MC-GPGI( b) Clinical Protocol Page 78
LY3298176with type 2 diabetes treated with liraglut ide: result s from the LEADER rando mized trial. 
Diabetes Care. 2017a;40(7):[ADDRESS_526395] of 
liraglutide on amylase, lipase, and acute pancr eatitis in part icipants wi th overwei ght/obesi ty 
and normoglycemia, prediabetes, or ty pe 2 di abetes: secondary  analyses of pool ed data from 
the SCALE clinical development program. Diabetes Care. 2017b;40(7):839 -848.
Weinberg ME, Bacchetti P, Rushakoff RJ. Frequent lyrepeated gl ucose m easurements 
overestimate the incidence of inpatient hy poglycemia and severe hyperglycemia. J Diabetes 
Sci Technol . 2010;4(3):[ADDRESS_526396] treatm ents: a sy stematic review and network 
meta -analysis. Ann Intern Med 2016;164 :102-113.
I8F-MC-GPGI( b) Clinical Protocol Page 79
LY329817612. Appendices
I8F-MC-GPGI( b) Clinical Protocol Page 80
LY3298176Appendix 1. Abbreviations and Definitions
Term Definition
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorabl e and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOVA analy sis of covariance
APPADL Ability to Perform Physical Activities of Daily Living
AST aspartate aminotransferase
BG Blood glucose
blinding/masking A double -blind study is one in which neither the patient/subject nor any of the 
investigator or sponsor staff who are involved in the treatment or clinical evaluation of 
the subjects are aware of the treatment received.
BMI body mass index
CEC clinical endpoint committee
CHF congestive heart failure
complaint A com plaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all st udy-related, good clinical practice (GCP), and applicable regulatory 
requirements.
COVID -19 Coronavirus Disease 2019
CRF case report form
CRP clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CSR Clinical Study Report
I8F-MC-GPGI( b) Clinical Protocol Page [ADDRESS_526397]
ET early  termination
FBG fasting blood glucose
FDA Food and Drug Administration
FSG fasting serum glucose
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GI gastrointestinal
GIP glucose -dependent insulinotropic polypeptide
GLP-1 glucagon -like peptide -1
HbA1c hemoglobin A1c
IB Investigator’s Brochure
ICF informed consent form
Informed consent A process by [CONTACT_9444] a patient voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the patient’s decision to participate.   Informed consent is documented by 
[CONTACT_3553] a written, signed and dated informed consent form.
ICH International Council for Harmonisation
I8F-MC-GPGI( b) Clinical Protocol Page 82
LY3298176investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
ITT intention to treat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by [CONTACT_41445] a patient (that is, the 
planned treatment r egimen) rather than the actual treatment given.  It has the 
consequence that patients allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.
IWRS interactive web -response sy stem
IW-SP Impact of Weight on Self -Perception
MedDRA Medical Dictionary for Regulatory Activities
mITT modified intent -to-treat
MMRM mixed model for repeated measures
MRI magnetic resonance imaging
MTC medullary thyroid carcinoma
NAFLD nonalcoholic fatty liver disease
OTC over the counter
p-amylase pancreatic amylase
PK/PD pharmacokinetics/pharmacodynamics
PRO/ePRO patient -reported outcomes/electronic patient -reported outcomes
QW once weekly
SAE serious adverse event
SAP statistical analysis plan
SARS -CoV-[ADDRESS_526398] deviation
SDP single -dose pen
I8F-MC-GPGI( b) Clinical Protocol Page 83
LY3298176SMBG self-monitoring of blood glucose
SS safety analysis set
S[LOCATION_003]Rs suspected unexpected serious adverse reactions
T1DM type 1 diabetes mellitus
T2DM type 2 diabetes mellitus
TBL total bilirubin level
TEAE Treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
TTT treat to target
ULN upper limit of normal
I8F-MC-GPGI( b) Clinical Protocol Page 84
LY3298176Appendix 2. Clinical Laboratory  Tests
Clinical Laboratory Testsa
Hematology Clinical Chemistry
Hemoglobin Serum Concentrations of:
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Bicarbonate
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Direct bilirubin
Leukocytes (WBC) Alkaline phosphatase
Neutrophils, segmented Alanine aminotransferase (ALT)
Lymphocy tes Aspartate aminotransferase (AST)
Monocytes Blood urea nitrogen (BUN)
Eosinophils Creatinine
Basophils Uric acid
Platelets Calcium
Glucose, fasting
Urinalysis a,b
Albumin
CreatininePregnancy Test (females only) b
Follicle -stimulating hormone (FSH)c
Estradiol
HbA1c eGFR (calculated by [CONTACT_9289] -EPI [INVESTIGATOR_10908])d
Endocrine
Calcitonin 
Immunogenicity
Tirzepatide anti -drug antibod y
Anti-GAD antibodies
Nonpharmacogenetic Stored Samples
EDTA plasma
Serum
P800 plasmaPancreas (exocrine)
Serum pancreatic amylase
Serum lipase
Lipid Panel
Total cholesterol
LDL
HDL
VLDL
Triglycerides
Samples for PK Analysis
I8F-MC-GPGI( b) Clinical Protocol Page 85
LY3298176Abbreviations :  CKD -EPI=Chronic Kidney Disease -Epi[INVESTIGATOR_623]; GAD =glutamic acid decarboxylase ; 
EDTA =ethylenediaminetetraacetic acid; eGFR =estimated glomerular filtration rate; HbA1c =hemoglobin 
A1c; HDL =high-density lipoprotein; LDL =low-density  lipoprotein; RBC =red blood cells; VLDL =very 
low-density  lipoprotein; WBC =white blood cells.
aAll tests will be performed by a Lilly -designated central laboratory, unless otherwise noted .
bSerum pregnancy test will be performed by [CONTACT_82408] [ADDRESS_526399] 
injection of study drug(s) for women of childbearing potential only.  Additional pregnancy tests will be 
performed at Visits 13, 19 and 22. Pregnancy  tests may  be performed at the investigator’s discretion during the 
study.  If required per local regulations and/or institutional guidelines, pregnancy testing can also occur at other 
times during the study treatment period .
cFollicle -stimulating hormone test perform ed at Visit [ADDRESS_526400] had spontaneous amenorrhea for more than 6 months and 
less than 12 months and estradiol levels consistent with a postmenopausal sta te (FSH ≥40 mIU/mL and estradiol 
<30 pg/mL).
dEstimated glomerular filtration rate will be calculated by [CONTACT_417396].
I8F-MC-GPGI( b) Clinical Protocol Page 86
LY3298176Appendix 3. Study  Governance Considerations
I8F-MC-GPGI( b) Clinical Protocol Page [ADDRESS_526401] igator is responsible for:
ensuring that the patientunderstands the nature of the study , the potential 
risks and benefits of participat ing in the study , and that thei r participat ion is 
voluntary.
ensuring that informed consent is given by [CONTACT_417397].  This includes obtaining the appropriate signatures and dates 
on the informed consent form ( ICF) prior to the performance o f any protocol 
procedure s and prior to the administration of investigat ional product.
answering any quest ions the patient may have throughout the study  and 
sharing in a t imely manner any  new informat ion that m ay be relevant to the 
patient’s willingness to continue his or her part icipation in the study .
ensuring that a copy  of the ICF is provi ded to the participant or the 
participant’s l egal representative and is kept on file.
ensuring that the medical record includes a statement that written informed 
consent was obtained before th e parti cipant was enrolled in the study  and the 
date the written consent was obtained. The authorized person obtaining the 
inform ed consent m ust al so sign the ICF.
Appendix 3.1.[ADDRESS_526402] (ERB) was properly  consti tuted and convened as required by [CONTACT_266482] (ICH) guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the must be provided to Lilly before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by [CONTACT_41429], before it is used at the invest igative site(s).  All ICFs 
must be compliant with the ICH guidelin e on Good Clinical Pract ice (GCP ).
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
theprotocol and related amendments and addenda ,current Invest igator 
Brochure ( IB)and updates during the course of the study
inform ed consent form  
I8F-MC-GPGI( b) Clinical Protocol Page 88
LY3298176other relevant docum ents ( for example , curri cula vi tae, adverti sements)
Appendix 3.1. 4. Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol and with the:
consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council forInternational
Organizat ionsofMedical Sciences (CIOMS ) Internat ional Ethi cal Guidelines
applicable ICH GCP Guidelines
applicabl e laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party .
Appendix 3.1 .5. Investigator Information
Physicians with a specialt y indiabetes/endocrinology , internal  medicine, family  medicine, 
general medicine , or any  other speci alty physician who ha veexperience treating type 2 di abetes 
mellitus (T2DM )and clinical research in T2DM will parti cipate as invest igators in this clinical 
study .
Appendix 3.1. 6. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_417403] d 
send a copy  of the signed page to a Lilly representative.
Appendix 3.1. 7. Final Report Signature
[CONTACT_100359] C linical Study Report (CSR coordinat ing investigator will sign the final CSR for this study , 
indicat ing agreement that, to the best of his or her knowled ge, the report accurately describes the 
conduct and results of the study .
A qualified invest igator will serve as the CSR coordinat ing invest igator.  If this invest igator is 
unable to fulfill this funct ion, another invest igator will be chosen by [CONTACT_417398].
The sponsor’s responsible medical o fficer and statistician will approve the final CSR for this 
study , confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
Appendi x 3.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
I8F-MC-GPGI( b) Clinical Protocol Page 89
LY3298176provi de sponsor start -up training to instruct the investigators and study 
coordinators.  This training will give instruction on the protocol, the complet ion 
of the CRFs, and study  procedures.
make periodic visit s to the study  site
be available for consultation and stay  in contact [CONTACT_417399], tel ephone, and/or fax
review and verify  data reported to detect potential errors 
In addit ion, Lilly or its representatives will periodically check a sample of the patientdata
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_47551] i ts 
representatives, and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, medical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to original source 
docum ents.
Appendix 3.2.1. Data Capture System
The invest igator i s responsible for ensuring the accuracy , com pleteness, l egibili ty, and timeliness 
of the data reported to the sponsor.
An electronic data capture sy stem  (EDC) will be used in this study  for the collect ion of CRF 
data.  The investigator maintains a separat e source for the data entered by  [CONTACT_32864] -provided EDC system.  The invest igator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  [CONTACT_11003] .
Addit ionally , clinical  outcom e assessment data (scales, self -reported di ary data) will  be collected 
by [CONTACT_102]/investigator site personnel, via a paper source document, and will be transcribed 
by [CONTACT_417400] .
Data collected via the sponsor- provided data capture system (s) will be stored at third parties. 
The invest igator will have cont inuous access to the data during the study and unt il 
decommissio ning of the data capture sy stems.  Prior to decommissio ning, the invest igator will 
receive an archival copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system ,and electronic transfers will be provided to the invest igator 
for review and retent ion.  Data will subsequently be transferred fro m the central  vendor to the 
Lilly data warehouse.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global produ ct 
complaint m anagement sy stem .
I8F-MC-GPGI( b) Clinical Protocol Page [ADDRESS_526403] igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Appendix 3.3.2. Discontinuation of the Study
The study  will be discontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory, or other reasons consistent with applicable laws, regulat ions, and GCP.
Appendix 3. 4. Publication Policy
The publicat ion policy for Study  I8F-MC-GPGI is described in the Clinical Trial Agreement.
I8F-MC-GPGI( b) Clinical Protocol Page [ADDRESS_526404]
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = aspi[INVESTIGATOR_82355]; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalised 
ratio; RBC = red blood cells; WBC = white blood cells.
aAssay ed by [CONTACT_11007] -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
I8F-MC-GPGI( b) Clinical Protocol Page 92
LY3298176Appendix 5. World Health Organization Classification 
of Diabetes and Diagnostic Criteria
Type 1 Diabetes:   Type 1 di abetes is j udged to be present when the classical symptoms of 
diabetes (thi rst, polyuri a, wast ing and stupor, or coma) are associated with readily  detectabl e 
concentrations of glucose and ketone bodies in the blood and urine.  Insulin treatment is 
necessary  not only to control  hyperglycemia but also to prevent spontaneous ketosis and death.
Type 2 Diabetes :  Type 2 di abetes, al though often asymptomat ic, may also present with 
classical hyperglycemic symptoms (thirst, polyuria, weight loss), but despi[INVESTIGATOR_126153], 
ketone bodi es are present in only low concentrations in the blood and urine.  Coma is rare i n type 
2 diabetes ,but m ay resul t from extrem e hyperglycemia and hyperosmo larity; lactic aci dosis or 
ketoacidosis can also occur in fulminat ing illness (for example, severe infect ion or m esenteri c 
artery  throm bosis) due to an acute increase in insulin requ irements, but spontaneous ketosis does 
not occur.  Some patients with t ype 2 diabetes later progress to a state of abso lute insulin 
deficiency (Albert i and Zimmet 1998). 
I8F-MC-GPGI( b) Clinical Protocol Page 93
LY3298176Appendix 6. Classification of Contraceptive Methods
Highly Effective Methods of Contraception :
Combined oral contraceptive pi[INVESTIGATOR_10917]
NuvaRing
Implantable contraceptives
Injectable contraceptives (such as Depo -Provera®)
Intrauterine device (such as Mirena®and ParaGard®)
Contraceptive patch –ONLY women <198 pounds or 90 kg
Total  abstinenc e (if this is their preferred and usual lifestyle) or in a same -sex rel ationship 
with no sexual  relati onship wi th males (as part of their preferred and usual lifest yle).  
Note:  periodic abst inence ( for example , calendar, ovul ation, symptothermal, 
postovul ation methods), declarat ion of abst inence just for the duration of a trial, and 
withdrawal  are not acceptabl e methods of contraception
Vasectomy  –for men in clinical studies
Effective Methods of Contraception (must use combination of 2 methods):
Male condom  with spermicide
Female condo m with spermicide
Diaphragm  with spermicide
Cervical sponge
Cervical cap wit h spermicide
Men, regardless of their fertilit y status, with nonpregnant women of childbearing potential 
partners must agree to either remain abstinent (if this is their preferred and usual lifest yle) or use 
condoms plus 1additional highly  effect ive (less than 1% fail ure rate) m ethod of contraception 
(such as co mbinat ion oral  contraceptives, implanted contraceptives, or intrauterine device) or 
effect ive method of contraception (such as diaphragms wit h spermicide or cervical sponge) for 
the duration of the study  and for at least [ADDRESS_526405] imated relevant potential exposure in women of childbearing potential. 
Men who are in exclusively same sex relat ionships (as their preferred and usual lifest yle) are not
requi red to use contraception.
I8F-MC-GPGI( b) Clinical Protocol Page [ADDRESS_526406] 
Circumference
The fo llowing inform ation has been adapted fro m standardized physical measurement protocols 
for the World Healt h Organization’s STEPwise approach to Surveillance (STEPS) (WHO 2017 ) 
(Available at:
https://www.who.int/ ncds/surveillance /steps/ Section%204%20Step%202%20Physical%20Measu
rements.pdf)) Accessed January  17, 2019.
Measuring Height
Step 1. Ask the pati ent to rem ove their footwear and any headgear (light headgear worn for 
religious reasons can remain, but this should be worn by [CONTACT_417401]) .
Step 2. Ask the pati ent to stand on the calibrated height measuring board (stadio meter) or 
against a wall wit h their feet together and their knees straight with their heels against 
the backboard, the stadi ometer or the wall .
Step 3. Ask the pati ent to l ook strai ght ahead wi thout til ting their head up.
Step 4. Ask the pati ent to breathe in and stand tall.  If using a stadiometer or fixed measuring 
device, move the device’s measurement arm gent ly down onto the top of the patient’s 
head.  Record the patient ’s height in cent imeters (cm).
Measuring Weight
Body  weight m easurements shoul d be done in a consistent manner using a calibrated 
electroni c scale capable of measuring weight in kilograms.
All weights for a given patient should be measured using the same s cale, whenever possible, 
at approximately the same time in the morning after evacuat ion of bladder contents .  
Patients shoul d be light ly clothed but not wearing shoes while their weight is measured.
Step 1 .Ask the pati ent to rem ove their footwear, outerw ear (coat, jacket, etc .), and any 
headgear (light headgear worn for religious reasons can remain, but this should be worn 
by [CONTACT_417402]).
Step 2 .Make sure the scale is placed on a firm, flat, even surface (no t on carpet, on a slopi[INVESTIGATOR_126154], or a rough, uneven surface).
Step [ADDRESS_526407] weight in kilograms 
(kg) to the nearest one-tenth kg.
I8F-MC-GPGI( b) Clinical Protocol Page [ADDRESS_526408] Circumference
Waist circumference should be measured at midpoint, between lower margin o f least 
palpable rib and top of iliac crest ( approximately 1 inch (2.54 cm ) above the navel) .
Patients shoul d be light ly clothed.
Step 1. Ask the pati ent to stand wi th their feet cl ose together, and arms at their side wit h their 
body  weight evenly distributed.
Step 2. Ask pati ent to rel ax
Step 3. Measurements should be recorded at the end of a normal expi[INVESTIGATOR_57774].
I8F-MC-GPGI( b) Clinical Protocol Page 96
LY3298176Appendix 8. Changes to Study  Procedures due to the 
COVID -19 Pandemic
Severe acute respi[INVESTIGATOR_19960] 2 ( SARS -CoV -2), the virus that causes the novel
COVID -[ADDRESS_526409] a 
patient’s abilit y and/or willingn ess to attend their onsite study visit as original lyscheduled .  In 
such a situation, please fo llow the gui dance below :
1)Patients shoul d com e for the primary  endpoint visit (Visit 22) at the ori ginally planned 
40-week (± 7 days) schedule whenever possible and safe to do so, at the invest igator's 
discreti on.  However, in order to maximize the abilit y for onsi te visi ts for Vi sit 22, 
minimize missing data ,and preserve the intended conduct of the study, the visit window 
for Visit 22may be brought forward no s ooner than 14 days (Week 38) or extended up to 
28days (Week 44).  The subsequent safety follow-up v isit (Visit 801) should take place 
4weeks ±7 day s after Vi sit 22.  
2)For patients requiring an extensio n for Visit [ADDRESS_526410] (ti rzepat ide or placebo) will be provided to allow patients to remain on study  
drug uninterrupted during the extended treatment period, to ensure patient safet y, and to 
maintain the overall integrityof the tri al. 
3)Addit ional consent from the patientwill be obtained per local regulat ions for those 
patients who will be dispensed addit ional invest igational product (tirzepat ide or placebo)
during the extended treatment period.
4)The sites will need to ident ify and document the details of how all patients and visits 
were affected by [CONTACT_25963] -[ADDRESS_526411] ions.
5)Mobile (in-home)healthcare visits:
Mobile visits may be performed at participants’ homes when participants cannot 
travel  to the si te due to extenuating circumstances. These will be performed by  a 
qualified ho me nursing service provider fo llowing sponsor approval, if permitted by  
[CONTACT_54019]. Procedures performed may include, but are not limited to, taking 
blood sam ples, conduct ing physical assessments, administering PROs, and co llecting 
healt h informat ion. Please note that requirements related to the reporting of SAEs 
remain unchanged. Every  effort shoul d be made for the participant to return to onsite 
visits as soon as reasonably  possible, while ensuring the safety  of the parti cipant and 
investigat ional site staff. 
Addit ional consent fro m the parti cipant will  be obtained for those who participate in 
home healt h services.
I8F-MC-GPGI( b) Clinical Protocol Page 97
LY3298176Appendix 9. Protocol A mendment I8F -MG-GPGI (b)
A Randomized, Phase [ADDRESS_526412] of the A ddition of Tirzepatide versus Placebo 
in Patients with Ty pe 2 Diabetes Inadequately  Controlled 
on Insulin Glarg ine w ith or without Metformin 
(SURPA SS-5)
Overview
Protocol  I8F-MC-GPG Ititled “A Randomized, Phase 3, Double -Blind Tri al Com paring the 
Effect of the Addit ion of Ti rzepat ideversus Pl acebo in Pat ients with Type 2 Di abetes 
Inadequately Controlled on Insulin Glargine with or without Metformin (SURPASS -5)” has been 
amended.  The new protocol is indicated by  [CONTACT_61504] ( b) and will be used to conduct the study  
in place of any  prec eding versio n of the protocol.
The overall changes and rationale for the changes made to this protocol are described in the 
following table.
I8F-MC-GPGI( b) Clinical Protocol Page 98
LY3298176Amendment Summary for Protocol I8F -MC-GPGI Amendment ( b)
Section # and 
NameDescription of Change Brief Rationale
Appendix 8 
Changes to Study 
Procedures due to 
the COVID -19 
PandemicAdded language about the mobile (in-
home )healthcare visits.This provides an option to conduct a clinical 
trial visit and all the applicable procedures in 
a mobile healthcare facility o rat the home of 
a patient when the patient is not able or not 
willing to go to the site due to COVID -19 
restrictions.
L e o  D o c u m e n t  I D  =  f d 6 1 2 3 8 1 - b e 4 6 - 4 c b 0 - a f 8 8 - 6 0 1 a f 3 d 0 7 4 b c 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  2 6 - J u n - 2 0 2 0  1 8 : 3 9 : 3 2  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  2 6 - J u n - 2 0 2 0  1 8 : 4 8 : 3 2  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 
P P D 